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Abstract 
 
Alzheimer’s disease (AD) represents the most prevalent form of dementia and is 
characterized by the cerebral deposition of the neurotoxic amyloid beta (Aβ) peptide. Aβ 
is produced upon sequential cleavage of the amyloid precursor protein (APP) by β- and γ-
secretase. In addition, APP is constitutively shed by another protease activity referred to 
α-secretase. This is considered to be an important mechanism preventing the generation 
of Aβ, as cleavage of APP by α-secretase occurs within the Aβ domain. The protease 
activities of α- and β-secretase are thought to be inversely coupled, as they are assumed 
to compete for the same substrate APP. The molecular identity of α-secretase is unknown, 
but appears to be a member of a disintegrin and metalloprotease (ADAM) family of 
proteases. The aim of this thesis was to study the processing of APP by α-secretase in 
more detail. Therefore, a novel α-secretase-cleavage site-specific antibody was developed. 
RNAi-mediated knockdown of putative proteases with α-secretase activity showed that 
only the loss of function of ADAM10, but not of ADAM9, 17 or the matrix 
metalloproteinase 14 (MMP14), completely suppressed APP α-secretase cleavage in 
immortalized cell lines and in neuronal like cells. ADAM10 was essential for the 
constitutive α-cleavage of APP, whereas other proteases were unable to compensate for 
the loss of α-cleavage activity. Surprisingly, upon the genetically or pharmacologically 
induced loss of function of either ADAM10 or the β-secretase BACE1, almost no 
compensatory relationship between these two protease activities towards APP cleavage 
was observed. Instead, α- and β-secretase contributed to the proteolytic processing of 
APP in a stable ratio. However, ADAM10 could partially compete with γ-secretase for 
the cleavage of a C-terminal APP fragment generated by β-secretase. In conclusion, it 
was shown that ADAM10 is the only physiologically relevant, constitutive α-secretase of 
APP. 
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Zusammenfassung 
 
Die Alzheimer Krankheit, die häufigste Form von Demenz, wird durch eine zerebrale 
Ablagerung von beta Amyloid (Aβ) Peptiden gekennzeichnet. Aβ entsteht bei der 
Spaltung des Amyloid-Vorläufer-Proteins (Amyloid precursor protein, APP) durch die 
beiden Proteasen β- und γ-Sekretase. In einem anderen Proteolyseprozess wird APP 
durch die α-Secretase konstitutiv gespalten. Dieser Prozess ist ein wichtiger 
Mechanismus, der die Bildung der Aβ-Peptide verhindert, indem die α-Secretase 
innerhalb der Aβ-Domäne spaltet; es wird angenommen, dass in der Regel arbeiten α-and 
β-Secretase umgekehrt gekoppelt arbeite. Die α-Sekretase scheint eine Metalloprotease 
der ADAM (A disintegrin and metalloproteinase)-Familie zu sein, wobei diese Identität 
noch establiert werden muss. In dieser Arbeit wurde ein spezifischer Antikörper zur 
Untersuchung der α-Sekretase-Spaltung entwickelt. Das RNAi-basierte Ausschalten 
verschiedener Proteasen in Zellen zeigte, dass nur der Funktionsverlust von ADAM10, 
aber nicht von ADAM9, 17 oder MMP14 (Matrix metalloprotease 14) die α-Sekretase 
Spaltung von APP in immortalisierten Zell-Linien komplett unterdrückte. ADAM10 war 
für die konstitutive α-Spaltung von APP essentiell, während andere Proteasen den Verlust 
an α-Spaltung nicht kompensieren konnten. Überraschenderweise zeigte der 
Funktionsverlust von ADAM10 und β-Sekretase BACE1 untereinander fast gar keine 
kompensierende Beziehungen bezüglich der APP α-Spaltung, weder genetisch noch 
pharmakologisch in immortalisierten Zellen; α- und β-Sekretase trugen in einem stabilen 
Verhältnis zum APP proteolytischen Prozess bei. Dagegen konnte ADAM10 teilweise 
mit der γ-Sekretase um die Spaltung eines C-terminalen APP Fragments konkurrieren, 
das durch die β-Sekretase erzeugt wurde. Abschließend lässt sich sagen, dass ADAM10 
die einzige physiologisch gesehen relevante konstitutive α-Sekretase von APP ist.
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1 Introduction 
 
1.1 Alzheimer’s disease (AD) 
The research on Alzheimer’s disease (AD), which is named after the famous German 
psychiatrist and neuropathologist Alois Alzheimer, has been carried out since 1906 
(Alzheimer, 1907; Stelzmann et al., 1995). In the following 100 years, interdisciplinary 
studies have been unlocking the secrets of biochemical aspects the disease. AD-related 
amyloid beta (Aβ) peptide was purified (Glenner & Wong, 1984); the amyloid precursor 
protein (APP) was decoded (Kang et al., 1987); and the disease-related genetic mutations 
were revealed (Goate et al., 1991; Sherrington et al., 1995). The following table lists the 
most important milestones in the AD research (Table 1). The fascinating achievements 
provide possible direction of AD and related molecular biochemical research. 
 
Table 1 A historical perspective of AD research. 
Years Events References 
1906 Clinical phenotype definition 
Alzheimer, 1907;  
Stelzmann et al., 1995 
1984 Aβ purified from amyloid plaques and sequenced Glenner & Wong, 1984 
1986 Phosphorylated tau protein found in neurofibrillary tangles Grundke-Iqbal et al., 1986 
1986 APP sequence decoded Kang et al., 1987 
1991 The first APP mutation related to familial AD decoded Goate et al., 1991 
1995 PS mutations related to familial AD decoded Sherrington et al., 1995 
 
1999 BACE1 identified as β-secretase of APP Vassar et al., 1999 
 
Due to the dramatic rise in life expectancy during the 20th century, neurodegenerative 
disorders have become more threatening to the elder population. AD is becoming the 
most prevalent adult-onset dementia form nowadays (reviewed by Selkoe, 2001; 
reviewed by Karran et al., 2011). Although there are two types of AD described - the 
familial AD and the non-familial sporadic AD - they are phenotypically highly similar 
(reviewed by Selkoe, 2001). The phenotypic similarity makes it reasonable to assume that 
they also share similar molecular pathology and mechanism. The greatest risk factor for 
sporadic AD is age. With the predicted demographic increase of elderly populations, it is 
estimated that well over 100 million patients will develop AD by 2050 (reviewed by 
Karran et al., 2011).  
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1.1.1 Clinical symptoms of AD  
AD patients undergo progressive decline in various aspects of behavior, including 
memory impairment, disordered cognitive function, altered psychological performance, 
loss of social appropriateness and decline in language ability (reviewed by Selkoe, 2001; 
reviewed by Sisodia & St George-Hyslop, 2002). The clinical symptoms develop in 
various stages according to the severity of dementia (Table 2). In the first stage, the mild 
or early dementia stage, patients only show short-term memory impairment. They do not 
remember a conversation or activity and have difficulties to keep new information. After 
the first couple of years, most of them develop additional problems with cognitive 
functions, including spatial orientation and language disability. Patients may start to have 
growing problems to easily and correctly execute complex tasks. The personalities and 
emotions of patients would also receive a remarkable change, like losing interest to their 
surroundings and being often aggressive. Over several years or even a decade or more, 
patients are completely mentally disoriented with full disorientation, profound memory 
impairment and global cognitive deficits (reviewed by Selkoe & Schenk, 2003). 
 
Table 2 Clinical symptoms of AD development. 
 
Step 1 Step 2 Step 3 
Amnestic stage 
Progressive memory and  
motor decline 
Marked dementia 
• mild or early dementia 
• short-term memory impairment 
• difficulties to keep new information 
• problems with orientation and language 
• incorrect execution of complex tasks 
• changes in personality and emotion 
• completely 
mentally disoriented 
 
1.1.2 Pathological features of AD 
The molecular pathological description of AD began with the identification of a marked 
decrease in choline acetyltransferase (ChAT) in the cerebral cortex (reviewed by Selkoe 
& Schenck, 2003) and later characterized by abnormal protein deposition. Starting from 
1980s and during the decade following, the two brain lesions were recognized as 
diagnostic criteria of AD: the amyloid (senile) plaques and the neurofibrillary tangles 
(Figure 1) (reviewed by Selkoe, 1998; reviewed by Sisodia & St George-Hyslop, 2002; 
reviewed by Serrano-Pozo et al., 2011). 
Introduction 
13 
 
Figure 1 Morphological hallmarks of AD pathology. 
A) Amyloid deposits: plastic-embedded sections showing a mixture of spherical cores and an amorphous 
deposit (figure from Masters et al., 1985). 
B) Neurofibrillary tangles: immunochemical staining section of AD hippocampus with protein tau antibody 
(figure from Grundke-Iqbal et al., 1986). 
 
Amyloid plaques are deposits of aggregated amyloid beta (Aβ) peptides (Glenner & 
Wong, 1984; Masters et al., 1985), which are found almost exclusively in the 
extracellular space of the brain and the cerebral vascular system (reviewed by Selkoe, 
1999). In amyloid plaques, fibrillar Aβ peptides are found mainly as a 42-amino acid-
long form (Aβ42) (Iwatsubo et al., 1994). This is the more hydrophobic form that 
aggregates particularly easily and quickly (Jarrett et al., 1993; reviewed by Harper & 
Lansbury, 1997; Walsh et al., 1997). Together with Aβ42, a low proportion of a 40-
amino acid-long form (Aβ40) is found in the plaque, although it is normally more 
abundantly produced by cells (Asami-Odaka et al., 1995; reviewed by Selkoe, 1999). 
Amyloid plaques have a dense amyloid core, infiltrated by the dystrophic axons and 
dendrites and colocalized with activated microglia and reactive astrocytes (Pike et al., 
1994). It indicates a potential inflammatory component in the process. This form of 
plaques is specific for AD. An alternative form of amyloid plaques is called diffuse 
plaques or pre-amyloid deposits. The diffuse plaques contain only Aβ42 (Iwatsubo et al., 
1994; Lemere et al., 1996; Lambert et al., 1998) and are not surrounded by activated glial 
cells and neurons (Itagaki et al., 1989). These plaques are considered the immature form 
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of amyloid plaques. The diffuse plaques in the brain, however, can also be found in non-
demented elderly people (Tagliavini et al., 1988; Dickson et al., 1995).  
 
Neurofibrillary tangles are the second neuropathological hallmark of AD. They are 
intracellular lesions and consist mainly of a microtubule-associated abnormally 
phosphorylated form of the tau protein (Grundke-Iqbal et al., 1986), whose physiological 
function is to stabilize the axonal microtubule-associated cytoskeleton (reviewed by 
Mandelkow & Mandelkow, 1998; reviewed by Friedhoff et al., 2000). Under 
pathological conditions the protein is hyperphosphorylated, leading to a destabilization of 
microtubules and consequently to reduced mass transport and impaired impulse in 
neurons, which may be caused by an imbalance of various kinases and phosphatases 
(Illenberger et al., 1998; reviewed by Mandelkow & Mandelkow, 1998; reviewed by 
Selkoe, 2001).  
 
However, the two hallmarks of AD can be observed only in postmortem brain and 
considered to indicate the late stage of the disease. Thus, they are unlikely to provide 
crucial information for early diagnosis or epidemiological research. But still they shed 
light on the molecular biochemical research on AD pathology and help to better 
understand the etiology and molecular mechanisms behind. 
 
1.1.3 Amyloid cascade 
After the observation of two neuropathological hallmarks of AD, the idea that they are 
the result of disease-associated biochemical steps became accepted. Some more research 
was carried out to reveal the complete biochemical metabolism process. The 
identification of the Aβ peptide as a component of amyloid plaques is a milestone in the 
study of AD (Glenner & Wong, 1984; Masters et al., 1985). Later Kang et al. decoded 
the full length gene of precursor protein APP (Kang et al., 1987), whose proteolytic 
processing leads to the Aβ peptide generation. At the beginning of 1990s, there was an 
enthusiasm towards AD biochemical and genetic studies. The search for genetic linkages 
provided clues that missense mutations in APP caused autosomal dominant, early-onset 
AD. These mutations occurred in or around the Aβ region or γ-secretase cleavage site of 
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APP (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991) and increased 
the production of Aβ (Citron et al., 1992; Cai et al., 1993; Haass et al., 1994; Suzuki et 
al., 1994). Some more mutations were found in the genes encoding presenilins (PSs), the 
subunits of γ-secretase (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 
1995), an enzyme involved in Aβ production. These mutations increased the production 
of Aβ42 (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 
1997; reviewed by Hardy, 1997; Tomita et al., 1997; Xia et al., 1997; Holcomb et al., 
1998). Another strong genetic risk factor for late-onset AD is the ε4 allele of 
apolipoprotein E (APOE) gene (Strittmatter et al., 1993). These findings, together with 
observations that Aβ readily forms neurotoxic, threadlike structures called fibrils in vitro 
or in vivo (Hilbich et al., 1991; Pike et al., 1993; Lorenzo & Yankner, 1994; LaFerla et 
al., 1995), bolstered the view that the accumulation of Aβ is a common initiating event 
that ultimately leads to neuronal dysfunction and eventually clinical manifestation of the 
disease in both familial and sporadic AD. The so called “amyloid cascade hypothesis” 
(Figure 2), positing that the deposition of the Aβ in the brain is a central event in AD 
pathology, has dominated research for the past twenty years (reviewed by Karran et al., 
2011). 
 
Although the direct relationship between the occurrence of amyloid plaques and neuronal 
degeneration in the central nervous system is so far not clear, the formation of plaques is 
thought to be the crucial primary insult in AD pathogenesis. However, evidence also 
assumed that the plaques were insufficient to cause neuronal death in vivo. The soluble 
Aβ oligomers may be responsible for neuronal dysfunction, while the plaques only form 
a reservoir for these species (Hartley et al., 1999; reviewed by Hardy and Selkoe, 2002; 
reviewed by Kawasumi et al., 2002; Walsh et al., 2002; reviewed by Glabe, 2006; 
reviewed by Haass & Selkoe, 2007; review Walsh & Selkoe, 2007). At the beginning of 
the cascade, changes happen to Aβ metabolism, such as an increased Aβ formation, a 
reduced degradation of Aβ, or a shift in the Aβ balance in favor of Aβ42 and the 
formation of diffuse plaques, which can induce the toxic effect to neurons directly or 
indirectly. The next step is to convert diffuse Aβ plaques to Aβ deposit fibrillars. The 
conversion activates microglia and astrocytes, triggering a local inflammatory reaction 
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and thereby damaging the surrounding neurons. The aggregation of Aβ peptide leads 
directly to an increased damage of neurons and changes in the intracellular milieu of cells, 
resulting in changes in kinase and phosphatase activities. Neurofibrillary tangles occur 
under such condition, which enhance neuronal dysfunction and death, together with 
amyloid plaques. The wide-spread neuronal dysfunction is regarded as the immediate 
cause of the disease (reviewed by Hardy & Selkoe, 2002; reviewed by Sisodia & St 
George-Hyslop, 2002). 
 
Figure 2 Amyloid cascade hypothesis. 
A shift in the Aβ balance in favor of Aβ42 leads to the formation of diffuse amyloid plaques, which may 
have the indirect toxic effect on neurons. Diffuse Aβ deposition then develops to mature amyloid plaques, 
which activates microglia and astrocytes, triggering a local inflammatory reaction from which damages the 
surrounding neurons. It also leads to changes in kinase and phosphatase activities resulting in the formation 
of neurofibrillary tangles. The tangles together with the Aβ deposition progressively give stress to neurons 
and therefore lead to wide spread neuronal dysfunction, which is regarded as the immediate cause of the 
disease. (modified picture from Hardy & Selkoe, 2002) 
 
1.1.4 Therapeutic approaches of AD 
Current therapeutic approaches of AD towards symptomatic aspects include the 
acetylcholinesterase (AChE) inhibitors (galantamine and rivastigmine), psychotropic 
drugs modifying behavioral symptoms and potential neurotrophic strategies (reviewed by 
Selkoe & Schenck, 2003; reviewed by Karran et al., 2011). These drugs improve some of 
the disease symptoms but do not treat the underlying mechanism, so the effects are 
limited. 
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Because Aβ is at the beginning of the amyloid cascade, considerable attention has been 
focused on attempts to develop therapies for AD towards metabolic pathways that 
involve Aβ (reviewed by Sisodia & St George-Hyslop, 2002). Such therapeutic 
approaches include: inhibition of Aβ monomers developing into toxic oligomers, or 
enhancement of clearance and disaggregation of fibrillar aggregates from cerebral cortex 
(Kisilevsky et al., 1995; Soto et al., 1998; Fraser et al., 2001); modulation of the fate and 
toxicity of Aβ by using antibodies against Aβ (Schenk et al., 1999; Bard et al., 2000; 
Janus et al., 2000; Morgan et al., 2000) or anti-inflammatory strategy; inhibition of the 
production of Aβ, by inhibiting either β- or γ-secretase that generates Aβ from APP. β- 
and γ-secretase are two proteases that participate in APP cleavage resulting to Aβ 
generation (see details in 1.2.3 and 1.2.4). Although there have been already some highly 
potent inhibitors identified to block γ-secretase activity, they still have trouble in moving 
further on the clinical trial.  That is because γ-secretase also plays an important role in 
shedding of many other proteins, like Notch receptor (reviewed by Annaert & De 
Strooper, 1999); the inhibition of γ-secretase may induce some unrespectable side effect. 
Thus, β-secretase inhibitor is considered a better therapeutic target, because the 
phenotype of BACE1 knockout mice was much milder than γ-secretase-deficit mice (Cai 
et al., 2001; Luo et al., 2001b).  
 
1.2 Amyloid precursor protein (APP) 
Aβ proteolytically derives from its precursor protein APP, which is ubiquitously present 
in all tissues (Tanzi et al., 1987). The three major APP isoforms are APP695, APP751, 
and APP770. APP695 is the only isoform lacking a 57-residue domain homologous to the 
family of kunitz serine protease inhibitors (KPI) and is the isoform most highly expressed 
in neurons (Goedert, 1987; LeBlanc et al., 1991).  
 
1.2.1 Structure of APP 
APP is a type I transmembrane protein with an amino-terminal signal peptide, a large N-
terminal ectodomain, a transmembrane domain and a short cytoplasmic domain (Figure 3) 
(Kang et al., 1987; Dyrks et al., 1988). There are two APP homologues, namely amyloid-
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precursor like protein 1 (APLP1) and amyloid-precursor like protein 2 (APLP2). They 
share the conserved structure and several identical motifs. The intracellular domain 
exhibits the highest sequence identity between APP, APLP1 and APLP2. However, Aβ 
sequence is unique to APP.  
 
Figure 3 APP structure and Aβ sequence. 
APP structure and the cleavage sites of α-, β- and γ-secretases. β- and γ-secretase cleavages generate the Aβ 
peptide, while α-secretase and an alternative β-cleavage site (β’) occur inside the Aβ domain precluding Aβ 
production.  
 
1.2.2 Physiological functions of APP 
While the role of APP processing in AD is becoming clearer, physiological functions of 
APP are not completely elucidated (reviewed by De Strooper & Annaert, 2000). Because 
of the domain structure and the striking similarity of proteolytic processing of APP to the 
Notch receptor, a receptor function for APP has been postulated (Kang et al., 1987; 
reviewed by Annaert & De Strooper, 1999; reviewed by Selkoe & Kopan, 2003). APP 
has also been suggested to have a role in synaptic plasticity, adhesion and cell migration 
via dimerization (Qiu et al., 1995; Perez et al., 1997; Soba et al., 2005; Weyer et al., 
2011). Some other research by gene knockout animals suggested an essential function of 
APP and its homologues during early development, postnatal survival, compromised 
neuronal or muscular function (Zheng et al., 1995; Heber et al., 2000; Herms et al., 2004; 
Wang et al., 2005); and the secreted APP α-cleavage fragment (sAPPα) has been even 
reported to rescue APP knockout phenotype (Ring et al., 2007; Weyer et al., 2011), 
which raises its possible therapeutic importance. More interestingly, the ectodomain 
fragments of APP, especially sAPPα, were supposed to have the neuroprotective and 
synaptotrophic functions (Furukawa et al., 1996; Meziane et al., 1998; Stein et al., 2004; 
Thornton et al., 2006; Gralle et al., 2009); while the secreted APP β-cleavage fragment 
(sAPPβ) was supposed to bind the death receptor 6 (DR6) to induce cell death (Nikolaev 
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et al., 2009); and the intracellular domain of APP was considered to be involved in 
phosphorylation and protein-protein interaction (reviewed by Zheng & Koo, 2011).  
 
1.2.3 Proteolytic processing of APP 
APP proteolysis has recently been recognized as a special case of regulated 
intramembrane proteolysis (RIP), a process that generates intra- and/or extracellular 
fragments from transmembrane proteins involved in signal transduction (reviewed by 
Edwards et al., 2008; reviewed by Lichtenthaler et al., 2011). APP can be processed by 
two different protease activities, called α- and β-secretase (Figure 4). β-secretase is the 
aspartyl protease BACE1 (β-site APP cleaving enzyme 1). It cleaves APP at N-terminus 
of the Aβ domain to release sAPPβ and the remaining C-terminal fragment (CTF) C99 
which can be further cleaved by γ-secretase resulting in the formation of the Aβ peptide 
(Vassar et al., 1999) (Figure 3, 4). This process is called the APP amyloidogenic 
proteolytic pathway. In the alternative non-amyloidogenic pathway, APP is cleaved by α-
secretase within the Aβ domain, between the 16th (Lysine, Lys) and 17th (Leucine, Leu) 
amino acid of Aβ domain (Esch et al., 1990; Anderson et al., 1991; Wang et al., 1991) 
(Figure 3, 4). This cleavage releases the large, soluble ectodomain sAPPα into the 
medium and allows the resultant 83-residue, membrane-retained CTF C83 to be cleaved 
by γ-secretase, generating the small p3 peptide (Haass et al., 1992b). Another alternative 
cleavage performed by β-secretase takes place at the β’-cleavage site which is between α- 
and β-cleavage site (Figure 3). 
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Figure 4 APP proteolytic processing. 
APP can be cleaved by α-secretase releasing the sAPPα. The remaining fragment C83 can be further 
cleaved by γ-secretase to generate the small peptide p3. It can also be cleaved by β-secretase releasing 
sAPPβ. The remaining fragment C99 can be further cleaved by γ-secretase to generate the Aβ peptide.  
 
1.2.4 Secretion and transportation of APP 
The vast majority of secretory proteins share a common biosynthetic origin in the rough 
endoplasmic reticulum (ER), from where they are transported to the Golgi complex. The 
protein destined for secretion is then further processed through the Golgi apparatus and 
finally ends up in vesicles that fuse with the plasma membrane (reviewed by Halban & 
Irminger, 1994). APP also complies by such trafficking route. APP matures post-
translationally while being transported through the secretory pathway, modified by N- 
and O-glycosylation and tyrosine-sulfation while moving through the trans-Golgi 
network (TGN) to the cell surface (Weidemann et al., 1989; Oltersdorf et al., 1990). 
Immature APP (being N-glycosylated only) can be proteolytically processed in the ER, in 
the TGN, at cell surface or in the endocytic vesicles. The mature APP is degraded rapidly 
during the way where it is either transported to the cell surface via a biosynthetic pathway 
or from the cell surface via an endocytic pathway. 
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Evidence is accumulating that α-, β-, and γ-secretases localize differentially within the 
cell. α-secretase cleavage of APP appears to occur either in the late compartment of 
constitutive secretory pathway (TGN or post-Golgi compartment) or mostly at the plasma 
membrane (Sambamurti et al., 1992; De strooper et al., 1993; Kuentzel et al., 1993). 
Early research also suggested that membrane association was required for APP cleavage 
(Sisodia, 1992) as well as its internalization via the endocytic pathway (Carey et al., 
2005). On the other hand, the β-cleavage of APP seems to happen after APP endocytosis 
(Golde et al., 1992; Koo & Squazzo, 1994; Grbovie et al., 2003; reviewed by Tang, 
2009). Aβ production by cleavage of both β- and γ-secretase occurs in the endosomal 
compartment (Shoji et al., 1992; Siman et al., 1993; Schrader-Fischer & Paganetti, 1996; 
Yamazaki et al., 1996; Peraus et al., 1997; Perez et al., 1999). γ-secretase is suggested to 
work at plasma membrane (Chyung & Selkoe, 2003; Chyung et al., 2005; reviewed by 
Kaether et al., 2006a) or in early endosome (Kaether et al., 2006b), in parallel or even 
earlier than β-secretase. However, proteolytic metabolism of sAPPβ and Aβ was also 
reported to happen in trans-Golgi compartment in absence of vesicle formation under 
disease condition or in the presence of certain APP mutations (Xu et al., 1997). In vivo 
evidence proved that endocytosis is required for Aβ generation (Cirrito et al., 2008). The 
exact cleavage compartment by β-secretase is still not revealed completely. The exosomal 
organelle is considered necessary for the production and transportation of a fraction of 
the secreted APP fragments (sAPP), including sAPPα, sAPPβ or Aβ (Yu et al., 2004; 
Rajendran et al., 2006; Vingtdeux et al., 2007). 
 
Piling all the evidences together, APP can be processed in different pathways (Figure 5): 
in the constitutive secretory pathway, APP is transported towards the cell surface where it 
meets α-secretase and releases sAPPα (Figure 5 secretory pathway); the full length APP 
which is not cleaved by α-secretase can be rapidly internalized to enter the endosomal-
lysosomal pathways and can be cleaved by β- and γ-secretase (Figure 5 endocytic 
pathway) (Hare, 2010); a part of APP recycles back to the cell surface (Figure 5 recycling 
pathway) (Marquez-Sterling et al., 1997; reviewed by Small & Gandy, 2006; reviewed 
by Sannerud & Annaert, 2009), or it is degraded directly in the lysosome. Given the short 
Introduction 
22 
half-life of APP, even subtle changes in APP transportation through these various 
secretase-containing compartments may have large effects on the net steady-state levels 
of sAPP and Aβ. 
 
Figure 5 APP trafficking and ectodomain shedding. 
In the constitutive secretory pathway, APP is transported through ER and TGN towards the cell surface 
where it comes across α-secretase and releases sAPPα; the full length APP or CTFs could then rapidly enter 
the endosomal-lysosomal pathways and be cleaved by γ- and β-secretases; The rest of APP and CTFs enter 
the recycling pathway reaching the cell membrane again or is degrade directly in the lysosome.  
 
1.2.5 Secretases responsible for APP cleavage 
Several key players involved in APP proteolytic processing, such as β- and γ-secretase, 
have been precisely identified or at least had a rough idea. In contrast, the identity of α-
secretase remains unclear but it is assumed to belong to a disintegrin and 
metalloproteinase (ADAM) family (see details in 1.3).  
 
β-secretase leads to the cleavage of APP at the N-terminus of the Aβ domain in the 
amyloidogenic route. In 1999, Vassar et al. identified the aspartyl protease BACE1 to be 
β-secretase of APP. Overexpression of BACE1 increased the amount of β-secretase 
cleavage products, and antisense inhibition of BACE1 messenger RNA decreased the 
amount of sAPPβ (Vassar et al., 1999). BACE1 is a 501 amino acid long type I 
transmembrane, glycosylated aspartyl protease with an N-terminal signal peptide, a 
prodomain, a large catalytic domain, a transmembrane domain and a small cytoplasmic 
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domain (Hussain et al., 1999). This finding was subsequently confirmed by several 
research groups using different experimental approaches (Sinha et al., 1999; Yan et al., 
1999; Lin et al., 2000). BACE1 is expressed highly in brain tissue (Vassar et al., 1999), 
consistent with its role in amyloidogenic pathway. BACE1 was shown to be the unique 
protease for APP β-proteolytic processing (Cai et al., 2001; Luo et al., 2001b). 
Nevertheless, APP is not the unique substrate for BACE1, although the identification of 
other BACE1 substrate is poorly understood (reviewed by Haass, 2004). A BACE1 
homologue, BACE2, has also been characterized (Acquati et al., 2000; Solans et al., 
2000). Interestingly, although lowly expressed in the brain (Bennett et al., 2000), BACE2 
cleaves APP predominately inside the Aβ domain closer to the transmembrane domain 
than α-cleavage site. For that reason BACE2 would be rather classified as an alternative 
α-secretase. 
 
After α- or β-secretase cleavage, the remaining membrane bound CTFs of APP are cut 
within the transmembrane region by γ-secretase. The cut can be carried out at different 
positions in C99 to generate different lengths of Aβ peptides. It arises predominantly 
Aβ40, while the much more pathogenic form Aβ42 makes up only 5-10% percentage 
(Selkoe, 1999). The γ-secretase is a high molecular weight complex comprising the four 
subunits: presenilin1 (PS1) or the homologous presenilin2 (PS2), APH-1 (anterior 
pharynx defective 1), nicastrin and Pen-2 (presenilin enhancer protein 2). These four 
subunits are necessary for the activity of the complex (Francis et al., 2002) and also 
sufficient (Edbauer et al., 2003). PSs are the active catalytic subunits of γ-secretase and 
belong to the family of GxGD aspartyl proteases (De Strooper et al., 1998; Wolfe et al., 
1999; Haass & Steiner, 2002; reviewed by Wolfe, 2006). Missense mutations in the PS 
genes are the major cause of familial AD (Sherrington et al., 1995), which is 
biochemically characterized by a shift of the C-terminal cleavage site of γ-secretase, 
leading to more Aβ42 generation. 
 
1.3 Proteases involved in α-secretase cleavage of APP 
Despite that β- and γ-secretase have been identified since a decade ago, the molecular 
identity of α-secretase is still unclear, controversial and remains to be fully established. 
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Some proteases of ADAM and matrix metalloprotease (MMP) family were supposed to 
be involved in APP α-secretase cleavage. Furthermore, because α-secretase cleavage has 
the potential to prevent Aβ generation and sAPPα has even been shown to have 
neuroprotective effects (see details in 1.2.2); it is considered to be a crucial target in the 
therapeutic approach for AD treatment. 
 
1.3.1 ADAM proteases family 
The α-secretase of APP was considered to be a metalloprotease due to the fact that APP 
α-secretase cleavage could be blocked by certain metalloprotease inhibitors. TAPI-1, -2 
and 10-phenanthroline inhibits metalloproteases by removal and chelation of metal ions 
required for their catalytic activity, leaving an inactive apoenzyme (Arribas et al., 1996). 
Some further researches concerning to metalloproteases inhibition revealed that 
metalloproteases were involved in APP α-cleavage process (Buxbaum et al., 1998; Koike 
et al., 1999; Lammich et al., 1999; Skovronsky et al., 2000; Lopez-Perez et al., 2001; 
Slack et al., 2001; Kim et al., 2008). The most frequently named ones are three members 
of the ADAM family: ADAM9, 10 and 17 (see details in Table 3). 
 
1.3.1.1 Structure of ADAM proteases 
ADAMs are type I transmembrane proteins belonging to the zinc-dependent protease 
superfamily. They compromise a signal sequence, a prodomain, a large luminal domain 
containing the catalytically active metalloprotease domain and cysteine-rich domain, an 
EGF (epidermal growth factor)-like domain, a transmembrane domain and a short 
cytoplasmic domain (Figure 6) (reviewed by Seals & Courtneidge, 2003). The prodomain 
contains a conserved cysteine residue and the catalytic domain has to be coordinated with 
the zinc ions. In the trans-Golgi compartment, ADAM proteases can be activated by the 
removal of prodomain by a furin-like proprotein convertase (Lammich et al., 1999; 
Anders et al., 2001; Endres et al., 2003). In ADAM10, proprotein convertase recognition 
sequence (RKKR) is essential for activation of the zymogen, and both furin and PC7 can 
act as proprotein convertases (Anders et al., 2001). The cytoplasmic domain varies the 
most among the different ADAM proteases. It contains the motifs for protein-protein 
interactions and serves for signal transduction and cellular transport of ADAM proteases. 
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ADAM9, 10 and 17 have PXXP motifs and serine, threonine and tyrosine residues, which 
can be phosphorylated. The modifications of PXXP motifs and phosphorylation provide 
binding sites for SH3 and SH2 domain-containing proteins (Howard et al., 1999).  
 
Figure 6 ADAM protease structure. 
ADAM proteases are type I transmembrane protein with a signal sequence, a prodomain, a large luminal 
domain containing the catalytically active metalloprotease domain and cysteine-rich domain, a 
transmembrane domain and a short cytoplasmic domain. 
 
1.3.1.2 Physiological functions of ADAM proteases  
The ADAM proteases catalyze the cleavage of different type of type I transmembrane 
proteins, including cytokines and cytokine receptors, growth factors and their receptors, 
extracellular matrix proteins and adhesion proteins. Of the 21 human ADAMs identified, 
only 13 are proteolytically active. ADAMs shown to exhibit protease activity include 
ADAM9, 10, 12, 15, 17, 19, 28 and 33 (reviewed by Duffy et al., 2011). Because of the 
diversity and variety of substrates, ADAM proteases are supposed to regulate many 
different functions in the various types of cells, like membrane fusion, cell migration, and 
also early development, fertilization and cell fate determination (reviewed by Seals & 
Courtneidge, 2003). 
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1.3.1.3 ADAM9, 10 and 17 
ADAM9, 10 and 17 are the best described candidates providing APP α-secretase activity. 
Research about involvements of these three ADAM proteases in APP α-proteolytic 
process has been performed by various research group using different techniques in either 
in vitro cell lines or in vivo animal experiments. The following table summarizes the 
research about APP α-secretase candidates (Table 3). 
 
Table 3 Research summary of APP α-secretase candidates (ADAM9, 10 and 17).  
 
Cell lines and 
ADAMs manipulations 
References 
in vitro   
Cell free assay ADAM9 Roghani et al., 1999 
 ADAM10  Lammich et al., 1999 
Cell based assay   
APP-COS ADAM9 ↑ Koike et al., 1999 
HEK ADAM9 ↑ Taylor et al., 2009 
HEK/APP-HEK ADAM10 ↑ Lammich et al., 1999 
LoVo ADAM10 ↑ Lopez-Perez et al., 2001 
HEK ADAM10 ↑ Taylor et al., 2009 
APP-HEK ADAM17 ↑ Slack et al., 2001 
Overexpression of 
individual protease 
LoVo ADAM17 ↑ 
 
Lopez-Perez et al., 2001 
ADAM9 KO-MEF Weskamp et al., 2002 
COS ADAM9 ↓ Asai et al., 2003 
HEK ADAM9 ↓ Taylor et al., 2009 
ADAM10 KO-MEF Hartmann et al., 2002 
COS ADAM10 ↓ Asai et al., 2003 
SH-SY5Y ADAM10 ↓ Allinson et al., 2004 
1321N1 ADAM10 ↓ Camden et al. 2005 
U373 ADAM10 ↓ Freese et al., 2009 
HEK ADAM10 ↓ Taylor et al., 2009 
ADAM10 KO-neuron Jorissen et al., 2010 
COS ADAM17 ↓ Asai et al., 2003 
SH-SY5Y ADAM17 ↓ Allinson et al., 2004 
gene knockdown or 
knockout of individual 
protease 
1321N1 ADAM17 ↓ Camden et al. 2005 
in vivo   
overexpression ADAM10-mouse brain Postina et al., 2004 
“↑” represents gene overexpression; “↓” represents gene knockdown or knockout. 
 
Some research was performed by in vitro enzyme activity assay. The corresponding α-
cleavage product together with the exact α-cleavage site was verified between the 16th 
and 17th amino acid of Aβ domain (Lammich et al., 1999; Roghani et al., 1999). Other 
studies tried to elucidate the identity of α-secretase by candidate overexpression. 
ADAM9, 10 and 17 overexpressions in different cell lines resulted to an increase of APP 
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α-cleavage product (Koike et al., 1999; Lammich et al., 1999; Lopez-Perez et al., 2001; 
Slack et al., 2001; Hotoda et al., 2002; Postina et al., 2004). Catalytic inactive mutations 
of ADAM9 and 10 overexpressions could either inhibit the APP α-cleavage or at lease 
keep sAPPα generation at normal level (Koike et al., 1999; Lammich et al., 1999).  
 
However, since the overexpression of a protease could only up-regulate APP α-secretase 
cleavage artificially or indirectly, the physiological relevance of a candidate protease 
needs to be shown using the corresponding protease knockdown or knockout cells. In fact, 
different kinds of cells derived from ADAM9-, 10- or 17-deficient mice showed either no 
or a variable degree of reduction of APP shedding (Buxbaum et al., 1998; Hartmann et 
al., 2002; Weskamp et al., 2002; Jorissen et al., 2010). Besides, cell based gene 
disruption experiments showed that ADAM9, 10 and 17 were all involved in the APP α-
shedding. RNAi-mediated knockdown of the individual proteases in cultured cells led to 
the reduction of APP shedding to different extents (Asai et al., 2003; Allison et al., 2004; 
Camden et al., 2005; Freese et al., 2009; Taylor et al., 2009).  
 
The finding that APP shedding was never fully suppressed has led to the conclusion that 
ADAM9, 10 and 17 may contribute to α-secretase activity all together and they may 
exhibit considerable functional redundancy. However, this is in clear contrast to the fact 
that many other ADAM protease substrates are predominantly cleaved by a single 
ADAM protease, such as transforming growth factor α (TGFα), EGF, the low-affinity 
immunoglobulin E receptor CD23 and N-cadherin (Sahin et al., 2004; Reiss et al., 2005; 
Weskamp et al., 2006; Le Gall et al., 2009; reviewed by Pruessmeyer & Ludwig, 2009). 
This raises the doubt that whether all three candidates of APP -secretase provide the 
physiologically relevant α-secretase activity. 
 
Moreover, some MMPs and other ADAMs may also have to be involved in the α-
secretase activity. At least, upon overexpression of MMP2, 9, 14, 16 and ADAM8, 19, 
APP α-cleavage increased (Ahmad et al., 2006; Naus et al., 2006; Talamagas et al., 2007; 
Tanabe et al., 2007; Vaisar et al., 2009). Whether they are relevant as α-secretase at 
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endogenous level remains unclear. They were also supposed to cleave APP at other site 
different from α-cleavage site. 
 
1.3.2 Problems of APP α-secretase identification research 
Investigation of APP α-secretase has always been complicated by two major factors. One 
aspect is the fact that APP is cleaved by distinct proteases at different sites in close 
proximity (Figure 3). For example, there is a secondary β-secretase cleavage site (termed 
β’-site) within the Aβ sequence in close proximity to the α-secretase-cleavage site. 
Antibodies used in previous studies, like WO2 or 6E10, have not specifically detected 
sAPPα, but also the alternative β-secretase-cleavage product sAPPβ' (Miles et al., 2008), 
which may have confounded the study of α-secretase cleavage. The other difficulty to 
study APP shedding is that the endogenous APP is expressed at very low levels, typically 
at the limit of assay sensitivity, especially in non-neuronal cells. Indeed the major part of 
research about APP shedding was performed using APP overexpressing cell lines, which 
simplified the analysis of APP shedding behavior but in an artificial environment. The 
heterogeneous results may also be caused by the off-target effects raised up by the 
overexpression of APP. Furthermore, many studies were carried out using activators of 
APP ectodomain shedding, like protein kinase C (PKC) signaling activator phorbol ester, 
which would imply the identity of α-secretase under regulated condition (see details in 
1.4.1) but not constitutive condition. 
 
1.4 Regulation of APP α-secretase 
APP is processed in two different proteolytic pathways by α- and β-secretase (Figure 4). 
APP is a common substrate for both proteases. So theoretically upregulation of one’s 
activity would lead to the reduction of the ectodomain shedding by the other secretase. 
This is the reason why in general the regulation of sAPPα and Aβ production is thought 
to occur in an inversely coupled manner. An increase of APP α-secretase activity is 
considered a possible therapeutic approach for AD, as it could be preventive in terms of 
Aβ generation. In contrast, a reduction of the α-cleavage is assumed to increase the risk 
of AD by leading to enhanced β-secretase cleavage and Aβ levels. Understanding the 
regulatory mechanisms of both secretases and their reciprocal coupling is of main 
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importance since the modulation of their activities could be promising therapeutic 
approach for AD. 
 
1.4.1 Regulated α-secretase of APP 
α-secretase activity has two components: a constitutive part and a regulated part. Both 
pathways contribute to APP α-proteolytic process. The constitutive pathway plays its role 
under normal physiological conditions; additionally, α-secretase activity can be increased 
above the constitutive level by some stimulation, which is called the regulated pathway. 
Due to its therapeutic potential, the activation of the regulated α pathways has roused the 
interest of AD community in the last decade. Different kinds of stimuli have been 
suggested to increase the secretion of sAPPα under certain conditions. The first evidence 
about the regulated α-secretase was shown in 1992. In that report, the release of sAPP 
was stimulated by muscarinic acetylcholine receptor (mAChR) agonist (Nitsch et al., 
1992). Later, some other activators were also successfully tested, such as activation of G 
protein-coupled receptors (GPCRs) and receptor tyrosine kinases, like PKC, mitogen-
activated protein kinase (MAPK), phosphoinositid-3-kinase (PI3K), cAMP and calcium 
(reviewed by Postina, 2011). The following table summarizes some physiological stimuli 
involved in the modulation of APP α-secretase activity (Table 4). Another most 
frequently used sAPPα stimuli is phorbol-12-myristate-13-acetate (PMA) (see details in 
1.4.2). 
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Table 4 Research summary of physiological APP secretion stimuli. 
Sorts Stimuli References 
Interleukin-1 α (IL-1α) Bandyopadhyay et al., 2006 
 
Cytokines 
Interleukin-1 β (IL-1β) Dash & Moore, 1995; Chong & Lee, 1999; Gitter et 
al., 2000; Ma et al., 2005; Tachida et al., 2008; 
Kong et al., 2009 
 
EGF Slack et al., 1997; Santiago-Josefat et al., 2007 
 
Growth factors 
Insulin-like growth factor 1 
(IGF-1) 
 
Adlerz et al., 2007; Jacobsen et al., 2010 
Estrogen Manthey et al., 2001; Zhang et al., 2005; Amtul et 
al., 2010 
 
Hormones 
Insulin Solano et al., 2000; Chen et al., 2007 
 
Glutamate receptor (GluR) 
agonist 
Lee et al., 1995; Nitsch et al., 1997; Jolly-Tornetta 
et al., 1998; Marcello et al., 2008; Hoey et al., 2009 
 
Neurotransmitters 
mAChR agonist Buxbaum et al., 1992; Nitsch et al., 1992; Nitsch et 
al., 1993; Slack et al., 1995; Wolf et al., 1995; 
Caccamo et al., 2006; Cho et al., 2006; Shirey et al., 
2009; Davis et al., 2010 
 
However, for most of them it remains to be shown whether they activate α-secretase 
cleavage through ADAM9, 10, 17 or yet other metalloproteases. The identification of 
such a regulated α-secretase of APP would be helpful for AD therapy development. 
 
1.4.2 Relationship between α- and β-secretase on APP cleavage 
Evidence from early reports demonstrated that Aβ release could be modulated 
physiologically or pharmacologically by a number of agonists which increase APP α-
shedding through phospholipase C and/or PKC activation (Table 5). PKC activation by 
PMA or phorbol 12,13-dibutyrate (PDBu), or activation of neurotransmitter receptors 
linked to phospholipase C, like mAChR, increased the α-cleavage of APP in cell lines 
with endogenous or overexpressed APP or Swedish APP (K670N, M671L) (Citron et al., 
1992). As a result, sAPPα and p3 production increased apparently, while the toxic 
product Aβ decreased correspondingly (Hung et al., 1993; Jacobsen et al., 1994; Wolf et 
al., 1995; Citron et al., 1996; Buxbaum et al., 1998; Kioke et al., 1999; Skovronsky et al., 
2000; Zhu et al., 2001; Allinson et al., 2004; Kim et al., 2008; Fu et al., 2009). PMA 
Introduction 
31 
treatment in neurons from Tg2576 mouse (transgenic mice overexpressing APP Swedish 
mutation) (Hsiao et al., 1996) also produced a significant increase in the levels of sAPPα, 
which was associated with a significant decrease in the levels of soluble Aβ (Qiu et al., 
2001). Postina et al. reported that neuronal overexpression of ADAM10 in human 
APPV717I overexpressed mice increased the secretion of the neurotrophic sAPPα, reduced 
the formation of Aβ peptides and prevented their deposition in plaques (Postina et al., 
2004). Other research related to AD diagnosis or therapy implied the compensative or 
competitive position of α- and β-secretase on APP cleavage (Colciaghi et al., 2002; Yao 
et al., 2011). However, in all these research, sAPP level was hardly measured. Thus, the 
activated α-secretase seems to compete with β-secretase on APP cleavage and 
upregulation of α-secretase activity is considered a potential therapeutic application in 
AD.  
 
Conversely, PKC activation in human primary neurons was shown to not affect Aβ 
production or even increase it (LeBlanc et al., 1998; Blacker et al., 2002). Another report 
showed that Aβ and sAPPβ levels were significantly reduced after intracortical injection 
of PMA in human APP overexpressing mouse, whereas sAPPα level was unchanged 
(Savage et al., 1998). On the other hand, pharmacological down-regulation of α-secretase 
cleavage of APP led to variant results about β-cleavage changes (Skovronsky et al., 2000; 
Gandhi et al., 2004; Kim et al., 2008). Using an ADAM10 conditional knockout mice, 
Saftig and colleagues found an obvious diminished appearance of CTFα and sAPPα 
together with a paradoxical reduction in CTFβ, sAPPβ, and total Aβ peptide production 
including the amount of Aβ40 and Aβ42 (Jorissen et al., 2010). Due to these 
heterogeneous findings, the scenario about the relationship between α- and β-secretase on 
APP cleavage is still unclear. The following table summarizes the regulation of α-
secretase and the corresponding compensative and competitive effect from β-secretase on 
APP cleavage (Table 5). 
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Table 5 Research summary of relationship of α- and β-secretase on APP cleavage. 
 
  
APP shedding 
behaviors 
References 
in vivo ADAM10-/- 
mouse 
sAPPα ↓ CTFα ↓,  
sAPPβ ↓ CTFβ ↓ Aβ ↓ 
 
Jorissen et al., 2010 
TAPI 
(metalloprotease 
inhibitor) 
 
sAPPα ↓ C83 ↓,  
sAPPβ -- C89 ↑ C99 ↑ 
Skovronsky et al., 2000 
Compensation 
α-secretase 
activity down-
regulation in vitro 
TAPI sAPPα ↓ CTFα ↓,  
sAPPβ – CTFβ – Aβ -- 
 
Kim et al., 2008; Gandhi et 
al., 2004 
in vivo ADAM10 mouse sAPPα ↑ CTFα ↑,  
sAPPβ ↓ CTFβ – Aβ ↓ 
 
Postina et al., 2004 
PMA sAPPα ↑ p3 ↑ Aβ -- Dyrks, 1994; Blacker et al., 
2002; Gandhi et al., 2004 
 
PMA/PDBu sAPP ↑ p3 ↑ CTFα ↑,  
sAPPβ ↓ CTFβ ↓ Aβ ↓
  
Hung et al., 1993; Jacobsen 
et al., 1994; Citron et al., 
1996; Buxbaum et al., 1998; 
Koike et al., 1999; 
Skovronsky et al., 2000; 
Qiu et al., 2001; Zhu et al., 
2001; Allinson et al., 2004; 
Kim, 2008; Fu et al., 2009 
 
PMA/PDBu sAPP ↑, Aβ ↑ LeBlanc et al., 1998 
 
Competition  
α-secretase 
activity up-
regulation in vitro 
PMA sAPPα --,  
sAPPβ ↓ Aβ ↓ 
Savage et al., 1998 
“↓” represents reduction; “↑” represents increase; “--” represents no change. 
 
Because of the discrepancies from the literature, the complex relationship between α- and 
β-secretase is not yet totally clear. It seems to be affected by factors from various aspects, 
like cell lines, in vivo/in vitro environments, the way of regulation achieved and APP 
trafficking involvement. Therefore, this topic has to be further investigated, in order to 
draw a final conclusion. In particular, most of the previous reports were performed using 
cell lines overexpressing APP or AD related APP mutation because of the difficulty of 
endogenous APP fragments detection. It would be extremely fruitful to investigate the 
relationship of α- and β-secretase cleavage at endogenous APP expression level. On the 
other hand, the majority of the research describing the relationship of these two proteases 
was performed under the condition of activity up-regulation. Little evidence has been 
shown their compensatory relationship under the condition of proteases activity down-
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regulation. So it would provide additional evidence for the relationship between these 
two proteases under the condition of protease inactivation. 
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2 Aim of the work  
 
Alzheimer’s disease (AD), the most prevalent form of dementia, is characterized by the 
deposition of amyloid beta (Aβ) peptides in the brain. Aβ is a proteolytic product of the 
larger amyloid precursor protein (APP). There are two different proteolytic activities, 
referred to as α- and β-secretase, responsible for the cleavage of the APP ectodomain. 
Ectodomain shedding of APP by β-secretase and the subsequent cleavage of the 
remaining C-terminal fragment by γ-secretase contribute to Aβ generation; whereas 
cleavage by α-secretase occurs within the Aβ domain, releasing secreted APP α-fragment 
(sAPPα) and therefore precludes Aβ generation. Unlike β- and γ- secretase, the molecular 
identity of α-secretase is still ambiguous. Proteases belonging to a disintegrin and 
metalloproteinase (ADAM) family, especially ADAM9, 10 and 17 are the most named α-
secretase candidates. The exact identification of APP α-secretase would help to complete 
the understanding of APP processing and facilitate pharmacological intervention; and the 
potential compensatory relationship between α- and β-secretase offers therapeutic 
potential. Despite the large body of evidence showing the relationship between these two 
proteases under activity upregulation condition, few studies based on inhibition or 
knockdown have been performed. Therefore, two major questions should be addressed in 
this thesis:  
 
• Which protease represents the physiologically relevant, constitutive α-secretase of APP? 
In order to facilitate the specific detection of APP α-cleavage, new cleavage-site specific 
sAPPα antibodies should be generated. Afterwards, the APP α-secretase candidates 
ADAM9, 10, 17 and metalloprotease 14 (MMP14) should be knocked down in order to 
identify the proteases that contribute to APP α-cleavage under endogenous APP 
expression conditions. Different cell lines should be analyzed to account for the potential 
cell type-specific expression levels of the studied proteases. To analyze the proteases 
under short- and long term loss of function conditions, transient knockdowns by siRNA 
transfection as well as stable knockdowns upon viral transduction of shRNAs should be 
performed. The concentration and sequences of applied siRNAs/shRNAs should be 
optimized in order to minimize off-target effects. Different APP ectodomain fragments 
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should be analyzed to reveal the shedding contribution of α- and β-secretase. In addition, 
the identification of regulated APP α-secretase will be carried out upon PMA stimulation.  
 
• What is the relationship between α- and β-secretase in terms of APP cleavage? 
In order to address the compensative relationship between α- and β-secretase under 
physiological conditions, different cell lines, from peripheral tumor cell lines to neuron-
like cells, should be studied. The loss of function of α- or β-secretase should be achieved 
by different methods, both pharmacologically and genetically. Pharmacological inhibition 
by protease inhibitors as well as siRNA/shRNA mediated knockdowns of α- and β-
secretase should be used to monitor compensatory effects of one protease in the absence 
of the other. 
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3 Materials and methods 
 
3.1 General materials 
 
3.1.1 Equipments and consumables 
Equipments/consumables Manufacturers 
Analytical balance (200 - 0.0001 g)  Ohaus 
Autoclave (Tuttnauer 3850 EL)  Systec 
Balance (2000 - 0.01 g)  Ohaus 
Falcon tube Sarstedt 
Fridge (Santo 4 ○C)  AEG 
Freezer (-20 ○C)  Liebherr 
Freezer (-80 ○C)  Heraeus 
Micro tubes (1.5 ml, 2 ml) Sarstedt 
Milli Q plus filtration system  Millipore 
Multi-channel pipette (300 μl) Eppendorf 
pH electrode  Schott 
pH meter (Inolab pH Level 1)  WTW 
Pipettes (1 ml, 200 μl, 20 μl)  Gilson 
Pipettes (10 μl) Eppendorf 
Pipettes (Accu-Jet) Brand 
Pipette tips (1 ml, 200 μl, 20 μl, 10 μl)  Sarstedt 
Pipette tips (25 ml, 10 ml, 5 ml)  Sarstedt 
Thermomixer compact Eppendorf 
Vortex VF2 IKA labortechnik 
 
3.1.2 Reagents 
Reagents Manufacturers 
Calcium chloride (CaCl2) J.T. Baker 
Disodium hydrogen phosphate (Na2HPO4) Sigma 
Dimethyl sulfoxide (DMSO) Merck 
Ethylenediaminetetraacetic acid (EDTA) Sigma 
Ethanol Merck 
Glycerol Sigma 
Hydrogen chloride (HCl) Merck 
Magnesium chloride (MgCl2) Merck 
Potassium chloride (KCl) Merck 
Potassium dihydrogen phosphate (KH2PO4) J.T. Baker 
Sodium chloride (NaCl)  Roth 
Tris hydroxymethyl aminomethane (Tris) Biomol 
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3.1.3 Buffers 
All solutions were dissolved with Mili-Q plant deionized H2O (double-distilled water, 
ddH2O) if not specifically described, whose electric resistance was purified to › 18.2 MΩ 
at 25 ○C.  
Buffers Recipes 
10* PBS 
 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4 
2 g KH2PO4 
add ddH2O to 1 L 
 
3.2 Molecular biological techniques 
 
3.2.1 Equipments and Consumables 
Equipments/consumables Manufacturers 
Cooling centrifuge (Avanti J-20XP) Beckman Coulter 
Centrifuge biofuge Heraeus 
Electrophoresis Owl separation system 
Microwave  Alaska 
Multifuge 3  Heraeus, Thermo Fischer 
NucleoBond Xtra Midi kit  Macherey-Nagel 
NucleoSpin extract II kit Macherey-Nagel 
NucleoSpin plasmid kit  Macherey-Nagel 
Thermal cycler Bio-Rad 
Thin-walled PCR tubes  Sarstedt 
UV lamp Intas 
 
3.2.2 Reagents 
Reagents Manufacturers 
10* complete PCR buffer  Peqlab 
10* T4 DNA ligase buffer  Fermentas 
1 kb DNA ladder  Gibco 
Acetic acid Merck 
Agar  BD 
Agarose NA  Invitrogen 
Ampicillin  Sigma 
Ethidium bromide (EB)  Roth 
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Reagents Manufacturers 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Biomol 
Orange G Sigma 
PCR Nucleotide Mix (dNTP) (10 mM) Roche 
Pwo DNA polymerase (1 U/μl)  Peqlab 
T4 DNA ligase (5 U/μl)  Fermentas 
Tryptone  BD 
Yeast extract  BD 
 
3.2.3 Buffers 
Buffers Recipes 
4* DNA sample buffer 15 ml Glycerol 
1 ml 0.5 M EDTA 
25 mg Orange G 
add ddH2O to 50 ml 
 
50* TAE 24.2 g Tris 
57.1 ml Acetic Acid 
100 ml 0.5 M EDTA (pH 8.0) 
add ddH2O to 1 L 
 
1000* Ampicillin solution 100 mg/ml ampicillin in 70% ethanol 
 
LB agar gel 
 
15 g/L agar solution is autoclaved 1.2 kPa for 20 min.  
The solution was poured into the plate and cooled down 
below 50 ○C. 
 
LB medium 1% tryptone 
0.5% yeast extract 
0.5% NaCl 
ddH2O solution pH was adjusted to pH 7.0. 
The solution was autoclaved at 1.2 kPa for 20 min. 
 
SOB medium 0.2% tryptone 
0.05% yeast extract 
0.5% NaCl 
ddH2O solution pH was adjusted to 7.0. 
 
TB buffer 10 mM HEPES buffer 
15 mM CaCl2 solution 
250 mM KCl solution 
55 mM MgCl2 solution 
ddH2O solution pH was adjusted to 6.7. 
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3.2.4 Plasmids and oligonucleotides 
The following plasmids were used in the thesis (Table 6). The table lists the names of the 
plasmids, the cDNA or shRNA, the source and the restriction endonucleases (RE) sites. 
The restriction enzymes and their specific buffers were from Fermentas or New England 
Biolabs.  
 
Table 6 Plasmids used in the thesis. 
Plasmids Vectors cDNA/shRNA RE sites sources 
P12-APP695 Peak12 APP695 HindIII/NotI Dr. S. Lichtenthaler 
P12-sAPPα Peak12 sAPPα HindIII/NotI Cloned from P12-APP695 
P12-sAPP15 Peak12 sAPP15 HindIII/NotI Cloned from P12-APP695 
P12-sAPP14 Peak12 sAPP14 HindIII/NotI Cloned from P12-APP695 
P12-sAPPβ’ Peak12 sAPPβ’ HindIII/NotI Cloned from P12-APP695 
P12-sAPPβ Peak12 sAPPβ HindIII/NotI Cloned from P12-APP695 
P12-Hygro-hAPP Peak12 hAPP695 MfeI Dr. P. Kuhn 
PLVTH-control PLVTH Control shRNA XhoI/NotI Dr. P. Kuhn 
PLVTH-ADAM10-sh6 PLVTH ADAM10-sh6 XhoI/NotI Dr. P. Kuhn 
PLVTH-ADAM10-sh9 PLVTH ADAM10-sh9 XhoI/NotI Dr. P. Kuhn 
PLKO-control PLKO Control shRNA XhoI/NotI Dr. P. Kuhn 
PLKO-ADAM10-sh7 PLKO ADAM10-sh7 XhoI/NotI Dr. P. Kuhn 
PLKO-ADAM10-sh9 PLKO ADAM10-sh9 XhoI/NotI Dr. P. Kuhn 
PLKO-BACE1-sh1 PLKO BACE1-sh1 XhoI/NotI Dr. P. Kuhn 
PLKO-BACE1-sh2 PLKO BACE1-sh2 XhoI/NotI Dr. P. Kuhn 
sPAX2 sPAX2  XhoI/NotI Dr. P. Kuhn 
pcDNA3.1-Delta.Zeo (-)-
VSV-G 
pcDNA
3.1 
VSV-G XhoI/NotI 
Dr. P. Kuhn 
 
Table 7 lists the template plasmids, the primers used in the PCR reaction, the primers 
used in plasmid sequencing and the final plasmids. Primers were purchased from 
ThermoFisher or Sigma.  
 
Table 7 Primers used in the thesis. 
Template plasmids Primer sequences 
Primer sequences 
(sequencing) 
Final plasmids 
P12-APP695 
P12-APP695-PmlI-for 
P12-sAPPα-NotI-rev 
P12-APP695-PmlI-for P12-sAPPα 
P12-APP695 
P12-APP695-PmlI-for 
P12-sAPP15-NotI-rev 
P12-APP695-PmlI-for P12-sAPP15 
P12-APP695 
P12-APP695-PmlI-for 
P12-sAPP14-NotI-rev 
P12-APP695-PmlI-for P12-sAPP14 
P12-APP695 
P12-APP695-PmlI-for 
P12-sAPPβ’-NotI-rev 
P12-APP695-PmlI-for P12-sAPPβ’ 
P12-APP695 
P12-APP695-PmlI-for 
P12-sAPPβ-NotI-rev 
P12-APP695-PmlI-for P12-sAPPβ 
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Table 8 lists the sequences of primers. The oligonucleotides used were dissolved in 
ddH2O by vortexing. The stock solution (100 mM) was stocked at -20 
○C, and a 10 mM 
solution served as working solution. 
 
Table 8 Sequences of primer used in the thesis. 
primers Sequences 
P12-APP695-PmlI-for 5’-GATCGGCCTCGTCACGTGTTCAATATGC-3’ 
P12-sAPPα-NotI-rev 5’-GATCGCGGCCGCCTATTTTTGATGATG-3’ 
P12-sAPP15-NotI-rev 5’-GATCGCGGCCGCCTATTGATGATGAACTTCATATC-3’ 
P12-sAPP14-NotI-rev 5’-GATCGCGGCCGCCTAATGATGAACTTCATATC-3’ 
P12-sAPPβ’-NotI-rev 5’-GATCGCGGCCGCCTAATATCCTGAGTCATGTCG-3’ 
P12-sAPPβ-NotI-rev 5’-GATCGCGGCCGCCTACATCTTCACTTCAGAGATC-3’ 
 
3.2.5 Methods 
 
3.2.5.1 Polymerase chain reaction (PCR) 
The PCR reaction solution was prepared according to the following recipe: 
Pwo polymerase (1 U/μl)         1 μl 
10* complete reaction buffer   5 μl 
dNTP (10 mM)                         1 μl 
Forward primer (10 mM)         4 μl  
Reverse primer (10 mM)          4 μl  
Template                              100 ng 
add ddH2O to                         50 µl 
ddH2O was used instead of template as the negative control. 
The reaction solution was prepared in thin-walled PCR tubes. Subsequently, the 
amplification of the target sequence was carried out in a PCR machine. The amplification 
was carried out for 30 cycles, each cycle consists of the following individual steps:  
1. Denature: disconnection of the deoxyribonucleic acid (DNA) duplexes for 30 s at 95 
○C;  
2. Primer hybridization: annealing of primers to the DNA single strands for 30 s (the 
annealing temperature depends on the GC temperature of primer pairs);  
3 Elongation: synthesis of the complementary strand at 72 ○C (the elongation time 
depends on the base pair number of the target duplex, approximately 750 kb/min).  
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Before the first cycle, there was a 5 min melting procedure at 95 °C. And after the 
completion of the total 30 cycles, the reaction was kept at 72 ○C for 10 min for 
stabilization. Then it was kept at 4 ○C. 
 
3.2.5.2 Agarose gel electrophoresis 
DNA fragments were separated by 1-1.5% agarose gel electrophoresis. The gels were 
prepared by agarose solution in TAE buffer and added 0.2 mg/ml EB before use. The 
comb was put into the gel until the gel was coagulated. The DNA samples were mixed 
with 4* DNA loading buffer and loaded on the gel. The 1 kb standard DNA ladder was 
used as the marker. Electrophoresis was performed at 120 V in TAE buffer for 20-40 min.  
 
3.2.5.3 DNA extraction from agarose gel 
The desired DNA fragments were carefully excised under UV light with a scalpel from 
the gel. Subsequently, the DNA was purified by the NucleoSpin extract II Kit following 
manufacturer’s instructions. The gel was first lysed with 200 μl binding buffer by 
incubating the tube at 50 ○C until the gel was melted. The gel lysis was then transferred 
into the column. The column was centrifuged at 13,000 rpm/1 min to make DNA 
combining with the silica membrane. The silica membrane was washed with 600 μl wash 
buffer (add ethanol each bottle before use) and centrifuged at 13,000 rpm/1 min to wash 
down the impurity except DNA. The silica membrane was dried with centrifugation at 
13,000 rpm/2 min. DNA was eluted from the silica membrane by 15-50 μl elution buffer 
after combination at room temperature (RT) for 1 min and centrifugation at 13,000 rpm/1 
min. 
 
3.2.5.4 Subcloning of target DNA into expression vector 
To subclone the target cDNAs into the expression vectors, the PCR fragments and the 
respective vectors were digested. Two different REs were used to ensure correct 
orientation of the cDNA into the vectors. The reaction buffers were selected according to 
http://fermentas.com/en/tools/doubledigest/?country_code=DE. The digestion reaction 
buffer was mixed at RT and then incubated at 37 ○C in a heating block for 1-3 h. 
The digestion reaction solutions were prepared according to the following recipe:  
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PCR fragments               80 ng  
or vector                       800 ng 
10* RE reaction buffer     3 μl 
REs                                0.8 μl for each 
Add ddH2O to                 30 μl 
The target DNA or vector fragments were separated and purified by agarose gel 
electrophoresis (see 3.5.3.2) and NucleoSpin extract Kit (see 3.5.3.3). Subsequently, the 
ligation of vector and insert was performed at RT for 2 h or 16 ○C overnight. 
The ligation reaction solutions were prepared according to the following recipe: 
vector                        1 μl 
insert                         6 μl 
T4 ligase                   1 μl 
10* T4 ligase buffer 2 μl 
add ddH2O to          20 μl 
ddH2O was used instead of insert as the negative control. 
 
3.2.5.5 Preparation of competent DH5α E. coli bacterial strain  
DH5α Escherichia coli (E. coli) colonies were picked up from an agar plate under sterile 
conditions and these colonies were inoculated in 100 ml SOB medium at 37 ○C/200 rpm 
for 16 h. Subsequently, these bacterials were diluted in approximately 250 ml SOB 
medium to an optical density (OD605) of 0.1 and incubated at 18 ○C /200 rpm. After 24 h 
incubation, the bacterial culture solution reached an OD605 of 0.6-0.8 in 50 ml Falcon 
tubes and was incubated on ice for 10 min. The bacterial sediment was centrifuged at 4 
○C/3500 rpm/20 min. They were resuspended in 80 ml of cold TB buffer and incubated 
on ice for 10 min. The bacterial sediments were centrifuged down and resuspended in 20 
ml TB buffer with 7% DMSO at 4 ○C. The bacterial suspension was aliquoted and flash 
frozen in liquid nitrogen. The bacterial stock solution was kept at -80 ○C. 
 
3.2.5.6 DNA transformation 
For DNA transformation, competent E. coli DH5α cells were thawed on ice. 10 μl DNA 
and 60 μl E. coli DH5α cells were mixed and incubated on ice for 30 min. Then they 
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were incubated at 42 ○C for 2 min without shaking, followed by incubation on ice for 
another 2 min. 800 μl LB-medium was added into the mixture and incubated at 37 ○C/200 
rpm/30 min. For retransformation, 100 ml LB-medium (with selection antibiotics, 1:1000 
dilution) and E. coli DH5α cells were mixed in flasks. For transformation, E. coli DH5α 
cells were seeded onto the LB-agar plate (with selection antibiotics, 1:1000 dilution) and 
incubated at 37 ○C overnight. 
 
3.2.5.7 Plasmid DNA purification  
For DNA preparation in mini format, bacterial colonies were picked up and cultivated in 
5 ml LB-medium (with antibiotics, 1:1000 dilution) at 37 ○C for at least 6 h or overnight. 
The plasmid DNA was purified by using Nucleospin Plasmid Kit following 
manufacturer’s instruction. Bacterial cells were harvested into a tube and spinned at 8000 
rpm/4 ○C/1 min. The supernatant was discarded and cells were resuspended by 250 μl 
Buffer A1. 250 μl Buffer A2 was added and the mixture was incubated for 3 min at RT. 
Then proteins were precipitated by adding 300 μl Buffer A3. The lysate was clarified by 
centrifugation at 8000 rpm/5 min. The supernatant was loaded on the column and spinned 
at 8000 rpm/1 min to combine the DNA. The silica membrane was washed by adding 600 
μl Buffer A4 and centrifugation at 8000 rpm/1 min. DNA was eluted from the silica 
membrane by 50 μl elution buffer after combination at RT for 1 min and centrifugation at 
8000 rpm/2 min. 
 
For DNA preparation in midi format, plasmid DNA was purified by using NucleoBond 
AX500 Kit following manufacturer’s instruction. The E.coli DH5α cells were poured into 
a Falcon tube and centrifuged at 4 ○C/6000 rpm with JA-10 rotor for 20 min after 
overnight incubation. The supernatant was discarded and cells were resuspended with 8 
ml RES Buffer (+ RNase). 8 ml LYS Buffer was added and the mixture was incubated at 
RT for 3 min. Then 8 ml NEU Buffer was added to precipitate the proteins. 12 ml EQU 
buffer was used to pre-equilibrate the column. Then cell lysates were poured into the 
columns. Another 5 ml EQU buffer was added to wash off the rest DNA. 8 ml wash 
buffer was added to wash off the rest protein. Then 5 ml ELU buffer was used to wash 
down the DNA. DNA solution was harvested in a Falcon tube and 3.5 ml isopropanol 
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was added to precipitate the DNA. The mixture was centrifuged at 4 ○C/4600 rpm with 
6641 rotor for 30 min. The precipitation was washed with 1 ml 70% ethanol with 
centrifugation at 13,000 rpm/1 min. DNA was dissolved with 300 μl ddH2O. DNA 
concentrations were measured by nanometer. 
 
3.2.5.8 DNA constructs sequencing 
The sequencing of the DNA constructs was carried out by GATC Biotech AG 
http://www.gatc-biotech.com/en/home.html (Constance). The correctness of the 
sequences was checked by VectorNTI. 
 
3.3 Cell culture 
 
3.3.1 Equipments and consumables 
Equipments/consumables Manufacturers 
Biological safety cabinet  Thermo Scientific 
Bunsen burner  Heraeus 
Cell culture dish (6 cm, 10cm)  Nunc 
Cell culture flask (75 cm2) Nunc 
Cell culture plate (24-well, 12-well, 6-well) Nunc 
CO2 incubator Thermo Scientific  
Centrifuge Megafuge 40 Heraeus 
Fridge Libherr 
Hemocytometer (Neubauer)  Optik Labor 
Microscope (Wiloverts 10* 4/10/20)  Hund 
N2-Tank (Chronos)  Messer Griesheim 
Pipette tips, steril (2 ml, 5 ml, 10 ml, 25 ml)  Sarstedt 
Syringe fliter (0.45 μM) VWR International 
Water bath GFL 
 
3.3.2 Reagents 
Reagents Manufacturers 
5* siRNA buffer Dharmacon 
β-secretase inhibitor IV (C3) Calbiochem 
γ-secretase inhibitor IX (DAPT) Calbiochem 
Dulbecco’s modified eagle medium (DMEM) high glucose  Gibco 
DMEM/F12 (1:1) medium Lonza 
DMEM high glucose with pyruvat  Invitrogen 
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Reagents Manufacturers 
Fetal bovine serum (FCS)  Gibco 
Hygromycin  Invitrogen 
Lipofectamine 2000  Invitrogen 
Lipofectamine RNAiMAX Invitrogen 
Non essential amino acids (NEAA) Invitrogen 
Opti-MEM I reduced serum medium with GlutaMAX I Invitrogen 
Penicillin/streptomycin (P/S) Gibco 
PMA Calbiochem 
Poly-L-lysine hydrobromide  Sigma 
TAPI-1  Peptides International 
Trypsin-EDTA (0.05%)  Gibco 
 
3.3.3 Cell lines 
The following cell lines were used in the thesis (Table 9). The table lists the names of the 
cell lines, the medium used to cell culture and the source of the cell lines. 
 
Table 9 Cell lines used in the thesis. 
Cells lines Medium Source 
Human embryonic 
kidney 293 cells 
(HEK293) 
 
DMEM + 10% FCS + P/S ATCC 
HEK293T low passage 
 
DMEM + 10% FCS + P/S ATCC 
Human neuroblastoma 
cells (SH-SY5Y) 
 
DMEM/F12 + 15% FCS + NEAA + P/S Dr. S. Lichtenthaler 
APP-HEK293 
 
DMEM + 10% FCS + P/S + hygromycin Dr. S. Neumann 
APP-SH-SY5Y DMEM/F12 + 15% FCS + NEAA + P/S 
+ hygromycin 
Generated from wide type SH-
SY5Y cells 
 
3.3.4 Methods 
 
3.3.4.1 Cultivation of cells 
The cell lines were cultured in 10-cm dishes or 75-cm2 flasks in an incubator at 37 ○C 
with 5% CO2. Upon reaching 70-80% confluence, the cells were washed with 3 ml sterile 
PBS and replaced with 2 ml sterile PBS-EDTA solution or typsin-EDTA solution to 
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detach the cells. The cells were resuspended with 3 ml fresh medium. Appropriate 
amount of cells were splitted to a new dish or flask with 8 ml fresh medium. 
 
3.3.4.2 Coating of cell culture dishes with poly-L-lysine 
To improve the adhesion of some cell lines (HEK293 cells especially), the cell culture 
dishes have to be coated with poly-L-lysine. The cell culture dishes were completely 
covered with sterile poly-L-lysine solution (100 μg/ml in PBS) and incubated for at least 
30 min at RT. After removing the poly-L-lysine solution, the dishes were washed twice 
with PBS and then dried. 
 
3.3.4.3 Transient gene overexpression by DNA transfection 
Transient gene overexpression was achieved by DNA transfection. The following 
procedure was used to transfect DNA into mammalian cells in a 24-well format. One day 
before transfection, 2-3*105 cells were seeded in 500 μl of growth medium without 
antibiotics so that cells would be 90-95% confluent at the time of transfection. For each 
transfection sample, transfection complex was prepared according to the following recipe: 
a. 200 μg DNA was diluted in 50 μl of Opti-MEM and mixed gently. 
b. Appropriate amount lipofectamine 2000 was diluted in 50 μl of Opti-MEM, RT/5min.  
c. After the 5 min incubation, the two solutions mentioned above were mixed gently and 
incubated for 20 min at RT. 
100 μl of complex was added to each well containing cells and medium. The cell culture 
medium was mixed gently by rocking the plate back and forth. 
Cells were incubated at 37 ○C in a CO2 incubator for 18-48 hours prior to testing for 
transgene expression. Medium may be changed after 4-6 hours. 
For other formats, see scaling up or down transfection mixture preparation (Table 10). 
 
Table 10 DNA transfection mix preparation. 
Culture vessel 
Relative 
surface area 
Volume of 
plating 
medium 
Dilution 
medium 
cDNA 
Lipofectamine 
2000 
96-well 0.2 100 μl 2 x 25 μl 0.2 μg 0.5 μl 
24-well 1 500 μl 2 x 50 μl 0.8 μg 2.0 μl 
6-well 5 2 ml 2 x 250 μl 4.0 μg 10 μl 
60 mm 10 5 ml 2 x 0.5 μl 8.0 μg 20 μl 
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3.3.4.4 Gene transient knockdown by siRNA transfection  
ADAM9, 10, 17 and MMP14 knockdowns in SH-SY5Y or HEK293 cells were achieved 
by variant amount of siGENOME or on-target plus pool siRNA transfection according to 
the protocol described below. Table 11 lists the sequences, the concentrations and the 
sources of siRNA used in the gene knockdown experiments. 
 
Table 11 siRNA used in the thesis. 
Target 
genes 
siRNA products Cell lines Concentration Sources 
HEK293 10 nM Dharmacon ADAM9 siGENOME SMARTpool 
SH-SY5Y 
 
0.1 nM Dharmacon 
HEK293 10 nM Dharmacon ADAM10 
SH-SY5Y 0.1 nM Dharmacon 
 
siGENOME SMARTpool 
Differentiated SH-SY5Y 
 
10 nM Dharmacon 
siGENOME SMARTpool HEK293 10 nM Dharmacon ADAM17 
siGENOME on-target plus SH-SY5Y 
 
0.5 nM Dharmacon 
MMP14 siGENOME SMARTpool SH-SY5Y 
 
10 nM Dharmacon 
BACE1 Qiagen pool Differentiated SH-SY5Y 10 nM Qiagen 
 
Gene transient knockdown was achieved by siRNA interference. For each well to be 
transfected, RNAi duplex-lipofectamine RNAiMAX complexes were prepared according 
to the following recipe (Table 12): siRNA was diluted in Opti-MEM Medium without 
serum and mixed gently. Lipofectamine RNAiMAX was added into diluted siRNA 
solutions and mixed gently. The mixture was then added into the wells and incubated for 
10-20 min at RT. In siRNA interference, the complexes are prepared before cells and 
medium were added. 
 
Table 12 siRNA interference transfection mix preparation. 
Culture vessel 
Relative 
surface area 
Volume of 
plating 
medium 
Dilution 
medium 
siRNA (nM) 
Liofectamine 
RNAiMAX 
96-well 0.2 100 μl 20 μl 0.1-50 0.1-0.3 μl 
48-well 0.4 200 μl 40 μl 0.1-50 0.2-0.6 μl 
24-well 1 500 μl 100 μl 0.1-50 0.5-1.5 μl 
6-well 5 2.5 ml 500 μl 0.1-50 2.5-7.5 μl 
60 mm 10 5 ml 1 ml 0.1-50 5-15 μl 
100 mm 30 10 ml 2 ml 0.1-50 15-35 μl 
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Appropriate number of cells was diluted in medium without antibiotics which gave 30-
50% confluence 24 h after plating. The cell solution was added into each well and mixed 
gently by rocking the plate back and forth. Cells were incubated for 24-72 h at 37 ○C in a 
CO2 incubator until they were ready to assay for gene knockdown. 
 
3.3.4.5 SH-SY5Y cells neuronal differentiation 
To neuronally differentiate SH-SY5Y cells, naive cells were seeded in 75 cm2-flask with 
40% cell density in DMEM/F12 + 15% FCS + NEAA + P/S medium. 24 h later, medium 
was change with 25 μM ATRA in DMEM/F12 + 3% FCS + P/S. 72 h later, cells 
differentiated into neuronal like cells. Cells were digested up with trypsin-EDTA and 
seeded out for experiments. 
 
3.3.4.6 Generation of hAPP overexpressing cell lines 
APP overexpressing SH-SY5Y and HEK293 cell lines were generated by DNA 
transfection. Before transfection, P12-Hygro-hAPP cDNA plasmid was linearized by 
single restriction enzyme digestion; linearized cDNA was transfected into cells by 
lipofectamine 2000. APP Overexpressing cells were selected by cell culture medium with 
specific antibiotics (hygromycin). Then cells were kept in culture with antibiotics, and 
very low density of cell solution was seeded into 96-well plate. There were only one or 
two cells in each well. Single cell clones were picked up and cells were spreaded in larger 
culture format. Cell lysate from each single cell clone was collected and APP expression 
level was detected to finally select the hAPP highly expressed cell lines. 
 
3.3.4.7 Generation of gene stable knockdown cell lines 
ADAM10 stable knockdown SH-SY5Y and HEK293 cells and BACE1 stable 
knockdown HEK293 cells were generated by shRNA viral transduction. The following 
shRNAs were used in the thesis (Table13). The table lists the sequences and sources of 
the shRNA. They were cloned into different vectors for viral transduction (see details in 
Table 6). 
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Table 13 shRNA used in the thesis. 
Name shRNA sequence 
Con. 5’-CCCCcaacaagatgaagagcaccaaTTCAAGAGAttggtgctcttcatcttgttgTTTTTGGAAA-3’ 
ADAM10-sh6 
5’-
CCCCaagttgcctcctcctaaaccactTTCAAGAGAgtggtttaggaggaggcaacttTTTTTGGAAA-3’ 
ADAM10-sh7 5’-CCCCgacatttcaacctacgaatttTTCAAGAGAaaattcgtaggttgaaatgtcTTTTTGGAAA-3’ 
ADAM10-sh9 5’-CCCCggacaaacttaacaacaatTTCAAGAGAattgttgttaagtttgtccTTTTTGGAAA-3’ 
BACE1-sh1 5’-CCCCggtacaaagactgcgtcttgattcaagagatcaagacgcagtctttgtaccTTTTTGGAAA-3’ 
BACE1-sh2 5’-CCCCgcgtgacagaacagagaaatcttcaagagagatttctctgttctgtcacgcTTTTTGGAAA-3’ 
 
For virus production, transfection reaction mixture was prepared according to the 
following recipe:  
For 6-well plate format (for each well):  
250 μl Opti-MEM + 6.3 μl lipofectamine 2000, RT/5 min;  
250 μl Opti-MEM + 1.3 μg transfer vector (PLVTHM, PLKO) + 0.75 μg sPAX2 + 0.45 
μg pcDNA3.1-Delta.Zeo (-)-VSV-G.  
The combination of both parts was mixed. 500 μl mixture was added into each well, 
RT/20 min.  
1.5 ml, 8*105/ml HEK293T/low passage cells were seeded in each well in Opti-MEM + 
10% FCS.  
24 h later, medium was changed by 2 ml packaging medium: DMEM High Glucose + 
Pyruvat + NEAA + 10% FCS.  
24 h later, the viral transduction was performed. Viral supernatant was filtered through 
0.45 μm filter from VWR directly into a 6-well plate with about 0.5-1*106 targeting cells. 
24 h after the viral transduction, 2 ml fresh normal medium was changed each well. Cells 
were kept into culture. Stable knockdown cells then seeded in 6-cm dishes and 
conditioned medium was collected for analysis.  
 
3.3.4.8 Cell lines freezing 
To freeze the cell lines, cells were washed after reaching 70-80% confluence with 2 ml 
sterile PBS and detached by 2 ml of PBS-EDTA (PBS with 25 M EDTA) or trypsin-
EDTA solution. Cells were resuspended with 3 ml fresh medium and centrifuged down at 
1000 rpm/5 min. Subsequently, cell pellets were resuspended in 1 ml freezing medium 
(FCS with 10% DMSO) and added into the freezing tubes. The cells were frozen at -80 
○C and transferred for long-term storage in liquid nitrogen. 
Materials and methods 
50 
 
3.3.4.9 Cells treatments with chemical compounds 
For pharmacological activation or inhibition of either α-secretase or β-secretase cleavage 
of APP, cells were treated with TAPI, PMA or C3 respectively. For HEK293 cells, cells 
were seeded in 6-well plates with 2*105/ml density, 1.5 ml/well in DMEM + 10% + P/S; 
for differentiated SHSY5Y cells, cells were seeded in 6-cm dishes with 4.5*105/ml 
density, 3 ml/dish in DMEM/F12 + 15% FCS + NEAA + P/S, followed by compounds 
treatment 24 h later. TAPI was added to the fresh cell culture medium at 50 μM 
concentration, 2 ml/dish with DMSO as the control; samples were collected 24 h later. 
PMA was added to the fresh cell culture medium at 1 μM concentration, 2 ml/dish with 
ethanol as the control; samples were collected 4 h later. C3 was added to the fresh cell 
culture medium at 2 μM concentration, 1 ml/dish with DMSO as the control for 2 h; 
medium was then changed by 2 ml fresh medium with 1 μM C3 each well; samples were 
collected 24 h later. For γ-secretase inhibition and APP CTFs detection, cells were treated 
with DAPT. Control or ADAM10 shRNA tranduced SH-SY5Y cells were seeded in 6-cm 
dishes with 3*105/ml density, 3 ml/well in DMEM/F12 + 15% FCS + P/S. Cells were 
treated with DAPT (1 μM) for 24 h, then supernatant and cell lysate were collected. 
 
3.4 Protein biochemical experiments  
 
3.4.1 Equipments and consumables 
Equipments/consumables Manufacturers 
Aβ peptides 3-plex ELISA plates MSD 
Blotter criterion Bio-Rad 
Cell Lifter Corning 
Cooling centrifuge 5417R Eppendorf 
Film processor 2000 IR  CAWO 
Heating block MR Hei-Tec Heidolph instrument 
Gel Transfer filter paper  Schleicher & Schuell 
Glass plates Bio-Rad 
Immobilon-P membrane, PVDF, 0.45 μM Millipore 
Microplate (96-well, transparent)  Nunc 
Mini-PROTEAN 3 Electrophoresis cell Bio-Rad 
Mini-PROTEAN Tetra cell Bio-Rad 
Mini Trans-Blot Transfer  Cell Bio-Rad 
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Equipments/consumables Manufacturers 
Nitrocellulose membrane (Protran)  Schleicher & Schuell 
Powerpac basic power supply Bio-Rad 
Power pac HC Bio-Rad 
PowerWave microplate spectrophotometer BioTek 
sAPPα+sAPPβ ELISA plate MSD 
Scanner scanjet 5590P HP 
Sector imager  Meso Scale Discovery 
Shaker 3015 GFL 
Shaker KM-2 Edmund Buehler 
X-ray films (SuperRX)  Fujifilm 
 
3.4.2 Reagents 
Reagents Manufacturers 
Acrylamid (Tris-Tricine gels)  Biomol 
Acrylamid solution (37.5:1 / 40 % (w/v))  Serva 
Ammonium persulfate (APS)  Roche 
BCA Assay protein quantitation Kit  Uptima, Interchim 
Bovine serum albumin (BSA)  Uptima, Interchim 
β-Mercaptoethanol (β-ME) Merck 
ECL Western blotting detection system  Amersham Biosciences 
ECL Plus Western blotting detection system Amersham Biosciences 
E. O. S. Developer AGFA 
E. O. S. Fixer AGFA 
Glycine  Biomol 
I-block  Tropix 
Isopropanol Merck 
MSD read buffer T Meso Scale Discovery (MSD) 
N-N’-Methylene-bisacrylamide (bisacrylamide) Serva 
Nonidet P-40 (NP-40) Sigma 
Protein A sepharose (PAS)  Sigma 
Protease inhibitor (PI)  Sigma 
Sodium dodecyl sulfate (SDS)  Calbiochem 
SeeBlue plus 2 pre-stained standard Invitrogen 
Skimmed milk powder (instant)  Frema 
TEMED (N,N,N',N'-Tetramethylethylendiamine)  Merck 
Tricine  Biomol 
Tween-20  Merck 
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3.4.3 Buffers 
Buffers Recipes 
10 * anode buffer 
(Tris-tricine gel) 
1 M Tris-HCl (242.2 g) pH 8.9 
add ddH2O to 1 L 
 
10 * cathode buffer 
(Tris-tricine gel) 
0.1 M Tris-HCl (121.1 g) 
0.1 M tricine (179.2 g) 
add ddH2O to 1 L 
10% SDS was added in working solution 
 
4* SDS-probe buffer 
 
4 ml 20% glycerin 
4 ml 20% SDS 
1 ml β-ME 
1.25 ml 1 M Tris pH 6.8 
10 μl 10% Bromphenol blue 
 
10* TBS 
 
24.23 g Tris 
80 g NaCl 
add H2O to 1 L,  
pH was adjusted to 7.4 
 
Acrylamid solution 
(49.5% total, 3% crosslinker) 
(Tris-Tricine gel) 
48 g acrylamide 
1.5 g bisacrylamide 
add ddH2O to 100 ml, 4 
○C store 
 
Blocking buffer (ELISA) 1% BSA in TBS-T 
 
Blocking solution 
(Western blotting) 
5% skimmed milk powder or 0.8 g I-block in PBS-T 
(PBS with 0.5% Tween20) 
 
Gel buffer 
(Tris-tricine gel) 
3 M Tris-HCl (182 g) 
dissolved in 300 ml ddH2O and adjust pH to 8.45 
0.3% SDS (1.5 g) 
add ddH2O to 500 ml, 4 
○C store 
 
Hypotonic buffer: 
 
10 nM Tris pH 7.4 
1 mM EDTA 
1 mML EGTA 
 
Low Tris buffer 0.4% SDS in ddH2O 
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Buffers Recipes 
Primary antibody solution 
(western blotting) 
 
Antibodies with appropriate concentration (see 
details in Table 16) 
0.25% BSA 
0.05% sodium azide 
in PBS-T 
 
SDS-PAGE electrophoresis buffer 
 
25 mM Tris 
0.2 M glycine 
0.1% SDS 
 
Secondary antibody solution 
(western blotting) 
Antibodies with appropriate concentration (see 
details in Table 17) 
0.25% BSA 
in PBS-T 
 
Solubilization buffer 
 
50*10-3 M Tris (pH 7.5) 
150*10-3 M NaCl 
1% NP-40 
 
STEN buffer 
 
0.05 M Tris-HCl pH 7.6 
0.15 M NaCl 
2 mM EDTA 
0.2% NP-40 
 
STEN-NaCl STEN-buffer with 175 mM NaCl 
 
STEN-SDS STEN-buffer with 0.1% SDS 
 
Transfer buffer 
 
25 mM Tris 
0.2 M glycine 
 
Upper Tris buffer 0.5 M Tris-HCl pH 6.8 
0.4% SDS in ddH2O 
 
3.4.4 Methods 
 
3.4.4.1 Cell lysate preparation 
Cells in the plate were taken out from the incubator and put on the ice. Cells were washed 
with PBS in the plate. And then PBS was carefully removed. Lysis buffer (Solubilization 
buffer:PI 1:500 mixture) was added directly into the well and the plate was incubated on 
ice for 10 min. Cell lysates were piptteted up and down several times. Then cell 
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suspension was transferred to a tube and incubated for another 10 min on ice. The lysis 
solution was centrifuged at 13,000 rpm/4 ○C/5 min. Cell lyates were stocked at -20 ○C. 
 
3.4.4.2 Membrane preparation 
For 6-well plate format, supernatants were collected and cells were washed with 1 
ml/well PBS. PBS was carefully removed and discarded. Cells were scraped up in 750 μl 
PBS to tubes (2 wells for 1 sample). 1/3 of cell suspension was taken out to make the cell 
lysate and protein concentration measurement. The rest of cell suspension was spinned 
down and the supernatant was discarded. Cells were resuspended by 800 μl hypotonic 
buffer with 1:500 PI and incubated on ice for 10 min. The lysis was pipetted up and down 
for 15 times with 1 ml syringe and 0.6 mm syringe tip. The lysis was spinned down at 
3200 rpm/4 ○C/15 min to pellet nuclei and cytoskeleton. 750 μl supernatant was 
transferred to a new tube and membranes were pelleted at 13,000 rpm/4 ○C/30 min. 
Supernatants were discarded and the pellets were resuspended with sample buffer and 
boiled at 900 rpm/95 ○C/5 min. 
 
3.4.4.3 Protein concentration measurement 
Protein lysates were measured in duplicate in a 96-well plates with 10 μl per well. BCA 
reagent B:A were 1:50 diluted and add 200 μl of the mixture into every well. The mixture 
was incubated it at 37 ○C/30 min. The determination of extinction was taken place 
photometrically at 562 nm after extrapolation of the curve. 
 
3.4.4.4 Immunoprecipitation (IP) 
Aim proteins were concentrated by immunoprecipitation (IP). For IP, 25 μl PAS solution 
was incubated with specific antibodies in 500 μl PBS at 4 ○C for 30 min. The antibodies 
used in the thesis for IP, together with their epitopes, species, dilutions and sources were 
listed in the following table (Table 14).  
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Table 14 Antibodies used for immunoprecipitation (IP) in thesis. 
Antibodies Epitopes Species Dilutions Sources 
5313 APP ectodomain mouse 1:150 Eurogentec 
6687 APP C-terminal rabbit 1:100 Eurogentec 
BAWT 8C10 sAPP　 mouse 1:10 Dr. E. Kremmer 
3552  APP ectodomain mouse 1:400 Eurogentec 
 
The mixture was centrifuged at 4 ○C/8000 rpm/1 min. The PAS pellet was then washed 
with 1 ml PBS-T (PBS with 0.5% Tween20). 500 μl sample supernatant was added into 
each tube and incubated on the shaker at 4 ○C/2 h. The mixture was centrifuged at 4 
○C/8000 rpm/1 min. The PAS pellet was then washed with 1 ml STEN-NaCl, STEN-SDS 
and STEN respectively. Sample buffer (30 μl) was then added onto the precipitation and 
boiled at 95 ○C/5 min. 
 
3.4.4.5 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins according to their molecular size were separated by a one-dimensional 
electrophoresis separation under denatured conditions. The mini-gel system of Bio-Rad 
was used For the SDS-PAGE, which has a collection gel of about 1 cm and a separation 
gel of about 7 cm. There were only gels with 15 samples with a pocket comb thickness of 
1.5 mm. Before using, the glass was cleaned by 70% ethanol and then added the 
resolving gel to a height of about 2 cm below the upper edge. Isopropanol was casted 
above. After the polymerization (about 15 min), the isopropanol was discarded and the 
separator was dried with absorbent paper, then the stacking gel was located above the 
area with a comb inserted. After the completely polymerization of electrophoresis gels 
(approximately 15-20 min), the comb was carefully removed and the gels can be moved 
to the electrophoresis chamber. The detail information about the gel preparation is listed 
in the following table (Table 15). 
 
 
 
 
 
 
 
Materials and methods 
56 
Table 15 Resolving and stacking gels preparation (for two gels). 
Resolving 
 4% 8% 10% 12% 15% 
stacking 
H2O 9.8 ml 7.8 ml 6.66 ml 6.0 ml 4.0 ml 3.25 ml 
30% Acrylamid 2.2 ml 4.2 ml 5.33 ml 6.0 ml 8.0 ml 0.65 ml 
Low Tris 4.0 ml 4.0 ml 4.0 ml 4.0 ml 4.0 ml 1.25 ml (Upper Tris) 
TEMED 30 μl 30 μl 30 μl 30 μl 30 μl 30 μl 
10% APS 60 μl 60 μl 60 μl 60 μl 60 μl 60 μl 
 
The running buffer was filled, so the pockets of the gels were rinsed several times. After 
comparing the protein concentrations, protein extracts were mixed with loading buffer, 
cooked 5 min at 95 ○C and applied on the gels. 7 μl “Blue Lake plus 2” was loaded as the 
molecular weight standard. The stacking was carried out by 90 V initially and after the 
entry of proteins into the separator, the voltage was increased to 140 V.  
 
For Tris-tricine gels, gels were prepared according to the recipe shown in Table 16. Gels 
were charged with separate cathode/anode buffer at 80 V first, and at 120 V later. 
 
Table 16 Tris-tricine gels preparation (for two gels). 
 16.5% separating gel 10% spacer gel 4% stacking gel 
Acrylamid (49.5%) 
Gelbuffer 
Water 
32% glycerol 
3.5 ml 
3.5 ml 
 
3.5 ml 
1.5 ml 
2.5 ml 
3.5 ml 
0.5 ml 
1.55 ml 
4.2 ml 
10% APS 
TEMED 
32.5 μl 
3.25 μl 
35 μl 
4 μl 
25 μl 
5 μl 
For one gel 5 ml 2.5 ml 2 ml 
 
3.4.4.6 Western-blot 
Transfer: 
After separation, proteins were transferred to a PVDF membrane or nitrocellulose 
membranes in a transfer chamber. Before the transfer, the membranes are activated by 
isopropanol incubation for 10 s. After activation, the membrane was briefly washed with 
deionized water and rinsed in transfer buffer to be equilibrated. For the transfer the Bio-
rad mini-gel-transfer system was used. The transfer took place at a constant flow of 400 
mA for 65 min at RT.  
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Transfer structure:  
• cathode plate (black) 
• porous sponge in transfer buffer 
• two layers of gel blotting paper in transfer buffer  
• SDS-polyacrylamide gel 
• PVDF membrane with isopropanol and activated in transfer buffer 
• two layers of gel blotting paper in transfer buffer 
• porous sponge with transfer buffer 
• anode plate (transparent) 
 
Blotting 
After the transfer, nonspecific protein binding sites on the PVDF membrane were 
saturated 30 min at RT in blocking solution. The membrane was then washed and 2 * 5 
min with PBS-T (PBS with 0.5% Tween20) on the shaker. Subsequently, the membrane 
was incubated with the primary antibodies for 1 h at RT or overnight at 4 ○C on the 
shaker. The primary antibodies used in the thesis, together with their epitopes, species, 
dilutions and sources are listed in the following table (Table 17).  
 
Table 17 Primary antibodies used for western blot in the thesis. 
Antibodies Epitopes Species Dilutions Sources 
ADAM9 Human ADAM9 C-terminus Rabbit 1:1000 Cell Signaling 
ADAM10 Human ADAM10 C-terminus rabbit 1:10000 Cell signaling 
ADAM17 Human ADAM17 C-terminus rabbit 1:1000 Oncogene 
MMP14 Human MMP14 C-terminus  rabbit 1:1000 Abcam 
BACE1 Human BACE1 mouse 1:2000 Dr. B. Vassar 
2C11 APP C-terminus mouse 1:10 Dr. E. Kremmer 
calnexin Calnexin rabbit 1:2000 Sigma 
β-actin β -actin mouse 1:5000 Sigma 
22C11 APP N-terminus mouse 1:200 Dr. K. Beyreuther 
WO2 Human sAPPα+sAPPβ’ mouse 1:1000 Dr. K. Beyreuther 
4B4 Human sAPPα Rat 1:10 Dr. E. Kremmer 
14D6 Human sAPPα Rat 1:10 Dr. E. Kremmer 
192wt sAPPβ Rabbit 1 μg/ml Dr. D. Schenk 
2D8 Aβ Rat 1 μg/ml Dr. E. Kremmer 
6687 APP C-terminus rabbit 1 μg/ml Dr. C. Haass 
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It was followed by a washing of the membrane for 3 * 10 min with PBS-T. The 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies were then 
incubated for 45 min at RT on the PVDF membrane. The secondary antibodies used in 
the thesis, together with their epitopes, species, dilutions and sources are listed in the 
following table (Table 18). 
 
Table 18 Secondary antibodies used for western blot in the thesis. 
antibodies  epitopes  Species  dilutions  Source  
mouse-HRP  mouse IgG  goat 1:10000  Promega  
rabbit-HRP  rabbit IgG  goat 1:10000  Promega  
rat-HRP  rat IgG  goat 1:5000  Santa Cruz 
 
Finally, the membranes were again four times per 5 min with PBS-T buffer washed. The 
detection of antibodies coupled with the proteins were carried out and developed by using 
X-ray films. For detection of weak signals, ECL plus western blotting detection system 
was used. 
 
3.4.4.7 Enzyme-linked immunosorbent assay (ELISA) 
Aβ or sAPPβ levels from cell supernatant of some experiments were measured by Aβ or 
sAPPα+β ELISA. For Aβ detection, Aβ triplicate plate was incubated with blocking 
buffer at 4 ○C overnight on a horizontal shaker. The plate was washed with TBS-T (TBS 
with 0.5% Tween20) for three times. And then 25 μl samples were added into each well. 
On top of that, another 25 μl human Aβ 6E10 antibody (1:50 dilution in blocking buffer) 
was added. The plate was incubated at RT on a horizontal shaker for 2 h. The plate was 
washed with TBS-T for three times. 150 μl reading buffer T (1:2 dilution in H2O) was 
added into each well, being very careful to avoid bubbles and incubated for 10 min at RT. 
The signals were measured on Sector Imager. 
 
For sAPPβ detection, sAPPα+β triplicate plate was incubated with blocking buffer at 4 
○C overnight on a horizontal shaker. The plate was washed with TBS-T (TBS with 0.5% 
Tween20) for three times. And then 25 μl samples were added into each well. The plate 
was incubated at RT on a horizontal shaker for 1 h. The plate was washed with TBS-T 
and then 25 μl sAPPα+β antibody (1:50 dilution in blocking buffer) was added each well. 
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The plate was incubated at RT on a horizontal shaker for 1 h. The plate was washed with 
TBS-T for three times. 150 μl reading buffer T (1:2 dilution in H2O) was added each well, 
being very careful to avoid bubbles and incubated for 10 min at RT. The signals were 
measured on Sector Imager. 
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4 Results 
 
4.1 Antibody characterization 
Antibodies for sAPPα detection in previous work were typically WO2 and 6E10 which 
recognize the epitope between the β- and β’- cleavage site. That means those antibodies 
did not specially detect sAPPα, but also sAPPβ’. To specifically detect the APP α-
secretase cleavage product sAPPα, two new monoclonal antibodies 4B4 and 14D6 were 
generated and used in this thesis, which was against a peptide comprising amino acids 
11-16 of the Aβ sequence. 
 
To examine the detection specificity of the antibody, cDNAs of full-length APP, sAPPβ, 
sAPPβ’, sAPPα ending after amino acid 16 of Aβ, together with truncated sAPPα that 
ends at the 14th, 15th amino acid of Aβ domain were cloned. cDNAs of different APP 
fragments were transfected to human embryonic kidney 293 (HEK293) cells. Samples 
were collected and detected by different antibodies. Western blot results showed that 4B4 
antibody detected sAPPα and the sAPPα truncated by one amino acid (sAPP15) (Figure 7 
B). And indeed, it did not detect full-length APP in the cell lysate. Conditioned medium 
blotting also showed that 22C11 detected all species since it binds to the N-terminus of 
APP, WO2 detected sAPPα and β’ since the epitope was between β- and β’-site. 4B4 
antibody detected only sAPPα, and even, only the sAPPα fragments that ended longer 
than the 15th amino acid which implied that Gln (glutamine) is necessary for the antibody 
epitope recognition and it does not detect sAPPβ’.  
 
To further test antibody 4B4, whether under the conditions, which increase or decrease 
sAPPα generation, would lead to a corresponding change in the 4B4 signal was examed. 
HEK293 cells were treated with the metalloprotease inhibitor TAPI-1 to reduce APP 
shedding or with PMA to increase APP shedding (Figure 7 C). TAPI-1 inhibited almost 
completely sAPPα generation by 4B4 detectionn. In contrast, total sAPP shedding was 
not as strongly reduced by 22C11 detection, consistent with the fact that this antibody 
detects all sAPP species. PMA strongly up-regulsted total APP shedding, but the extent 
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of the increase of sAPP by 4B4 detection was much more pronounced. Antibody W02, 
which detects the combined signal of sAPPα and sAPPβ’, detected intermediate changes 
between 22C11 and 4B4. The other antibody 14D6 was also validated specific as sAPPα 
antibody (data not shown). Taken together, these experiments show that antibody 4B4 
and 14D6 specifically detect sAPPα, not any other soluble APP fragments, in contrast to 
other commonly used APP antibodies. In the following experiments, sAPPα detections 
were all accomplished by these two antibodies ensuring the specificity of sAPPα signals. 
Figure 7 
Characterization of 
newly generated 
sAPPα-specific 
antibody 4B4. 
A) The exact APP 
cleavage site of α-, β- 
and γ-secretases. β- and 
γ-secretase cleavage 
generate the Aβ peptide, 
while α-secretase α 
cleaving site and β-
secretase β’ cleaving are 
located inside the Aβ 
domain. 22C11 and 
2C11 recognize the N- 
and C-terminal of APP 
respectively. WO2 and 
6E10 recognize the 
epitope between α- and 
β’-cleavage site, which 
means they detect both 
sAPPα and sAPPβ’. 4B4 
and 14D6 recognize 11-
15th amino acid of Aβ 
domain which detect 
specifically sAPPα. 
B) Full-length APP, 
sAPPα, sAPP15, sAPP14, 
sAPPβ’ and sAPPβ were 
transfected into HEK293 
cells. Conditioned 
medium was collected to 
test different antibodies. 
Antibody 22C11 detects 
all secreted APP species, antibody W02 detects sAPPα+β’, whereas antibody 4B4 specifically detect 
sAPPα and sAPP15. 
(C) HEK293 cells were treated with TAPI-1 (50 μM, 24 h) or PMA (1 μM, 4 h). Immunoblots of 
conditioned media and cell lysates were probed with antibody 22C11 (total sAPP), W02 (sAPPα+β’) and 
the sAPPα-specific antibody 4B4. Cellular APP is present in a lower molecular weight immature form and 
a higher molecular weight mature form and was detected with 22C11. The β-actin blot serves as a loading 
control. The reduction by TAPI-1 and the increase in shedding by PMA are more pronounced when 
analysed with the α-cleavage-specific antibody 4B4, compared with the other antibodies. 
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4.2 Transient knockdown of ADAM10 in wild type cells 
suppressed sAPPα generation 
 
4.2.1 ADAM9, 10, 17 and MMP14 knockdowns in SHSY5Y cells 
To identify the physiologically relevant α-secretase, the candidate α-secretase ADAM9, 
10, 17 and MMP14 were knocked down by siRNA transfection in neuroblastoma SH-
SY5Y cells. Cell toxicity was observed obvious initially when 50 nM concentration of 
siRNA was used, especially upon ADAM17 siRNA transfection. However, the toxic 
effect was abolished when lower concentration of siRNA was used. At the low 
concentration of siRNA pools, a good knockdown efficiency (~75% - 90%) was achieved 
for ADAM9, 10, 17 and MMP14 (Figure 8 A, C). Levels of cellular APP as well as of the 
control membrane protein calnexin were not affected. Among these knockdown 
experiments, only when ADAM10 was knocked down, a reduction of sAPPα generation 
was observed (to ~10%), which was consistent with the remaining expression level of 
ADAM10. The other APP cleavage fragments were also analyzed. The total sAPP 
detected by 22C11 decreased to 40% upon ADAM10 knockdown, while the combination 
of sAPPα+β’ detected by WO2 decreased to 20%. When ADAM10 was knocked down, 
the expression levels of other ADAM proteases did not have a major change, implying 
that they did not compensate for the loss of ADAM10 (Figure 8 B). ADAM9, 17 and 
MMP14 knockdowns led to only mild changes in all APP cleavage fragments. There 
might be some reduction of sAPPα generation upon ADAM9, 17 and MMP14 siRNA 
transfection, but it was only a trend and not statistically different compared to control 
siRNA. The results indicated that the ADAM10 was the only protease that was required 
for APP α-secretase cleavage under physiological condition in SH-SY5Y cells. 
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Figure 8 Transient knockdown of 
ADAM10 suppresses α-secretase 
cleavage of endogenous APP in SH-
SY5Y cells. 
A) SH-SY5Y cells were transfected 
with siGENOME siRNA pools directed 
against the proteases ADAM9, 10 or 17 
or with control siRNA (labeled as C, A9 
KD, A10 KD or A17 KD). All three 
proteases were detected by western blot 
in membrane preparations. The mature 
form of ADAM9, 10 and 17 are 
indicated by arrows. Calnexin served as 
a loading control. Cell lysates were 
analysed for cellular APP and 
conditioned media for total sAPP 
(22C11), sAPPα+β’ (W02) and sAPPα 
(4B4). sAPPα signal was detected by 
500 μl supernatant IP with 5313 and 
blotting with 4B4. The bar charts were 
the quantification of western blot 
signals. ADAMs expression levels were 
normalized to the calnexin signal. sAPP 
fragments levels were normalized to 
cellular APP signal. (n =10, * p ‹ 0.05) 
B) Knockdown of either ADAM9, 10 or 
17 does not alter the protein levels of 
immature and mature forms of the other 
proteases. Membrane preparations of 
SH-SY5Y cells either treated with 
siRNA pools against ADAM9, 10, 17 or 
a control siRNA pool were probed for 
ADAM9, 10 and 17. As loading control 
membranes were analyzed for calnexin. 
C) SH-SY5Y cells were transfected 
with siGENOME siRNA pools directed 
against MMP14 or with control siRNA (labeled as C or MMP14 KD). MMP14 expression level was 
detected by western blot by lysate preparations. Calnexin was detected as a loading control. Cell lysates 
were analyzed for cellular APP and conditioned media for total sAPP (22C11), sAPPα+β’ (W02) and 
sAPPα (14D6). The bar charts were the quantification of western blot signals. MMP14 expression level was 
normalized to the calnexin signal. sAPP fragments levels were normalized to cellular APP signal. (n = 4, * 
p ‹ 0.05) 
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4.2.2 ADAM9, 10 and 17 knockdowns in HEK293 cells 
The same experiments were performed using HEK293 cells to further validate the 
constitutive α-secretase of APP in a second cell line. siRNA transfection showed less cell 
toxicity in HEK293 cells even at higher concentrations in comparison to SH-SY5Y cells. 
Nevertheless the results perfectly fit to what was observed in the previous cell line. 
ADAM10 knockdown led to the reduction of sAPPα signal to ~ 10%, but the other 
ADAMs did not, while MMP14 was not detectable in HEK293 cells (Figure 9). The total 
sAPP and sAPPα+β’ decreased to 60% and 40%, respectively (Figure 9). The results 
from HEK293 showed that ADAM10 is again the physiologically relevant constitutive α-
secretase of APP.  
Figure 9  
Transient knockdown of 
ADAM10 suppresses α-
secretase cleavage of 
endogenous APP in 
HEK293 cells. 
A) HEK293 cells were 
transfected with 
siGENOME siRNA pools 
directed against the 
proteases ADAM9, 10 or 
17 or with control siRNA 
(labeled as C, A9 KD, A10 
KD or A17 KD). All three 
proteases were detected by 
western blot in membrane 
preparations. The mature 
form of ADAM9, 10 and 
17 were indicated in the 
blot by arrows. Calnexin 
was detected as a loading 
control. Cell lysates were 
analyzed for cellular APP 
and conditioned media for 
total sAPP (22C11), 
sAPPα+β’ (W02) and 
sAPPα (4B4). sAPPα 
signal was detected by 500 
μl supernatant IP with 
5313 and blotting with 4B4.  
B) The bar charts were the 
quantification of western 
blot signals. ADAMs 
expression levels were 
normalized to the calnexin 
signal. sAPP fragments levels were normalized to cellular APP signal. (n =10, * p ‹ 0.05) 
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4.3 Transient knockdown of ADAM10 in APP overexpressing 
cells suppressed sAPPα generation 
 
4.3.1 ADAM10 knockdown in APP-SH-SY5Y 
Most previous studies about identification of APP α-secretase were performed using APP 
overexpressing cells due to the detection difficulty of endogenous APP. To further 
confirm that ADAM10 also the α-secretase of overexpressed APP, APP overexpressing 
cells were also used in the experiments. ADAM10 siRNA transfections were performed 
in stably APP overexpressing SH-SY5Y cells, followed by the APP shedding behavior 
analysis (Figure 10). The reduction was nearly as strong as in wild-type cells. Total sAPP, 
sAPPα+β’ and sAPPα decreased to ~40%, 35% and 30% respectively. The higher 
remaining sAPP fragments could be owing to such high expression level of APP that 
some other proteases had to participate in the APP cleavage. 
 
Figure 10 Transient knockdown of ADAM10 suppresses α-secretase cleavage of overexpressed APP 
in SH-SY5Y cells. 
APP-SH-SY5Y cells were transfected with siGENOME siRNA pools directed against ADAM10 or with 
control siRNA (labeled as C or A10 KD). ADAM10 was detected by western blot in membrane 
preparations. Calnexin was detected as a loading control. Cell lysates were analyzed for cellular APP and 
conditioned media for total sAPP (22C11), sAPPα+β’ (W02) and sAPPα (4B4). The bar charts were the 
quantification of western blotting signals. ADAM10 expression level was normalized to the calnexin signal. 
sAPP fragments levels were normalized to cellular APP signal. (n = 8, * p ‹ 0.05) 
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4.3.2 ADAM10 knockdown in APP-HEK293 cells 
ADAM10 was also knocked down in APP overexpressing HEK293 cells (Figure 11). The 
results were similar to the findings from APP-SH-SY5Y cells. ADAM10 knockdown led 
to the strong decrease of sAPPα signal to ~ 20%. However, the reduction of total sAPP 
was stronger than that of sAPPα+β’ signal. That could be due to the off-target effect from 
siRNA transfection on the APP expression vector or the promoter inside. That could also 
provide a clue for the explanation that in the previous research ADAM10 was not the 
only proteases contributed to the APP α-cleavage.  
 
Figure 11 Transient knockdown of ADAM10 suppresses α-secretase cleavage of overexpressed APP 
in HEK293 cells. 
APP-HEK293 cells were transfected with siGENOME siRNA pools directed against ADAM10 or with 
control siRNA (labeled as C or A10 KD). ADAM10 was detected by western blot in membrane 
preparations. Calnexin was detected as a loading control. Cell lysates were analyzed for cellular APP and 
conditioned media for total sAPP (22C11), sAPPα+β’ (W02) and sAPPα (4B4). The bar charts were the 
quantification of western blot signals. ADAM10 expression level was normalized to the calnexin signal. 
sAPP fragments levels were normalized to cellular APP signal. (n = 8, * p ‹ 0.05) 
 
4.4 Stable knockdown of ADAM10 in wild type cells 
suppressed sAPPα generation 
To further validate the results from the transient knockdown of ADAM10, HEK293 cells 
with a stable knockdown of ADAM10 were generated using lentiviruses expressing two 
different shRNA sequences against ADAM10 or a negative control shRNA. It provided 
the evidence that in the long time period of loss of function of ADAM10, no other 
proteases could compensate for it and play the role of APP α-secretase. Similar to the 
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results from the transient ADAM10 knockdown, sAPPα decreased when ADAM10 was 
knocked down in HEK293 cells (Figure 12). In both shRNA transduced HEK293 cells, 
total sAPP, sAPPα+β’, and sAPPα decreased to ~50%, ~40%, and ~15%; while sAPP  　
and even Aβ level did not have major change due to ADAM10 knockdown compared to 
the control. sh7 shRNA performed more potent than sh9, represented by the ADAM 
expression level together with the corresponding sAPPα signal reduction. Quantification 
from the blots fit nicely with that of results from transient ADAM10 siRNA transfection. 
The similar results were obtained from SH-SY5Y cells transduced with the same shRNAs 
(data not shown). Results from ADAM10 transient knockdown and stable knockdown 
cells demonstrated that no other α-secretase candidates could compensate for the loss of 
ADAM10 either in short time or after long time culture period. 
Figure 12  
Suppressed α-
secretase cleavage of 
endogenous APP in 
ADAM10 stable 
knockdown HEK293 
cells. 
ADAM10 stable 
knockdown HEK293 
cells were generated 
by shRNA viral 
transduction using 
two distinct shRNAs. 
In shRNA 7 and 9 
transduced HEK293 
cells (labeled as C, 
sh7 or sh9), ADAM10 
was detected by 
membrane preparation. 
Calnexin was detected 
as a loading control. 
Cell lysates were 
analyzed for cellular 
APP and conditioned 
media for total sAPP 
(22C11), sAPPα+β’ 
(WO2), sAPPα (4B4), 
sAPPβ (192wt) and 
Aβ (2D8). sAPPα 
signal was detected by 
500 μl supernatant IP 
with 5313 and blotting 
with 4B4. sAPPβ signal was detected by 500 μl supernatant IP with BAWT 8C10 and blotting with 192wt. 
Aβ signal was detected by 500 μl supernatant IP with 3552 and blotting with 2D8. The bar charts were the 
quantification of western blot signals. ADAM10 expression level was normalized to the calnexin signal. 
sAPP fragments levels were normalized to cellular APP signal. (n = 6, * p ‹ 0.05) 
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4.5 ADAM10 knockdown in neuron-like cells suppressed sAPPα 
generation 
In order to create a more neuronal like cellular condition and to verify the APP α-
secretase in such a condition, SH-SY5Y cells were treated with all-trans retinoic acid 
(ATRA) in serum-free medium for 3 d and thereby differentiated into neuronal like cells. 
The western blot results showed that ATRA treatment and SH-SY5Y differentiation led 
to a mild increase in ADAM10 level, however, was not significant, together with the full 
length APP expression level (Figure 13 A). The APP shedding behavior of differentiated 
cells was not dramatically affected; secreted APP fragments, including total sAPP, 
sAPPα+β’, sAPPα and sAPPβ, retained the similar level as the naive SH-SY5Y cells 
(Figure 13 A). To characterize shedding of APP in differentiated SH-SY5Y cells, siRNA 
transfections were performed (Figure 13 B). Upon the siRNA treatment, ADAM10 level 
in differentiated SH-SY5Y cells decreased to a very low level (to ~ 13%), together with 
the secreted APP α-cleavage fragment signals (to ~18%), similar to the results obtained in 
SH-SY5Y and HEK293 cells. Total sAPP and sAPPα+β’ signal decreased as well but not 
as strong as sAPPα. Total sAPP decreased to ~50%, like the wide type SH-SY5Y cells 
upon ADAM10 siRNA transfection, consistent with the fact that SH-SY5Y cell 
differentiation did not affect the APP cleavage pattern. It implied that in the more 
neuronal like differentiated SH-SY5Y cells, ADAM10 played the major role of APP α-
secretase as well.  
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Figure 13  
Transient knockdown of 
ADAM10 suppressed α-
secretase cleavage of 
endogenous APP in 
neuron-like 
differentiated SH-SY5Y 
cells. 
A) SH-SY5Y cells were 
treated with 25 μM 
ATRA in serum-free 
medium for 3 d to trigger 
the differentiation. 24 h 
conditioned medium was 
collected and western blot 
analysis was performed. 
ADAM10 was detected 
by membrane preparation. 
Total sAPP, sAPPα+β’ 
and sAPPα signals were 
detected by 22C11, WO2 
and 14D6 respectively. 
sAPPβ signal was 
detected by 500 μl 
supernatant IP with 
BAWT 8C10 and blotting 
by 192wt. Cellular APP 
was detected by lysate 
samples with 2C11. 
Calnexin was detected as 
a loading control. The bar 
charts were the 
quantification of western 
blot signals. ADAM10 
expression level was 
normalized to the 
calnexin signal. sAPP 
fragments levels were 
normalized to cellular 
APP signal. (n = 4, * p ‹ 
0.05) 
B) Differentiated SH-
SY5Y cells were 
transfected with 
siGENOME siRNA pools 
directed against 
ADAM10 or with control 
siRNA (labeled as C or 
A10 KD). ADAM10 was 
detected by western blot 
in membrane preparations. Calnexin was detected as a loading control. Cell lysates were analyzed for 
cellular APP and conditioned media for total sAPP (22C11), sAPPα+β’ (W02), sAPPα (14D6) and sAPPβ 
(192wt). sAPPβ signal was detected by 500 μl supernatant IP with BAWT 8C10 and blotting by 192wt. Aβ 
spices were detected by Aβ triplicate ELISA. The bar charts were the quantification of western blot signals. 
ADAM10 expression level, cellular APP levels and sAPP fragments levels were normalized to the calnexin 
signal. (n = 8, * p ‹ 0.05) 
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4.6 ADAM10 is also APP α-secretase in serum-free medium 
 
4.6.1 ADAM10 stable knockdown SH-SY5Y cells in serum-free medium 
Serum in the cell culture media provides fundamental stimuli for the physiological 
signaling pathway. Thus further experiments were performed with serum-free cell culture 
medium to exclude a potential activating effect of APP α-secretase from serum. Because 
sAPPα are lower in the absence of serum (Pandiella & Massague, 1991), sAPPα in the 
conditioned medium was concentrated by immunoprecipitation (IP) and detected by 
western blot (Figure 14). The results showed that ADAM10 knockdown still led to strong 
reduction of sAPPα to ~10%, whose ratio was consistent with the figure obtained from 
normal cell culture conditions. The absence of serum seemed to only down-regulate the 
total APP secretion, but not affect the APP shedding pattern. It did not affect the ADAMs 
expression pattern in control, ADAM10 shRNA7 and 9 transduced SH-SY5Y cells, either. 
 
Figure 14 Suppressed α-secretase cleavage of endogenous APP in ADAM10 stable knockdown SH-
SY5Y cells with serum-free medium. 
ADAM10 stable knockdown SH-SY5Y cells (sh7, sh9) were pretreated with serum-free medium for 24 h, 
and then 24 h serum-free conditioned medium was collected. ADAM10 and 17 levels were detected by 
membrane preparation. Total sAPP and sAPPα+β’ signals were detected by 22C11 and WO2 respectively. 
sAPPα signal was detected by 500 μl supernatant IP with 5313 and blotting by 14D6. Cellular APP was 
detected by lysate samples with 2C11. The bar charts were the quantification of western blot signals. 
ADAM10 and 17 expression levels were normalized to the calnexin signal. sAPP fragments levels were 
normalized to cellular APP signal. (n = 6, * p ‹ 0.05) 
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4.6.2 ADAM10 stable knockdown HEK293 cells in serum-free medium 
The same experiments were also performed in HEK293 cells with a stable knockdown of 
ADAM10 cultured with serum-free medium (Figure 15). Similar results were achieved as 
in SH-SY5Y cells. In ADAM10 stable knockdown HEK293 cells, total sAPP, sAPPα+β’ 
and sAPPα decreased, with the strongest reduction shown by sAPPα (to ~10%). Both cell 
lines demonstrated that ADAM10 was the physiological α-secretase of APP even without 
serum as a shedding trigger. 
 
Figure 15 Suppressed α-secretase cleavage of endogenous APP in ADAM10 stable knockdown 
HEK293 cells with serum-free medium. 
ADAM10 stable knockdown HEK293 cells (sh7, sh9) were pretreated with serum-free medium for 24 h, 
and then 24 h serum-free conditioned medium was collected. ADAM10 and 17 levels were detected by 
membrane preparation samples. Total sAPP and sAPPα+β’ signals were detected by 22C11 and WO2 
respectively. sAPPα signal was detected by 500 μl supernatant IP with 5313 and blotting by 14D6. Cellular 
APP was detected by lysate samples with 2C11. The bar charts were the quantification of western blot 
signals. ADAM10 and 17 expression levels were normalized to the calnexin signal. sAPP fragments levels 
were normalized to cellular APP signal. (n = 6, * p ‹ 0.05) 
 
4.7 PMA induce APP α-shedding independent of ADAM10 
PMA stimulates the cleavage of many cell surface membrane proteins by metalloprotease, 
including APP. PMA-induced shedding of APP requires ADAM17 activity, because this 
stimulation is abcent in ADAM17-deficient mouse embryonic fibroblasts (MEF) 
(Buxbaum et al., 1998). Thus, whether ADAM10 was involved in the PMA stimulation 
of APP shedding was investigated next. To test this, wild type SH-SY5Y cells were 
transiently transfected with control siRNAs or siRNAs against ADAM9, 10 or 17 and 
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then treated with or without PMA (Figure 16). As expected, in control cells, PMA 
strongly increased sAPPα, in agreement with Figure 8 C. Knockdown of ADAM17 
eliminated the PMA-induced increase in sAPPα production. However, neither ADAM10 
nor 9 knockdown affected PMA induced APP shedding. This showed that ADAM10 was 
not required for PMA induction of APP shedding and suggested that under PMA-
stimualtion conditions ADAM17 can directly cleave APP. 
 
Figure 16 PMA-induced stimulation of APP shedding is independent of ADAM10, but requires 
ADAM17. 
SH-SY5Y cells were either transfected with control siRNA pool or siRNA pools against ADAM9, 
ADAM10 and ADAM17; 2 d after transfection, cells were treated with 1 μM PMA (+) or ethanol (-) as 
solvent control for 4 h.  
(A) Conditioned media were analyzed for sAPPα (4B4), sAPPα+β’ (W02) and cell lysates were analyzed 
for cellular APP (22C11).  
(B) Knockdown efficiency was analyzed by blotting against the different proteases ADAM9, 10 and 17 in 
membrane preparations of the respective experiments. 
 
4.8 β-secretase does not compensate for α-secretase loss of 
function on APP cleavage 
To study the compensatory effect of β-secretase in response of α-secretase 
downregulation, ADAM10 was genetically knocked down by siRNA transfection or 
pharmacologically inhibited. The corresponding -secretase cleaved APP fragments were 
analyzed. 
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4.8.1 ADAM10 knockdown 
As shown in Figure 12, ADAM10 knockdown led to the dramatic reduction of sAPP 
level. The β-secretase cleavage fragment was also detected in parallel by conditioned 
medium upon immunoprecipitation (IP) concentration and 192wt antibody blotting. 
Compared to control cells, endogenous sAPPβ and Aβ levels in HEK293 cells were 
unchanged for one ADAM10 knockdown construct (sh9), whereas a mild, but not 
significant, increase was observed for the other shRNA construct (sh7) (Figure 12). 
Similar results were obtained from ADAM10 knockdown experiments in differentiated 
SH-SY5Y cells. ADAM10 siRNA transfection led to the reduction of sAPPα signal but 
no upregulation of the β-secretrase cleaved fragments (Figure 13 B). Aβ levels (Aβ40, 42) 
showed only a trend to increase, but not statistically significant. This suggested that β-
secretase did not compensate in response of α-secretase down-regulation in immortalized 
cell lines. 
 
α- and β-secretases do not only generate sAPPα and sAPPβ. In parallel, they also 
generate the C-terminal fragments C83 and C99, respectively. Both fragments are further 
processed by γ-secretase, leading to a short half-life of the fragments, which makes it 
difficult to detect them at endogenous levels. In order to stabilize the endogenous C-
terminal fragments of APP, SH-SY5Y cells were treated with the γ-secretase inhibitor 
DAPT (Figure 17). In control cells with normal -secretase activity, the α-secretase 
fragment C83 was clearly detected and was strongly reduced in the ADAM10 
knockdown cells. Out of expectation, the β-secretase-cleavage product C99 was increased 
in this condition more than 2 fold upon ADAM10 knockdown. Besides, a mild increase 
of C89 was observed, which is the C-terminal fragment arising by BACE1 at β’-cleavage 
site. The increase in C99 and C89 is not consistent with sAPPβ levels, which were 
unchanged upon ADAM10 knockdown. The possible explanation is that C99 could also 
be processed by α-secretase. As ADAM10 is knocked down, together with the inhibition 
of γ-secretase activity, C99 was accumulated. These results from HEK293, SH-SY5Y 
and differentiated SH-SY5Y cells show that the strong reduction of α-cleavage does not 
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yield a correspondingly increased cleavage by β-secretase, which means β-secretase does 
not compensate for genetically loss of function of α-secretase on APP cleavage. 
 
Figure 17 DAPT treatment in ADAM10 knockdown SHSY-5Y cells and APP CTFs analysis. 
ADAM10 stable knockdown SHSY-5Y cells (sh7, sh9) were treated with DAPT (1 μM) for 24 h and 
conditioned medium was collected. sAPPα signal was detected by 500 μl supernatant IP with 5313 and 
blotting by 4B4. sAPPβ signal was detected by 500 μl supernatant IP with BAWT 8C10 and blotting by 
192wt. APP CTFs signals were detected by 500 μl lysate IP with 6687 and blotting by 6687. C89 and C83 
are indicated by * and ** respectively. C99 signal was detected by 500 μl lysate IP with 6687 and blotting 
by 2D8. Cellular APP was detected by lysate samples with 2C11. The bar charts were the quantification of 
western blot signals. All the data were normalized to the β-actin signal. (n = 6. * p ‹ 0.05) 
 
4.8.2 TAPI treatment 
The metalloproteases inhibitor TAPI-1 is a kind of hydroxamate inhibitor which works as 
a metal chelator removing the Zn2+-ion from metalloproteases resulting in the 
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inactivation of most of the metalloprotease (Arribas et al., 1996). α-secretase at cell 
surface in absence of the metal co-factor can no longer cleave APP at α-site to release the 
soluble sAPPα. TAPI treatment in HEK293 and differentiated SH-SY5Y cells also 
reduced sAPPα generation without a change in β-secretase cleavage product (Figure 18). 
APP shedding was affected in the same pattern as observed in ADAM10 knockdown 
experiments. In HEK293 cells, total sAPP (22C11), sAPPα+β’ (WO2), and sAPPα (14D6) 
fragments decreased, to ~ 59%, 36% and 23% respectively, which was consistent with 
ADAM10 knockdown results, while sAPPβ signal remained the same compared to the 
control (Figure 18 A). TAPI treatment performed similar in differentiated SH-SY5Y cells, 
down-regulating total sAPP, sAPPα+β’ and sAPPα to ~49%, 27% and 22% respectively 
(Figure 18 B). Surprisingly, Aβ level was increased upon TAPI-1 treatment. In HEK293 
cells, all three species of Aβ were detected by ELISA, only Aβ38 increased significantly 
compared to the control (Figure 18 A), although only to ~1.4 fold. While in differentiated 
SH-SY5Y cells, only Aβ40 was detectable and it increased even to ~2-fold compared to 
the control (Figure 18 B). Cellular APP and APP maturation ratio were not affected much 
by TAPI treatment, in both cell lines, indicating that TAPI treatment only led to the α-
secretase dysfunction but did not affected APP trafficking and maturation. Taken together, 
these experiments suggest that β-secretase cleavage of APP does not have major change 
upon genetically loss of function of constitutive α-secretase. While pharmacological 
inhibition of α-secretase also does not affect sAPPβ production but has the tendency to 
increase Aβ levels, which may be because TAPI-1 also inhibited Aβ degradation 
enzymes activity. In words, the loss of function of α-secretase does not lead to a change 
of β-secretase cleavage of APP. 
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Figure 18 
TAPI treatment 
in HEK293 and 
differentiated 
SH-SY5Y cells 
and APP 
shedding 
behavior analysis. 
A) TAPI treatment 
in HEK293 cells. 
HEK293 cells 
were treated with 
50 μM TAPI in 1 
ml medium for 24 
h. DMSO was 
served as the 
control. 
Conditioned 
medium was 
collected and total 
sAPP, sAPPα+β’ 
and sAPPα signals 
were detected by 
22C11, WO2 and 
14D6 respectively. 
sAPPβ signal was 
detected by 500 μl 
supernatant IP 
with BAWT 8C10 
and blotting by 
192wt. Aβ spices 
were detected by 
Aβ triplicate 
ELISA. Cellular 
APP was detected 
by lysate samples 
with 2C11. The 
bar charts were 
the quantification 
of western blot 
signals. All the 
data were 
normalized to the 
calnexin signal. (n 
= 8, * p ‹ 0.05) 
B) TAPI treatment 
in differentiated 
SH-SY5Y cells. 
Differentiated SH-
SY5Y cells were 
treated with 50 μM TAPI in 1 ml medium for 24 h. DMSO was served as the control. Conditioned medium 
was collected and total sAPP, sAPPα+β’ and sAPPα signals were detected by 22C11, WO2 and 14D6 
respectively. sAPP β signal was detected by sAPPα+sAPPβ triplicate ELISA. Aβ40 level was detected by 
Aβ triplicate ELISA. Cellular APP was detected by lysate samples with 2C11.The bar charts were the 
quantification of western blot signals. All the data were normalized to the calnexin signal. (n= 6, * p ‹ 0.05) 
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4.9 α-secretase does not compensate for β-secretase loss of 
function on APP cleavage 
To further test a possible compensation between α- and β-secretase of cleavage APP, now 
β-secretase was reduced and an effect on α-secretase cleavage of APP was analyzed, both 
genetically and pharmacologically. 
 
4.9.1 BACE1 knockdown 
Expression of the β-secretase BACE1 was reduced by lentiviral knockdown constructs 
(sh1 and sh2) in HEK293 cells (Figure 19 A). This resulted in a strong reduction of 
sAPPβ and Aβ generation, but not in a significant increase in sAPPα generation (~ 1.2 
fold). This clearly indicates that α-secretase cleavage did not compensate for the loss of 
β-secretase activity on APP cleavage. Similar results were obtained from differentiated 
SH-SY5Y cells transiently transfected with BACE1 siRNA (Figure 19 B). BACE1 
knockdown led to a mild reduction in total sAPP and sAPPα+β’ fragments, and only a 
mild but not significant increase in the sAPPα level. In differentiated SH-SY5Y cells, Aβ 
and sAPPβ levels were detected by ELISA. Both signals decreased to lower than 5% 
compared to the control, which provided nice control evidence for the specificity of the 
ELISA detection. 
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Figure 19 BACE1 knockdown in HEK293 and differentiated SH-SY5Y cells and APP shedding 
behavior analysis. 
A) BACE1 stable knockdown HEK293 cells were generated by shRNA viral transduction. In shRNA No.1 
and No.2 transduced HEK293 cells, total sAPP and sAPPα+β’ signals were detected by 22C11 and WO2 
respectively. sAPPα signal was detected by 500 μl supernatant IP with 5313 and blotting with 4B4. sAPPβ 
signal was detected by 500 μl supernatant IP with BAWT 8C10 and blotting by 192wt. Aβ signal was 
detected by 3 ml supernatant IP with 3552 and blotting with 2D8. Cellular APP was detected by lysate 
samples with 22C11. The bar charts were the quantification of western blot signals. All the data were 
normalized to the β-actin signal. (n = 6, * p ‹ 0.05) 
B) Differentiated SH-SY5Y cells were transfected with Qiagen siRNA pools directed against BACE1 or 
with control siRNA (labeled as C or B1 KD). BACE1 was detected by western blot in membrane 
preparations. Calnexin was detected as a loading control. Cell lysates were analyzed for cellular APP and 
conditioned media for total sAPP (22C11), sAPPα+β’ (W02) and sAPPα (14D6). sAPPβ signal was 
detected by sAPPα+sAPPβ ELISA.. The bar charts were the quantification of western blot signals. All the 
data were normalized to the calnexin signal. (n = 6, * p ‹ 0.05) 
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4.9.2 C3 treatment 
The β-Secretase BACE1 is an aspartic-acid transmembrane protease which has two active 
site aspartate residues in its extracellular protein domain. β-secretase inhibitor C3 is a 
kind of statine-based BACE inhibitor which constitutes a tetrahedral, hydroxymethylene-
isosteric replacement for the scissile peptide bond, mimicking the putative reaction 
intermediate and resulting in potent inhibition of aspartic proteases (Marcinkeviciene et 
al., 2001). C3 treatment completely blocked the β-secretase activity in HEK293 cells, 
sAPPβ signal was even not detectable (Figure 20 A). Nevertheless, α-secretase cleaved 
APP derivative did not have any change upon the β-secretase inhibition (~ 96% 
compared to control). A similar result was observed in differentiated SH-SY5Y cells, too, 
where C3 treatment led to ~28% total sAPP reduction, strong decrease of sAPPβ but no 
effect on sAPPα (~ 1.1 fold compared to control) (Figure 20 B). In addition, C3 treatment 
in differentiated SH-SY5Y cells increased cellular APP maturation to ~1.5 fold. In 
conclusion, both the genetic and the pharmacological approach showed that the loss of 
function of β-secretase did not result to a compensation of α-secretase cleavage of APP. 
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Figure 20 C3 treatment in HEK293 and differentiated SH-SY5Y cells and APP shedding behavior 
analysis. 
A) C3 treatment in HEK293 cells. HEK293 cells pre-treated with 2 μM C3 in 500 μl medium for 2 h, 
followed by 24 h incubation with 1 μM C3 in 1 ml medium. DMSO was served as the control. Conditioned 
medium was collected and total sAPP, sAPPα+β’ and sAPPα signals were detected by 22C11, WO2 and 
14D6 respectively. sAPPβ signal was detected by 500 μl supernatant IP with BAWT 8C10 and blotting by 
192wt. Cellular APP was detected by lysate samples with 2C11. The bar charts were the quantification of 
western blot signals. All the data were normalized to the calnexin signal. (n = 6, * p ‹ 0.05) 
B) C3 treatment in differentiated SH-SY5Y cells. Differentiated SHSY-5Y cells pre-treated with 2 μM C3 
in 500 μl medium for 2 h, followed by 24 h incubation with 1 μM C3 in 1 ml medium. DMSO was served 
as the control. Conditioned medium was collected and total sAPP, sAPPα+β’ and sAPPα signals were 
detected by 22C11, WO2 and 14D6 respectively. sAPPβ signal was detected by sAPPα+sAPPβ ELISA. 
Cellular APP was detected by lysate samples with 2C11. The bar charts were the quantification of western 
blot signals. All the data were normalized to the calnexin signal. (n = 6, * p ‹ 0.05) 
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5 Discussion 
 
A diverse range of membrane proteins undergoes proteolysis by a group of enzymes 
referred to collectively as “secretases” or “sheddases”. The cleavage generally occurs 
close to the extracellular surface of the membrane, releasing physiologically active 
protein ectodomains (Hooper et al., 1997). One of the secretases is α-secretase and it is 
considered important in AD since it cleaves APP inside the Aβ domain and could 
preclude the AD-related neuro-toxic Aβ generation (see APP details in 1.2.3). The 
identification of the α-secretase of APP and its regulation would help to better understand 
APP processing and the molecular parthenogenesis of AD.  
 
Furthermore, the α-secretase-cleaved secreted form of APP has also been considered 
neuroprotective and neurotrophic. From some early reports, sAPP or sAPPα was verified 
to have the effect to enhance the neuronal survival and neurite extension (Araki et al., 
1991; Milward et al., 1992; Small et al., 1994; Ohsawa et al., 1997; Luo et al., 2001a; 
Young-Pearse et al., 2008) and play a role in functional synaptic formation (Morimoto et 
al., 1998). Some other research demonstrated that sAPP could protect cells against toxic 
stress (Mattson et al., 1993; Schubert & Behl, 1993; Furukawa et al., 1996; Mattson et al., 
1999; Stein et al., 2004; Gralle et al., 2009). In vivo research further indicated that sAPP 
possessed the memory-enhancing effects in an AD mouse model (Meziane et al., 1998). 
One of the APP α-secretase candidates ADAM10 was also reported to be able to increase 
cortical synaptogenesis (Bell et al., 2008). That makes it more important and interesting 
to investigate the APP α-secretase in order to either understand its biological function and 
to evaluate its therapeutic potential.  
 
5.1 Identification of APP α-secretase 
The research about the identification of APP α-secretase has passed last decade but no 
homogenous results achieved. The candidates include some ADAM and MMP proteases 
(see details in Table 3). The ADAMs are a family of transmembrane proteins with 
important roles in regulating cell phenotype via their effects on cell adhesion, migration, 
proteolysis and signaling; The functional ADAM metalloproteinases are involved in 
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“ectodomain shedding” of diverse growth factors, cytokines, receptors and adhesion 
molecules (reviewed by Edwards et al., 2008). The application of some metalloprotease 
inhibitors had already indicated that ADAM9, 10 and 17 were involved in the α-cleavage 
of APP and release of secreted APP α-fragment (Arribas et al., 1996; Buxbaum et al., 
1998; Koike et al., 1999; Lammich et al., 1999; Skovronsky et al., 2000; Lopez-Perez et 
al., 2001; Slack et al., 2001; Kim et al., 2008). Cell free or cell based experiments 
indicated that ADAM9, 10 and 17 cleaved APP at the α-site between the 16th (Leu) and 
17th (Lys) amino acid of Aβ domain (Lammich et al., 1999; Roghani et al., 1999; Koike 
et al., 1999; Lopez-Perez et al., 2001; Slack et al., 2001; Hotoda et al., 2002). Gene 
inactivation experiments revealed that APP shedding reduced to 20%-60% but was never 
fully suppressed (Hartmann et al., 2002; Weskamp et al., 2002; Asai et al., 2003; Allison 
et al., 2004; Jorissen et al., 2010). Paradoxically, ADAM9, 10 or 17 knockdowns or 
knockouts showed no change in APP shedding in some other research (Buxbaum et al., 
1998; Hartmann et al., 2002; Weskamp et al., 2002). These heterogeneous results have 
led to the conclusion that ADAM9, 10 and 17 may all together contribute to α-secretase 
activity and that in the absence of one of them, the other proteases can still mediate APP 
α-secretase cleavage. 
 
As shown in the results part (see details in 4.2 - 4.6), to reveal the exact identity of APP 
α-secretase, gene knockdowns of the candidates ADAM9, 10, 17 and MMP14 were 
performed in different cell lines upon different conditions. In the following table, the 
experiments carried on about APP α-secretase identification are summarized (Table 19). 
The results show that by using the new, sAPPα specific antibodies 4B4 and 14D6 (see 
details in 4.1), only the inactivation of ADAM10 but not the other metalloproteases 
suppressed sAPPα generation completely in immortalized cell lines, neuronal like cells 
and primary cultured neurons (Kuhn et al., 2010). That means ADAM10 is the only 
physiologically relevant constitutive α-secretase of APP. 
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Table 19 Identification of constitutive α-secretase of APP. 
Cell lines siRNA transfection shRNA viral transduction 
ADAM9 KD → sAPPα --  
ADAM10 KD → sAPPα ↓ 
ADAM10 KD → sAPPα ↓ 
(in present or absent of serum) 
HEK293 
ADAM17 KD → sAPPα -- 
 
 
APP-HEK293 ADAM10 KD → sAPPα ↓ 
 
 
ADAM9 KD → sAPPα --  
ADAM10 KD →sAPPα ↓ 
ADAM10 KD → sAPPα ↓ 
(in present or absent of serum) 
ADAM17 KD → sAPPα --  
SH-SY5Y 
MMP14 KD → sAPPα -- 
 
 
APP-SH-SY5Y ADAM10 KD → sAPPα ↓ 
 
 
 
Differentiated SH-SY5Y ADAM10 KD → sAPPα ↓ 
 
 
“↓” represents reduction; “--” represents no change. 
 
5.1.1 ADAM10 is the only physiologically relevant α-secretase of APP 
The requirement of ADAM10 in APP α-cleavage was double validated by transient and 
stable knockdown cells (see details in 4.2 – 4.4). This is particularly remarkable, because 
although ADAM10 and 17 can cleave similar peptides in vitro at the same peptide bonds, 
regarding to their distinct role in biology, they appear to have quite different substrate 
specificity in vivo (Caescu et al., 2009). If compared to the other APP sheddase BACE1 
which has been demonstrated as the unique protease responsible for the APP β-site 
cleavage (Cai et al., 2001; Luo et al., 2001b), it would be reasonable to assume there is 
only one protease responsible for α-cleavage of APP. Furthermore, cytochemical 
evidence shown by in situ hybridization supported the ADAM10 but not ADAM17 as the 
authentic α-secretase of APP in human cortical neurons (Marcinkeviciene et al., 2001), 
which implied the uniquity of APP α-secretase. Results from my experiments show 
ADAM10 is the key player for APP α-cleavage. 
 
The novel antibodies 4B4 and 14D6 greatly improve the analysis of APP shedding 
because they specifically detect the α-secretase cleaved APP without contribution of any 
other APP cleavage products, such as sAPPβ or sAPPβ’ (see details in 4.1). Using these 
new antibodies, siRNAs and shRNAs against ADAM10 almost abolished the sAPPα 
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signal in SH-SY5Y and HEK293 cells which implied that ADAM10 is the only 
constitutive α-secretase in the physiological condition (see details in 4.2-4.4). ADAM9, 
17 and MMP14 knockdowns lead to hardly any change in sAPPα level, meaning these 
three proteases do not play the role of α-secretase of APP in normal condition (see 4.2.1). 
Only in HEK293 cells, the ADAM17 knockdown led to a very modest decrease in total 
sAPP, raising the possibility that in specific cell lines ADAM17 may have a modulatory 
function in sAPPα generation (see 4.2.2).  
 
In previous research, the gene inactivation could never fully eliminate the sAPPα 
generation. That could be due to two possibilities. On one hand, antibodies used 
previously also detect sAPPβ’, which is the alternative derivative from BACE1 cleavage 
but not affected by metalloproteases inactivation. The new antibodies 4B4 and 14D6 
provide accuracy and specificity for sAPPα detection, which exclude the recognition of 
any other APP ectodomain fragments. On the other hand, most of the previous research 
was performed by single siRNA or shRNA. The potential off-target effects from one 
single siRNA or relatively high siRNA concentration can not be ignored (Jackson et al., 
2003). Furthermore, I manage to use the combination of different single siRNA, to 
decrease the siRNA concentration to a very low level and to use the Dharmacon on-target 
plus siRNA to minimize the off-target effects, especially in case of the siRNA against 
ADAM17. The on-target plus siRNA is designed in seed region which is reported to be 
able to reduce miRNA-induced off-targets effects (Birmingham et al., 2006; Anderson et 
al., 2008). The abolishment of cell toxicity was achieved but no change or only a very 
mild reduction of sAPPα production was observed. The findings provide evidence that a 
physiological condition for the experiment was created, preventing as much as possible 
the artificial factors, to finally achieve the conclusion that ADAM10 is the only 
physiologically relevant α-secretase of APP. 
 
5.1.2 Other APP α-secretase candidates do not compensate for the loss 
of function of ADAM10 
The functional compensation among protein subtypes belonging to the same protein 
family seems to be important for the regulation of the homeostasis of the cell. One easy 
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example is the APP family which is supposed to play an important role in early 
development. The APP family knockout mice showed that the single knockdown of APP 
did not lead to major impairment of embryonic development since it could be 
compensated by its homologue APLP2 (Heber et al., 2000; Wang et al., 2005). ADAM10, 
as shown to be the APP α-secretase, however, seems not to be supported by other ADAM 
proteases under physiological conditions according to the experiments.  
 
The studies in HEK293 and SH-SY5Y cells demonstrated that the α-secretase candidates 
did not compensate for each other when one of them was knocked down transiently by 
siRNA transfection, in which the loss of function lasted in the time period less than 72 h 
(see details in 4.2 and 4.3). Following, stable ADAM10 knockdown cell lines were 
generated (see details in 4.4). In this condition, ADAM9 or 17 did not play the role of 
APP α-secretase in a long-term loss of function of ADAM10, either. This confirmed that 
ADAM10 is the only constitutive α-secretase of APP in physiological conditions. 
Moreover, ADAM10 expression level did not increase as the results of the loss of 
function of ADAM9 and 17, which indicated that ADAMs do not compensate for each 
other on APP α-cleavage (see 4.2.1).  
 
5.1.3 ADAM10 is involved in the constitutive α-cleavage of APP 
APP α-secretase cleavage occurs constitutively and it is mediated by ADAM10, as shown 
in this thesis. In addition, a heterogeneous group of molecules can stimulate APP α-
secretase shedding, which is referred to as regulated α-secretase cleavage (see details in 
Table 4). Actually, the serum included in the cell culture medium consists of many kinds 
of proteins and small molecules such as growth factors, hormones and cytokines. This 
combination of proteins can activate α-secretase activators (Pandiella & Massague, 1991). 
To exclude the effect from serum, ADAM10 stable knockdown cells were then cultured 
in serum-free medium (see details in 4.6). Although the total sAPP level was very low 
due to the absence of serum, ADAM10 still showed a major contribution to the α-
secretion of APP. Serum only up-regulated the base line of APP shedding but did not 
affect the function of ADAM10 as the unique α-secretase.  
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5.1.4 ADAM17 is involved in PMA-regulated α-cleavage of APP 
To further validate the findings concerning the physiological relevance of ADAM10, the 
question whether this secretase might also be involved in the inducible shedding was 
addressed. Different stimuli have been reported to activate APP α-cleavage: the PACAP 
(pituitary adenylate cyclase-activating polypeptide) peptide and PMA. The PACAP 
peptide appeared to stimulate the ADAM10 cleavage of APP (Kojro et al., 2006), 
suggesting that ADAM10 is not only the constitutive α-secretase, but also contributes to 
the regulated α-secretase activity. PMA is the most frequently used APP α-secretase 
activator (see details in Table 5). The results showed that PMA activation does not 
require ADAM10, but ADAM17, which is in agreement with a previous publication 
using ADAM17-deficient mouse fibroblast cells (MEF) cells (Buxbaum et al., 1998). 
These data suggest that ADAM10 plays the role under constitutive conditions but 
ADAM17 needs to be activated, although ADAM10 can be activated in some condition 
as well. Under normal physiological conditions, the constitutive APP α-shedding is only 
mediated by ADAM10. How do ADAM10 and 17 work under pathophysiologically 
relevant conditions would be interesting to be studied in the future. In that case, they may 
be activated in a therapeutically useful manner. 
 
5.1.5 Cell and tissue specificity of APP α-secretase 
The other problem of APP α-secretase identification is the cell or tissue specificity. At 
least in both SH-SY5Y and HEK293 cells, ADAM10 is the only constitutive α-secretase 
of APP. However, it is not always the case. It has been shown that APP α-cleavage had 
no reduction in ADAM10-/- MEF cells (Hartmann et al., 2002). Since the processing of 
AD related APP shedding happens in the brain or in neurons, further validation of 
ADAM10 α-secretase activity in neuronal like cells becomes more meaningful.  
 
SH-SY5Y cells were then differentiated into neuronal cells by all-trans retinoic acid 
(ATRA) treatment (see details in 4.5). Under these conditions, the cells develop neuronal 
like morphological phenotype but normal APP shedding behavior. ATRA treatment has 
been reported to result in the upregulation of ADAM10 expression, but only for short-
time period (Koryakina et al., 2009; Tippmann et al., 2009). The results from 
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experiments showed that ADAM10 expression levels had the tendency to be slightly 
increased. That could be due to the time window of the treatment (3 d): ADAM10 
expression level has already passed the increasing peak and is reduced to the normal level 
as the naive SH-SY5Y cells. Then siRNA transfection was performed to accomplish the 
ADAM10 knockdown. ADAM10 knockdown in neuron-like differentiated SH-SY5Y 
again confirmed that ADAM10 plays the major role of APP α-secretase. Further 
experiments were carried out using primary cultured murine neurons. ADAM9, 10 and 17 
knockdowns were achieved by shRNA viral transduction (cooperated with Dr. P. Kuhn), 
and only ADAM10 knockdown could sufficiently abolish sAPPα production (Kuhn et al., 
2010), which confirms ADAM10 as the physiological relevant α-secretase in neurons. 
 
5.2 The contribution of α-secretase cleavage of APP in cultured 
cell lines 
Although the idea that APP undergoes two different proteolytic pathways has been 
widely accepted, initially it was believed that only α-cleavage was the physiological one 
(Esch et al., 1990; Sisodia et al., 1990) and it prevented amyloidogenesis under non-
pathological conditions. However, later it was clearly known that not only α-cleavage, 
but β- and γ-secretase cleavage, including Aβ generation can also happen under 
physiological conditions (Haass et al., 1992a; Shoji et al., 1992). Indeed, Aβ peptides 
were detected in cerebrospinal fluid in healthy human beings (Seubert et al., 1992). How 
do α- and β-secretases contribute to the total APP secretion? Results from different cell 
lines suggest that they are in a stably balanced ratio. 
 
5.2.1 α- and β-secretase contribute to APP cleavage in a stable ratio 
under physiological conditions 
Summarized from siRNA and shRNA transfection experiments, total sAPP was reduced 
to ~60% in the ADAM10 knockdown HEK293 cells compared with controls (see details 
4.2.2 and 4.4). The extent of total sAPP reduction in SH-SY5Y cells by ADAM10 
knockdown was to ~ 40% (see details 4.2.1 and 4.5). On the other hand, β-secretase 
cleavage contributes about 20% to total APP secretion in the HEK293 and SH-SY5Y 
Discussion 
88 
cells according to the BACE1 knockdown manipulation (see 4.9.1). β-secretase inhibition 
led to the similar results in SH-SY5Y cells. These results suggested that α- and β-
secretases participate in APP cleavage by a stable ratio in cultured cell lines. In the 
primary cultured neurons, β-cleavage of APP contributes to over 90% of total sAPP 
which is completely different from the immortalized cell lines (Kuhn et al., 2010). The 
contributions of α- and β-secretase cleavage of APP are shown in Figure 21. 
 
Figure 21 The contributions of α- and β-secretase cleavage of APP. 
The contributions of α- and β-secretase cleavage of APP in different cell lines are shown in the bar chart. 
“α” represents α-cleavage of APP, mainly contributed by ADAM10; “β” represents β- and β’-cleavage of 
APP, mainly contributed by BACE1. There may be some other unknown proteases participating APP 
cleavage at different sites, represented in the figure as “?”. 
 
In HEK293 and SH-SY5Y cells, there is some percentage of APP shedding that is neither 
contributed by ADAM10 nor BACE1, raising up the possibility that some other unknown 
proteases participating in APP cleavage. In HEK293 cells, C3 treatment even led to a 
reduction of total sAPP to 40%. Taking away the 20% by BACE1, the rest 40% of APP 
shedding would be possibly from cleavage by some other proteases. One possibility is the 
BACE1 homologue BACE2, which can also be inhibited by β-secretase inhibitor C3. 
 
The stable ratio of contribution by α- and β-secretase on APP cleavage also confirms that 
all the experiments were carried out in a physiological condition. The fact that sAPP  　
generation suppressed upon ADAM10 knockdown indicated the participation of 
ADAM10 as the only physiological APP constitutive α-secretase. 
 
5.2.2 α-secretase processes C99 together with γ-secretase 
α-secretase cleavage is considered to occur directly after the action of α-secretase at the 
cell surface, cleaving C83 and releasing the AICD (APP intracellular domain) together 
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with the small p3 peptide. In the amyloidogenic pathway, APP is cleaved in the 
endocytosis pathway by β-secretase, and the resulting C99 is transported to the cell 
membrane to be cleaved by γ-secretase, leading to Aβ generation. However, C99 was 
found also be processed by α-secretase (see 4.8.1). When α-secretase activity was 
suppressed by shRNA mediated knockdown, C99 accumulated. Since the endogenous 
APP CTFs are cleaved by γ-secretase very quickly, the γ-secretase inhibitor DAPT was 
used to better analyze the CTFs processing. In accordance with the postulated APP 
trafficking route, the β-secretase cleavage product CTFβ could also be recycled to cell 
surface where it encounters both α- and γ-secretase. So as shown in Figure 23, C99 can 
be processed in two pathways. The first one consists of cleavage by γ-secretase leading to 
Aβ generation, the second one occurs by α-secretase, leading to C83 generation. For that 
reason, β-secretase is not the only one responsible for compensative or competitive 
relationship with α-secretase cleavage. The relationship between α- and γ-secretase 
should have been taken into account as well. However, I have to admit that the real 
contribution by α-secretase on C99 cleavage may be not as predominate as shown under 
the condition of γ-secretase inhibition. Further efforts have to be made to reveal this 
relationship under physiological conditions, without treatment of γ-secretase inhibitor. 
 
 
Figure 22 Relationship between α- and γ-secretase on C99 cleavage. 
β-secretase cleavage product C99 could also be recycled to cell surface where it encounters both α- and γ-
secretases. In case that α-secretase is activated, it cleaves not only more full length APP but also C99 
competing with γ-secretase.  
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5.3 The relationship between α- and β-secretase on APP 
cleavage 
The generation of sAPPα and sAPPβ/Aβ is generally thought to be inversely coupled. 
Multiple studies showed that an upregulation of α-secretase activity led to a reduction of 
APP β-cleavage (Hung et al., 1993; Jacobsen et al., 1994; Citron et al., 1996; Buxbaum 
et al., 1998; Koike et al., 1999; Skovronsky et al., 2000; Qiu et al., 2001; Zhu et al., 2001; 
Allinson et al., 2004; Postina et al., 2004; Kim, 2008; Fu et al., 2009) (see details in 
Table 5). On the basis of this assumption, the activation of α-secretase cleavage is 
considered a therapeutic approach in order to reduce β-secretase cleavage and therefore 
Aβ generation. However, contradictory studies about α-secretase activity regulation and 
corresponding β-cleavage behavior exist (Dyrks, 1994; Blacker et al., 2002; Gandhi et al., 
2004) (see details in Table 5). Discrepancies in different experiments may have different 
reasons. On one hand, some studies are based on mutants of APP found in familial AD 
(Hung et al., 1993; Citron et al., 1996; Qiu et al., 2001; Fu et al., 2009), whereas others 
focus on the wild type protein. And these familial AD mutants are extremely rare and not 
found in sporadic AD. On the other hand, the experimental details between the two 
proteases have to be carefully specified, such as different cell lines and the ways that the 
regulations are achieved. In order to systematically investigate the relationship between 
α- and β-secretases under physiological condition, a series of experiments were 
performed as described in results part (see details in 4.8 and 4.9). All experiments of this 
thesis were based on wild type APP. Surprisingly, no obvious compensatory effect 
between α- and β-secretase on APP cleavage in HEK293 and differentiated SH-SY5Y 
cells was observed, neither when these proteases were pharmacologically inhibited nor 
when they were genetically knocked down. The only condition where a compensatory 
change was observed was in primary cultured neurons, where ADAM10 partially 
compensated for the loss of BACE1. This experiment was carried out by my colleague Dr. 
Alessio Colombo in the lab in parallel with the work shown in this thesis. These results 
are in accordance with data shown by a recent study that reports increased sAPPα levels 
upon pharmacologic inhibition of β-secretase in human (May et al., 2011). The following 
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table summarizes APP shedding behavior changes due to activity modulation of α- and β-
secretase (Table 20). 
 
Table 20 Compensatory relationship between α- and β-secretase on APP cleavage. 
Cell lines α-secretase loss of function β-secretase loss of function 
ADAM10 KD → sAPPα ↓,  
                             sAPPβ --, Aβ -- 
BACE1 KD → sAPPβ ↓,  
                          sAPPα -- 
 
HEK293 
  
TAPI → sAPPα ↓,  
               sAPPβ --, Aβ -- 
C3 → sAPPβ ↓,  
           sAPPα -- 
 
ADAM10 KD → sAPPα ↓,  
                             sAPPβ --, Aβ -- 
BACE1 KD → sAPPβ ↓,  
                          sAPPα -- 
 
Differentiated SH-SY5Y 
TAPI → sAPPα ↓,  
               sAPPβ --, Aβ ↑ 
C3 → sAPPβ ↓,  
           sAPPα -- 
 
ADAM10 KD → sAPPα ↓,  
                          sAPPβ --, Aβ -- 
BACE1 KD → sAPPβ ↓,  
                         sAPPα ↑ 
 
 
Neurons (in cooperation with 
Dr. A. Colombo, Manuscript 
in preparation) 
TAPI → sAPPα ↓,  
              sAPPβ --, Aβ ↑ 
C3 → sAPPβ ↓,  
           sAPPα ↑ 
“↓” represents reduction; “↓” represents increase; “--” represents no change. 
 
5.3.1 The absence of a compensatory relationship between α- and β-
secretase on APP cleavage under physiological conditions 
Although it is accepted that α- and β-secretase work mutually under activation or 
overexpression condition, this theory is based on that the unique substrate recognition of 
these two proteases and the identical cleavage compartment. However, the trafficking 
route of APP and the cleavage compartment of α- and β-secretase seem to be different 
(see details in 1.2.4). The surprising lack of compensatory changes leads to the rethink of 
the working pattern of α- and β-secretase on APP cleavage. 
 
APP is transported through the TGN along the secretory pathway and finally reaches the 
plasma membrane, where α-secretase activity is found. It then enters the endocytic 
pathway, where the proteolytic processing by β-secretase takes place. Remaining full 
length APP enters a recycling pathway and is transported from the endosomal 
compartments back to the plasma membrane (see details in Figure 5). In immortalized 
cell lines, where α-secretase cleavage contributes to the majority of APP shedding (see 
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details in Figure 22), the loss of function of α-secretase is thus expected to lead to an 
increased amount of APP available for β-secretase cleavage. However, the results from 
experiments in immortalized cell lines, where ADAM10 activity was reduced by 
knockdown or TAPI treatment, did not confirm these expectations, as sAPPβ levels 
remained essentially unaltered. This could be due to the saturation of β-secretase activity 
in these cell lines. In fact, β-secretase cleavage is considered to be the rate-limiting step 
in Aβ generation, with a relatively slow turnover rate of BACE1 towards APP. 
Overexpression of PS1 does not increase Aβ generation, confirming BACE1 as the rate 
limiting enzyme of Aβ generation (Giliberto et al., 2009). In HEK293 and SH-SY5Y 
cells, the amount of endogenous APP that is routed from the cell surface to the 
endosomal/lysosomal compartment under basal conditions may already saturate BACE1 
activity, and increasing the quantity of APP molecules in this compartment after 
knockdown or inhibition of ADAM10 would therefore not enhance sAPPβ/Aβ 
production. This is in contrast to primary neurons, where BACE1 expression levels and 
hence its proteolytic activity are higher and more APP is cleaved by β-secretase, whereas 
α-secretase contributes only to a minor part of APP shedding (see details in Figure 22). 
According to this model, the loss of function of ADAM10 would lead to more APP 
available for β-secretase in primary neurons, although the expected increase of sAPPβ 
may be too minor to be observed. 
 
In the opposite case, when BACE1 activity is suppressed (see details in 4.9), the amount 
of APP that is cleaved in the endosomal compartment decreases. Therefore more APP 
enters the recycling pathway and is available for the proteolytic processing by α-secretase 
at the cell surface. In immortalized cell lines, the additional amount of APP that is 
recycled after the loss of BACE1 function is only minor and may not lead to an 
observable change in sAPPα generation. In primary neurons however, where BACE1 
represents the major sheddase of APP, the loss of function of BACE1 would lead to 
significant more APP available for recycling and subsequent processing by ADAM10. 
This could explain why the compensatory effect of α-secretase in response to BACE1 
suppression was observed in primary cultured neurons, but not in immortalized cell lines. 
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However, the major compartment where APP is cleaved by β-secretase remains 
controversial. Besides the endocytic compartment, several other locations of Aβ 
generation have been proposed. APP has been shown to be cleaved in the TGN and ER, 
particularly mutant forms of APP found in familial AD, such as APP harboring the 
Swedish mutation (Haass et al., 1995; Thinakaran & Koo, 1996; Hartmann et al., 1997; 
Xu et al., 1997). Therefore, under certain conditions, BACE1 can cleave APP already in 
the secretory pathway, thus before α-secretase. In this scenario, the loss of function of 
ADAM10 would not induce any compensatory effect, neither in immortalized cell lines 
nor in primary neurons. When BACE1 is knockdown or inhibited in primary cultured 
neurons where β-secretase takes the major job of APP cleavage, large more amount of 
APP is transported to cell membrane. The upregulation of substrate for α-secretase leads 
to the increase of sAPPα level. However, in immortalized cell lines, the loss of function 
of BACE1 may lead to the APP amount at cell membrane but only slightly. Since the 
large proportion of α-cleavage, the weak increase would not be observed.  
 
From the performed experiments, no definitive conclusion could be drawn on the absence 
of a compensatory relationship between α- and β-secretase on APP cleavage. This would 
require a precise and quantitative estimation of the turnover rate of APP by α- or β-
secretase at the plasma membrane and the endosomal compartment as well as the amount 
of full length APP that recycles back to the cell surface. In addition, the enzyme kinetics 
of both proteases has to be taken into consideration. Solid evidence has to be shown that 
β-secretase could also work in the TGN. The cellular trafficking of APP and therefore the 
access to the different secretases may differ in between immortalized cell lines and 
primary cultured neurons. Further research on APP trafficking would establish a solid 
basis for the investigation of the regulation and the compensatory relationship of APP 
secretases. 
 
5.3.2 Competitive relationship of α- and β-secretase on APP cleavage 
under pathological conditions  
Besides the compensatory relationship between α- and β-secretase on APP cleavage as 
discussed in 5.3.1, the existence of a competitive relationship between these two 
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proteases is also possible. This would implicate that upon activation or overexpression of 
one protease, APP cleavage by the other protease is diminished, as both proteases 
compete for the processing of the same substrate. Under pathological conditions, β-
secretase activity may be increased, as evidence enhanced BACE1 expression levels and 
a concordant increase in Aβ production are found in the brains of sporadic AD patients 
(Yang et al., 2003).  If the competitive relationship between α- and β-secretase holds true, 
this could in turn lead to a reduction of α-secretase activity towards APP. In fact, a 
reduction of sAPPα generation was observed when BACE1 was overexpressed in 
HEK293 cells (Kuhn et al., 2010). Reduced levels of ADAM10 are observed in platelets 
from AD patients when compared to age-matched controls, and a quantitatively similar 
decrease in sAPPα is present both in thrombin-activated platelets and CSF (Colciaghi et 
al., 2002).  
 
5.3.3 TAPI-1 treatment inhibits α-secretase activity together with Aβ-
degrading enzymes activity 
What does the discrepancy of Aβ levels from the genetically and pharmacologically 
induced loss of function of α-secretase tell us? Aβ levels increased in both cell lines when 
treated with TAPI-1, but surprisingly did not change when ADAM10 was knocked down. 
In both conditions, sAPPβ levels remained the same when compared to the control. One 
explanation for this phenomenon could be the fact that TAPI-1 is a broad spectrum 
inhibitor for metalloproteases and could therefore inhibit most of the Aβ-degrading 
enzymes. Insulin degrading enzyme (IDE) (Kurochkin & Goto, 1994; Qiu et al., 1998; 
Vekrellis et al., 2000; Farris et al., 2003; Leissring et al., 2003), endothelin converting 
enzyme (ECE) (Eckman et al., 2001; Eckman et al., 2003), angiotensin-converting 
enzyme (ACE) (Tucker et al., 2000; Hu et al., 2001) and endopeptidase (Howell et al., 
1995; Iwata et al., 2000; Iwata et al., 2001; Kanemitsu et al., 2003; Leissring et al., 2003) 
have all been reported to be involved in Aβ degradation (Wang et al., 2006) and most of 
them belong to the family of metalloproteases. Some matrix metalloproteinases, such as 
MMP2 and MMP9 were also reported to participate in the Aβ degradation (Backstrom et 
al., 1996; Yan et al., 2006; Yin et al., 2006). Therefore, TAPI-1 treatment may not only 
inhibit α-secretase activity but also inhibit one or several enzymes involved in Aβ 
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degradation. To conclude, the upregulation of Aβ levels in TAPI-1 treated cells is not due 
to the compensatory effect of increased APP cleavage by β-secretase of APP, but 
presumably because Aβ degradation is inhibited. 
 
5.4 Outlook 
The activity of α-secretase towards APP can be functionally classified as constitutive or 
regulated. ADAM10 has been verified throughout this thesis as the only physiologically 
relevant, constitutive α-secretase of APP. However, the molecular identity of the 
physiologically relevant regulated α-secretase activity remains enigmatic. And indeed 
some physiological stimuli have been reported to increase α-secretase activity (see details 
in Table 4). Although ADAM17 has been verified as the regulated α-secretase upon PMA 
stimulation, PMA is a chemically synthesized compound and is possibly unable to mimic 
the endogenous stimuli. It would be interesting to investigate on the identity of regulated 
α-secretase activity using the various described physiological stimulating factors. The 
identification of regulated α-secretase activity could be even more meaningful from a 
therapeutic perspective, as the design of α-secretase activity stimulating drugs may then 
be tailored towards the structural features of the specific protease. 
 
Interestingly, it was shown in this thesis that ADAM10, in addition to γ-secretase, 
contributes to C99 cleavage. However, due to the rapid degradation of APP CTFs by γ-
secretase, inhibitors had to be used in order to ensure the detection of these APP 
fragments. It would be fascinating to explore the contribution of α- and γ-secretase on 
C99 cleavage under physiological condition, in the absence of γ-secretase inhibitors, 
which would be an alternative way to down-regulate Aβ generation. Further research on 
C99 cleavage by ADAM10 should allow a deeper understanding of the relationship 
between α-secretase regulation and the corresponding Aβ levels.  
 
Furthermore, concerning to the recent finding that under pathological condition, not only 
β-secretase activity increases but also decrease the α-secretase activity, sAPPα would be 
also a potential AD biomarker. Development of sensitive sAPPα detection assay may 
make it easier to establish a standard biomarker screening system. Since the encoding of 
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two rare potentially disease-associated non-synonymous mutations (Kim et al., 2009), it 
would be a fascinating challenge to investigate on gene manipulation of α-secretase to 
mimic the AD-related pathological condition and corresponding β-cleavage of APP 
together with Aβ generation. 
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6 Conclusions 
 
The main goals of this thesis were to identify the physiologically relevant, constitutive α-
secretase of APP and to valuate its potential compensatory relationship with β-secretase. 
Specifically, the following results were obtained. 
 
• The newly generated sAPPα specific antibodies 4B4 and 14D6 allowed the specific 
detection of proteolytic APP fragments derived from α-secretase. The antibodies 
specifically recognized sAPPα and did not show cross reactivity with other APP 
fragments, including sAPPβ’. They provided the possibility to perform α-secretase 
research under endogenous APP expression levels, which facilitate the identification of 
α-secretase under the physiologically relevant condition. 
 
• Transient and stable knockdowns of α-secretase candidates in various wild-type 
peripheral cells identified ADAM10 as the only physiologically relevant, constitutive α-
secretase. The identity of ADAM10 as APP α-secretase was further validated in neuron-
like cells and cell lines with APP overexpression. Other α-secretase candidates were 
unable to compensate for the loss of ADAM10 activity. ADAM10 contributed to the 
constitutive α-secretase activity, while the induction of APP α-shedding by PMA 
occurred by ADAM17, but independently of ADAM10.  
 
• Detailed studies on the different secreted APP fragments under physiological conditions 
showed that α- and β-secretases contribute to APP cleavage in a stable ratio. They did not 
compensate for each other, when either one protease activity was lost, either genetically 
or inhibited pharmacologically. In addition, it was shown that both α- and γ-secretase 
participate in the cleavage of the β-secretase cleavage product C99.  
 
The identification of ADAM10 as the only physiologically relevant α-secretase of APP 
and its relationship with β-secretase finally complete the basic understanding of APP 
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proteolytic processing. This provides the possibility to evaluate ADAM10 as a drug 
target for the therapy of Alzheimer’s disease. 
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8 Abbreviations 
 
Aβ Amyloid beta peptide 
Aβ40 Aβ 40-residue form 
Aβ42 Aβ 42-residue form 
ACE Angiotensin-converting enzyme 
AChE Acetylcholinesterase 
AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
AICD APP intracellular domain 
APH-1 Anterior pharynx defective 1 
APLP1 Amyloid-precursor like protein 1 
APLP2 Amyloid-precursor like protein 2 
APP Amyloid precursor protein 
APS Ammonium persulfate 
Asn (N) Asparagine 
ATRA All-trans retinoic acid 
β-ME β-Mercaptoethanol 
BACE1 β-site APP cleaving enzyme 1 
Bisacrylamide N-N’-Methylene-bisacrylamide 
BSA Bovine serum albumin 
C3 β-Secretase inhibitor IV 
CaCl2 Calcium chloride 
ChAT Choline acetyltransferase 
CTF C-terminal fragment 
DAPT γ-Secretase inhibitor IX 
ddH2O Double-distilled water 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP PCR Nucleotide Mix 
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DR6 Death receptor6 
E. coli Escherichia coli 
EB Ethidium bromide 
ECE Endothelin converting enzyme 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
ER Endoplasmic reticulum 
FCS Fetal bovine serum 
Gln (Q) Glutamine 
GluR Glutamate receptor 
GPCRs G protein-coupled receptors 
HCl Hydrogen chloride 
HEK293 Human embryonic kidney 293 cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP Horseradish peroxidase 
IDE Insulin degrading enzyme 
IGF-1 Insulin-like growth factors 1  
IL-1α Interleukin-1 α 
IL-1β Interleukin-1 β 
KCl Potassium chloride 
KH2PO4 Potassium dihydrogen phosphate 
KPI Kunitz serine protease inhibitors 
Leu (L) Leucine 
Lys (K) Lysine 
mAChR Muscarinic acetylcholine receptor 
MAPK Mitogen-activated protein kinase 
MEF Mouse fibroblast cells 
Met (M) Methionine 
MgCl2 Magnesium chloride 
MMP Matrix metalloprotease 
Na2HPO4 Disodium hydrogen phosphate 
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NaCl Sodium chloride 
NEAA Non essential amino acids 
NP-40 Nonidet P-40 
P/S Penicillin/streptomycin 
PACAP peptide Pituitary adenylate cyclase-activating polypeptide 
PAS Protein A sepharose 
PCR Polymerase chain reaction 
PDBu Phorbol 12,13-dibutyrate 
Pen-2 Presenilin enhancer protein 2 
PI Protease inhibitor 
PI3K Phosphoinositid-3-kinasen 
PKC Protein kinase C 
PMA Phorbol-12-myristate-13-acetate 
PS1 Presenilin1 
PS2 Presenilin2 
RE Restriction endonucleases 
RIP Regulated intramembrane proteolysis 
RT Room temperature 
SDS Sodium dodecyl sulfate 
sAPP Secreted APP fragment 
sAPPα Secreted APP α-secretase cleaved fragment 
sAPPβ Secreted APP β-secretase cleaved fragment 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SH-SY5Y Human neuroblastoma cells 
TEMED N,N,N',N'-Tetramethylethylendiamine 
TGFα Transforming growth factor 　 
TGN Trans-Golgi network 
Tris Tris hydroxymethyl aminomethane 
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The amyloid precursor protein (APP) undergoes constitu-
tive shedding by a protease activity called a-secretase. This
is considered an important mechanism preventing the
generation of the Alzheimer’s disease amyloid-b peptide
(Ab). a-Secretase appears to be a metalloprotease of the
ADAM family, but its identity remains to be established.
Using a novel a-secretase-cleavage site-specific antibody,
we found that RNAi-mediated knockdown of ADAM10, but
surprisingly not of ADAM9 or 17, completely suppressed
APP a-secretase cleavage in different cell lines and in
primary murine neurons. Other proteases were not able
to compensate for this loss of a-cleavage. This finding was
further confirmed by mass-spectrometric detection of APP-
cleavage fragments. Surprisingly, in different cell lines,
the reduction of a-secretase cleavage was not paralleled
by a corresponding increase in the Ab-generating
b-secretase cleavage, revealing that both proteases do not
always compete for APP as a substrate. Instead, our data
suggest a novel pathway for APP processing, in which
ADAM10 can partially compete with c-secretase for the
cleavage of a C-terminal APP fragment generated by
b-secretase. We conclude that ADAM10 is the physiologi-
cally relevant, constitutive a-secretase of APP.
The EMBO Journal (2010) 29, 3020–3032. doi:10.1038/
emboj.2010.167; Published online 30 July 2010
Subject Categories: neuroscience; molecular biology of
disease
Keywords: ADAM; amyloid precursor protein; neuro-
degeneration; proteases; a-secretase
Introduction
The amyloid precursor protein (APP) is one of a large number
of membrane proteins that are proteolytically converted to
their soluble counterparts. This process is referred to as
ectodomain shedding and is an important way of regulating
the biological activity of membrane proteins (Pruessmeyer
and Ludwig, 2009; Reiss and Saftig, 2009). APP shedding
occurs constitutively by two different protease activities,
called a- and b-secretases, and leads to the secretion of
soluble APP (APPs) (Figure 1A). Both proteolytic cleavages
are central regulatory events in the generation of the amyloid-
b peptide (Ab), which has an important function in the
pathogenesis of Alzheimer’s disease (AD) (Selkoe and
Schenk, 2003; Haass, 2004). The a- and b-secretases are
assumed to compete for APP as a substrate (Selkoe and
Schenk, 2003; Postina et al, 2004), but have opposite effects
on Ab generation. The b-secretase is the aspartyl protease
BACE1 and cleaves APP at the N-terminus of the Ab domain,
thus catalysing the first step in Ab generation (Vassar et al,
1999). In contrast, a-secretase cleaves within the Ab se-
quence of APP (Esch et al, 1990), thereby precluding Ab
generation. In addition, a-secretase cleavage generates a
secreted form of APP (APPsa), which has been reported to
have neurotrophic and neuroprotective properties (Furukawa
et al, 1996; Meziane et al, 1998; Stein et al, 2004), whereas
the slightly shorter form (APPsb) generated by b-secretase
seems to have a proapoptotic function (Nikolaev et al, 2009).
An increase of APP a-secretase cleavage is considered a
therapeutic approach for AD (Fahrenholz, 2007), as it is
assumed to reduce Ab generation. However, the molecular
identity of a-secretase is controversially discussed and re-
mains to be fully established. Different metalloproteases were
suggested as potential a-secretases, because their overexpres-
sion increased APP cleavage. The most frequently named
ones are three members of the ADAM (a disintegrin and
metalloprotease) family: ADAM9, 10 and 17 (Koike et al,
1999; Lammich et al, 1999; Slack et al, 2001). However,
because the overexpression of a protease may artificially or
indirectly increase APP a-secretase cleavage, the physiologi-
cal relevance of a candidate protease needs to be shown using
the corresponding protease knockdown or knockout cells. In
fact, cells derived from ADAM9-, 10- or 17-deficient mice
showed either no or a variable degree of reduction of APP
shedding (Buxbaum et al, 1998; Hartmann et al, 2002;
Weskamp et al, 2002). Likewise, RNAi-mediated knockdown
of the individual proteases in cultured cells reduced APP
shedding to different extents (Asai et al, 2003; Allinson et al,
2004; Camden et al, 2005; Freese et al, 2009; Taylor et al,
2009). The finding that APP shedding was never fully sup-
pressed has led to the conclusion that ADAM9, 10 and 17 may
all together contribute to a-secretase activity and that in the
absence of one of them, the other proteases can still mediate
APP a-secretase cleavage. This assumption is in clear contrast
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to other ADAM protease substrates, many of which are
predominantly cleaved by a single ADAM protease, such as
transforming growth factor a, epidermal growth factor (EGF),
the low-affinity immunoglobulin E receptor CD23 and N-
cadherin (Sahin et al, 2004; Reiss et al, 2005; Weskamp
et al, 2006; Le Gall et al, 2009). One aspect that makes it
difficult to study APP a-secretase cleavage is the fact that APP
is cleaved by distinct proteases at different peptide bonds in
close proximity. For example, b-secretase has the main
cleavage site at the N-terminus of the Ab sequence, but a
secondary cleavage site (termed b0-site) within the Ab se-
quence close to the a-secretase-cleavage site (Figure 1A).
Antibodies used in previous studies have not only specifically
detected APPsa, but also the alternative b-secretase-cleavage
product APPsb0 (Figure 1A), which may have confounded the
study of a-secretase cleavage. Here, we systematically ad-
dress the identity of the physiologically relevant a-secretase.
We generated two new monoclonal antibodies specific for the
APP a-secretase-cleavage product APPsa. Using these anti-
bodies as well as mass spectrometry, we found that ADAM10,
but not ADAM9 or 17, is essential for the constitutive
a-secretase cleavage of APP.
Results
Generation of an APPsa-specific antibody
To specifically detect the APP a-secretase-cleavage product
APPsa, a new monoclonal antibody (4B4) was generated
against a peptide comprising amino acids 11–16 of the Ab
sequence (Figure 1A). The peptide had a free C-terminus,
mimicking the neoepitope generated upon a-secretase clea-
vage. Indeed, antibody 4B4 does not detect full-length APP in
the cell lysate (Figure 1B). It specifically detects APPsa end-
ing in amino acids 15 and 16 (APPs-15 and APPs-16), but
does not detect shorter APPs species, including APPsb0 and
APPsb (Figure 1B). In contrast, antibody W02 binds an
epitope between the b- and the b0-cleavage sites and corre-
spondingly detects both APPsa and APPsb0, but not APPsb.
This antibody detects a similar epitope as antibody 6E10 that
is frequently used for the detection of APPs (Miles et al,
2008). Antibody 22C11 binds to an N-terminal APP epitope
and detects all APPs species tested (Figure 1B). All antibodies
used specifically detect APP, because the antibodies do not
detect a signal in APP knockdown cells (Supplementary
Figure S1).
To further validate antibody 4B4, we tested whether con-
ditions, which increase or decrease APPsa generation, lead to
a corresponding change in the 4B4 signal. To this aim, human
embryonic kidney 293 cells (HEK293) expressing endogenous
APP were treated with the metalloprotease inhibitor TAPI-1 to
reduce APP shedding or with the phorbol ester PMA (also
known as TPA) to increase APP shedding. Both compounds
did not alter the expression of APP or actin in the cell lysate
(Figure 1C). TAPI-1 inhibited nearly completely APPsa gen-
eration (4B4 blot). In contrast, total APPs shedding was not
as strongly reduced (22C11 blot), consistent with the fact that
this antibody detects all APPs species and not only APPsa.
PMA strongly stimulated total APP shedding (22C11), but the
extent of the increase was much more pronounced when
specifically detecting APPsa (4B4). The strong increase in
APP shedding was paralleled by a reduction of the mature
APP in the cell lysate (Figure 1C, marked with x). Antibody
W02, which detects APPsaþAPPsb0, detected intermediate
changes between 22C11 and 4B4, in agreement with the
antibody detecting both APPsb0 and APPsa. In an additional
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Figure 1 Characterization of newly generated APPsa-specific anti-
bodies 4B4 and 7A6. (A) Schematic representation of APP. Indicated
are the antibodies used in this study as well as antibody 6E10
and the APP-cleavage sites (with arrow heads) at the b-, b0- and
a-secretases sites. Numbers below the sequence indicate the amino
acids of the Ab sequence. M, membrane. (B) Immunoblot of
supernatants and cell lysates of cells expressing endogenous APP
(Con) or transfected with the indicated constructs (APPwt, full-
length APP; APPs, soluble APP lacking the transmembrane and
cytoplasmic domain). Antibody 22C11 detects all secreted APP
species, antibody W02 detects APPsa and APPsb0, whereas anti-
bodies 4B4 and 7A6 specifically detect APPsa (APPs-15 and APPs-
16). (C) HEK293 cells were treated with the metalloprotease in-
hibitor TAPI-1 or the phorbol ester PMA. Immunoblots of condi-
tioned media and cell lysates were probed with antibody 22C11
(APPs total), W02 (APPsaþb0) and the APPsa-specific antibody
4B4. Cellular APP is present in a lower molecular weight immature
form (xx) and a higher molecular weight mature form (x) and was
detected with 22C11. The b-actin blot serves as a loading control.
The reduction by TAPI-1 and the increase in shedding by PMA
are more pronounced when analysed with the a-cleavage-specific
antibody 4B4, compared with the other antibodies.
ADAM10 is the constitutive APP a-secretase
P-H Kuhn et al
&2010 European Molecular Biology Organization The EMBO Journal VOL 29 | NO 17 | 2010 3021
control experiment, the b-secretase BACE1 was overex-
pressed, which is expected to increase b-secretase cleavage
and to reduce a-secretase cleavage. BACE1 expression
increased total APP shedding (22C11) in agreement with
previous publications (Neumann et al, 2006; Schobel et al,
2006), but reduced as expected APPsa (4B4) (Supplementary
Figure S2). Antibody W02 was not suited to detect the
decrease in APPsa, because it also detects the alternative
b-secretase-cleavage product APPsb0, which was strongly
enhanced upon overexpression of BACE1 (Supplementary
Figure S2). Taken together, these experiments show that
antibody 4B4 specifically detects APPsa, in contrast to other
commonly used APP antibodies.
Knockdown of ADAM9, 10 and 17 in HEK293 and
SH-SY5Y cells
Next, the three-candidate a-secretases ADAM9, 10 and 17
were transiently knocked down to evaluate their contribution
to the constitutive a-secretase cleavage of endogenous APP
in HEK293 and in human neuroblastoma SH-SY5Y cells.
Compared with control-treated cells, the siRNA pools
knocked down all three proteases with an efficiency of
75–90% (Figure 2A for HEK293; Figure 2D for SH-SY5Y;
quantifications in Figure 2C and F). Levels of cellular APP
as well as of the control membrane protein calnexin were not
affected (Figure 2A and D). Knockdown of ADAM10 in
HEK293 and SH-SY5Y cells reduced total APP shedding
(22C11, normalized to cellular APP levels) to about 40%
(Figure 2A, B, D and E), similar to the use of the metallopro-
tease inhibitor TAPI-1 (Figure 1C). In contrast, APPsa (4B4)
was reduced to 10%, which corresponds to the remaining
10% of ADAM10 protease expressed in the knockdown cells.
In contrast to ADAM10, the knockdown of ADAM9 did not
significantly reduce total APPs or APPsa levels (Figure 2A,
normalized to cellular APP levels). Knockdown of ADAM17
mildly reduced total APPs and APPsa in HEK293 cells (Figure
2A and B), but had no significant effect in SH-SY5Y cells
(Figure 2C and D). The knockdown of either protease did
not affect the expression level of the other proteases
(Supplementary Figure S3). Taken together, expression of
ADAM10, but not of ADAM9 or 17, is required for APP
a-secretase cleavage. Moreover, ADAM9 and 17 did not
compensate for the loss of ADAM10.
To further validate the results from the transient knock-
down of ADAM10, HEK293 cells (Figure 3) and SH-SY5Y cells
(Figure 4) with a stable knockdown of ADAM10 were gener-
ated using lentiviruses expressing two different shRNA se-
quences against ADAM10 or a negative control shRNA. In
HEK293 cells, both ADAM10 shRNA sequences (sh7, sh9)
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Figure 2 Transient knockdown of ADAM10 suppresses a-secretase
cleavage of endogenous APP. (A) HEK293 cells (293) were trans-
fected with siRNA pools directed against the proteases ADAM9
(A9), ADAM10 (A10) or ADAM17 (A17) or with control siRNA. All
three proteases were detected by western blot in membrane pre-
parations. The mature active form is indicated with * (ADAM9),
** (ADAM10) and *** (ADAM17). The immature form of ADAM17
was also detected in HEK293 cells at a higher molecular weight.
Calnexin was detected as a loading control. Cell lysates were
analysed for cellular APP and conditioned media for total secreted
APP (APPs total, 22C11, aþb0-cleaved APP (APPsaþb0, W02) and
a-cleaved APP (APPsa, 4B4). (B, C) Quantification of experiments
in (A). APPs total, APPsaþb0 and APPsa levels were normalized to
cellular APP (B). Quantification of the protease knockdown (KD)
efficiency is in (C). Given are mean and standard error of eight
independent experiments relative (rel.) to control. (D) SH-SY5Y
cells were treated as in (A). APP fragments were detected as in (A).
The immature protease form was not visible for ADAM9, but is
indicated with xx for ADAM10 and xxx for ADAM17, whereas the
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*** (ADAM17). (E, F) Quantification of experiments in (D). Given
are mean and standard error of eight independent experiments.
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reduced ADAM10 protease levels and APPsa levels to 10–20%
of controls (Figure 3A and B; quantification in Figure 3C–F),
respectively, which is similar to the transient knockdown
experiments. Similar results were obtained for the stable
knockdown of ADAM10 in SH-SY5Y cells (Figure 4A and B).
The remaining APPsa from the SH-SY5Y cells could be
fully inhibited by addition of the metalloprotease inhibitor
TAPI-1 (Figure 4A), which is in agreement with the remaining
B10% of ADAM10 protease in the knockdown cells.
The experiments in both cell lines show that also under
stable knockdown conditions, ADAM10 is essential for APP
a-secretase cleavage.
a- and b-secretase cleavage do not compete for each
other in HEK293 and SH-SY5Y cells
Next, we analysed whether the reduction of APPsa was
paralleled by an increase in APPsb and Ab generation.
Surprisingly, however, this was not the case (Figure 3A and
B; quantification in Figure 3E and F). Compared with control
cells, endogenous APPsb and Ab levels in HEK293 cells were
unchanged for one ADAM10 knockdown construct (sh9),
whereas a mild, but not significant, increase was observed
for the other shRNA construct (sh7) (Figure 3E and F). These
results show that the strong reduction of a-cleavage does not
yield a correspondingly increased cleavage by b-secretase. To
further validate this finding, the opposite experiment was
carried out. Expression of the b-secretase BACE1 was reduced
by lentiviral knockdown constructs (sh1 and sh2). This
resulted in a strong inhibition of APPsb and Ab generation,
but not in a significant increase in APPsa generation (Figure
3G and H). Similar results were obtained for SH-SY5Y cells.
The stable knockdown of ADAM10 did not increase APPsb
levels (Figure 4C and D) and conversely, the pharmacological
inhibition of BACE1 with the specific inhibitor C3 (Stachel
et al, 2004) did not increase APPsa levels (Figure 4C and D).
Thus, we conclude that under constitutive cleavage condi-
tions, a- and b-secretases do not significantly compete for
APP as a substrate in HEK293 and SH-SY5Y cells.
Contribution of a- and b-secretase cleavage to total APP
secretion
Total APP shedding (22C11) was reduced to B40% in the
stable ADAM10 knockdown SH-SY5Y cells compared with
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Figure 3 Analysis of APP processing in HEK293 cells with a stable
ADAM10 knockdown. (A, B) HEK293 cells were infected with
lentiviral vectors carrying GFP and different shRNAs: a non-target-
ing shRNA (Con) and two different ADAM10-targeting shRNAs (sh7
and sh9). Conditioned media of these cells were analysed with
antibody 22C11 (APPs total), W02 (APPsaþb0), 4B4 (APPsa),
192wt (APPsb) or 2D8 (Ab), whereas cell lysates were analysed
for cellular APP (22C11). Membranes were analysed for ADAM10
protein. Calnexin was detected as a loading control. (C, D)
Quantification of ADAM10 knockdown from experiments in (A, B)
relative (rel.) to control. (E, F) Quantification of APP fragments in
(A, B). Given are mean and standard error of four independent
experiments. (G) HEK293 cells were lentivirally infected as in (A).
with a non-targeting shRNA (Con) or two different BACE1-targeting
shRNAs (B1-sh1, B1-sh2). APP and its processing products were
analysed as in (A). Actin was used as a loading control. (H)
Quantification of experiments in (G), carried out as in (E) and
(F). Given are mean and standard error of three independent
experiments.
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controls (Figure 4C and D). Additional inhibition of BACE1
with the specific inhibitor C3 further reduced total APP
secretion to B20%, revealing that BACE1 contributes about
20% to total APP secretion in the SH-SY5Y cells. This result
also suggests that the remaining low level (o20%) of total
APP secretion may result from proteases other than ADAM10
and BACE1. This was further confirmed by a combined
pharmacological inhibition of a- and b-secretase cleavage in
SH-SY5Y cells, which resulted in a remaining total APP
secretion of 10–15% (Figure 4E and F).
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ADAM10 truncates APP C-terminal fragments C99
and C89 to C83
a- and b-secretases not only generate APPsa and APPsb, but
also the C-terminal fragments C83 and C99, respectively. Both
fragments are further processed by g-secretase, leading to a
short half-life of the fragments, which makes it difficult to
detect them at endogenous levels. Thus, we treated SH-SY5Y
cells with the g-secretase inhibitor DAPT, which stabilizes the
endogenous C-terminal fragments of APP (Figure 5A). In
control cells, the a-secretase fragment C83 was clearly detected
(marked with ***) and was strongly reduced in the ADAM10
knockdown cells in parallel to APPsa (quantification in
Figure 5B). To our surprise, the b-secretase-cleavage product
C99 was increased more than two-fold upon ADAM10 knock-
down (marked with *). In addition, a mild increase of C89 was
observed (marked with **), which is the C-terminal fragment
arising through BACE1 at its alternative b0-cleavage site (see
Figure 1A for schematic drawing). The increase in C99 and C89
is in contrast to the APPsb levels, which were unchanged upon
ADAM10 knockdown (Figure 5B). We interpret this result in the
following way. C99 and C89 can be processed in two pathways.
The first one consists of cleavage by g-secretase leading to Ab
generation, the second one occurs by a-secretase, leading to
C83 generation. Upon ADAM10 knockdown, the latter pathway
is blocked, leading to an increase in C99 and C89 and leaving
APPsb levels unchanged.
ADAM10 is required for a-secretase cleavage in primary
neurons
APP processing occurs in all cells and tissues analysed to
date. However, in AD, APP processing is particularly relevant
in the neurons of the central nervous system. Thus, we
next investigated the contribution of ADAM9, 10 and 17 in
a-secretase cleavage in primary murine cortical E16 neurons
from C57/BL6 mice, expressing endogenous APP. Murine and
human APP differ by three amino acids within the N-terminal
half of the Ab sequence. One of these amino-acid changes is
within the peptide sequence used to generate the antibody
4B4. For this reason, we generated an additional antibody,
called 7A6, which also detects the murine APPsa, but not
APPsb and APPsb0 (Figure 1B). Using two different shRNA
sequences, the lentiviral knockdown of ADAM10 reduced
murine ADAM10 expression as well as murine APPsa to
about 10–15% of the control (Figure 6A–C). This reveals
that also in primary neurons, ADAM10 activity is required for
APP a-secretase cleavage. As a control ADAM9 and 17 were
also knocked down in the primary neurons. As both proteins
could not be detected by immunoblot in the neuronal lysates,
their expression was measured by quantitative RT–PCR
(Figure 6F). Similar to the HEK293 and SH-SY5Y cells, knock-
down of ADAM9 or 17 did not affect APP a-secretase cleavage
(Figure 6D and E). Likewise expression of ADAM10 was not
affected, as determined by both immunoblot (Figure 6D) and
Figure 4 Analysis of APP processing in SH-SY5Y cells with a stable ADAM10 knockdown. (A) SH-SY5Y cells were infected with lentiviral
vectors carrying GFP and different shRNAs: a non-targeting shRNA (Con) and two different ADAM10-targeting shRNAs (sh6 and sh9). Cells
(Con, sh6 and sh9) were either treated with DMSO as solvent control or the metalloprotease inhibitor TAPI-1. Conditioned media of these cells
were analysed with antibody 22C11 (APPs total), W02 (APPsaþb0) or 4B4 (APPsa), whereas cell lysates were analysed for cellular APP
(22C11). Compared with HEK293 cells, the mature APP form is less well visible in SH-SY5Y cells. Membranes were analysed for ADAM10
protein. Calnexin was detected as a loading control. (B) Quantification of experiments in (A). APPs total, APPsaþb0 and APPsa were
normalized to calnexin. Given are mean and standard error of four independent experiments. (C) Cells (Con, sh6 and sh9) were either treated
with DMSO as solvent control or with the b-secretase inhibitor C3. Conditioned media of these cells were analysed as in (A). Antibody 192wt
was used for the detection of APPsb. (D) Quantification of experiments in (C), carried out as in (B) relative (rel.) to control. (E) Con and sh9
SH-SY5Y cells were treated with DMSO as a control or co-treated with the metalloprotease inhibitor TAPI-1 and the b-secretase inhibitor C3.
(F) Quantification of experiments in (E), carried out as in (B). Given are mean and standard error of three independent experiments.
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Figure 5 Absence of ADAM10 reduces C83. (A) Left panels: SH-SY5Y
cells were treated (þ ) or not () with the g-secretase inhibitor DAPT
to stabilize APP C-terminal fragments (CTFs). Endogenous CTFs were
only visible upon DAPT treatment. Right panels: SH-SY5Y cells stably
expressing ADAM10 shRNAs (sh7, sh9) or control shRNA (Con) were
treated with DAPT. Conditioned media were analysed for APPsa (4B4)
and APPsb (192wt). Cell lysates were analysed for cellular APP, all
C-terminal fragments (6687) and specifically C99 (2D8). C99 is
marked with (*), C89 with (**) and C83 with (***). (B)
Quantification of APPsa, APPsb, C83 and C99 normalized to cellular
APP relative (rel.) to control. Given are mean and standard error of
four independent experiments.
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quantitative RT–PCR (Figure 6F). Together, these results
show that both ADAM9 and 17 are not required for constitu-
tive APP a-secretase cleavage in primary neurons.
Interestingly, total APP secretion (22C11) was only mildly
reduced in the ADAM10 knockdown neurons, which is most
likely due to the fact that in primary embryonic neurons,
a-secretase cleavage contributes only to a smaller extent to
total APP secretion, compared with cell lines (Simons et al,
1996) (Figure 6A). Indeed, b-secretase expression is particu-
larly high during embryonic development and in the first 2
weeks after birth, but then drops sharply (Willem et al,
2006). In contrast to the HEK293 and SH-SY5Y cells, the
ADAM10 knockdown mildly increased APPsb generation
(1.4–2-fold) for both shRNAs tested. Ab followed a similar
trend. However, only one of the shRNA sequences (sh-I)
significantly increased Ab, whereas the other sequence (sh-
II) did not. This suggests that at least in embryonic neurons
with their high expression of b-secretase, a reduction of
ADAM10 may increase Ab levels.
Mass-spectrometric analysis of APP a-secretase-
cleavage products
The experiments above relied on the use of cleavage site-
specific antibodies for the detection of APPs and in particular
of APPsa. Next, we used mass spectrometry as an indepen-
dent method to detect APPsa and to investigate the reduction
of APPsa in ADAM10 knockdown cells. To this aim, the
following strategy was used. APP is N- and O-glycosylated
at different positions within its ectodomain, which leads to a
broadening of the peaks obtained for APPs by mass-spectro-
metric analysis, making identification of specific cleavage
sites difficult. To avoid this situation, two short peptide
tags were included into the APP ectodomain between the
most C-terminal glycosylation site and the N-terminus of the
Ab sequence (Figure 7A). One of the two peptide sequences
encodes a TEV protease-cleavage site, the other one encodes
a FLAG tag. This mutant APP construct (APP-TEV-FLAG)
was stably expressed in SH-SY5Y cells. The secreted form
of APP-TEV-FLAG was immunoprecipitated from the
conditioned medium with an anti-FLAG antibody and then
digested in vitro with TEV protease. This leads to the removal
A
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Figure 6 ADAM10 is essential for a-secretase cleavage of APP in
primary cortical neurons. (A) Primary cortical neurons were pre-
pared at E16 from C57/BL6 mice and infected with purified lenti-
viral particles carrying GFP and either a non-targeting control
shRNA (Con) or two distinct murine ADAM10-targeting shRNAs
(sh-I, sh-II). Four days before harvest, the medium was changed.
Media were analysed for total secreted APP (antibody 22C11),
APPsa (7A6) and APPsb (BAWT). Cell lysates were analysed for
cellular APP, ADAM10 and b-actin (loading control). Immature
ADAM10 is indicated with (*) and mature ADAM10 with (**).
Protein levels of ADAM10 were reduced by both shRNAs to about
10% of control (not shown). (B) Quantification of total secreted
APP, APPsb and APPsa, relative (rel.) to control. Ab was measured
by ELISA. Given are mean and standard error of eight independent
experiments. (C) Quantitative RT–PCR shows that ADAM10 mRNA
levels are strongly reduced, whereas levels of ADAM9 and 17 mRNA
were not affected. Given are mean and standard error of four
independent experiments. (D) Lentiviral knockdown of ADAM9
and 17 in primary neurons was carried out as in (A). (E)
Quantification of results in (D) was performed as in (B). Both
knockdowns did not affect APP processing. Given are mean and
standard error of five independent experiments. (F) Quantitative
RT–PCR shows efficient knockdown of ADAM9 and 17, whereas
ADAM10 levels were not affected. Knockdown of ADAM17 partially
reduced ADAM9 mRNA levels. Given are mean and standard error
of four independent experiments.
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of the glycosylated part of the APP ectodomain, resulting
in B5 kDa peptides having the FLAG tag at their new
N-terminus and C-terminally ending at the peptide bond,
where APP shedding occurs by the secretases (Figure 7A).
First, we verified that APP-TEV-FLAG was processed in a
manner similar to the wild-type, endogenous APP. Stable knock-
down of ADAM10 in APP-TEV-FLAG-expressing SH-SY5Y cells
reduced APP-TEV-FLAG shedding to a similar extent (Figure 7B;
quantification in Figure 7C) as observed for the endogenous,
wild-type APP in SH-SY5Y cells (compare with Figure 4). Total
APPs (22C11) was reduced to 40–50%, whereas APPsa (4B4)
was reduced to 15–30% (Figure 7C). Taken together, APP-TEV-
FLAG is processed similar to wild-type APP.
For the mass-spectrometric measurements, APP-TEV-FLAG
cells were incubated overnight. Secreted APP-TEV-FLAG was
immunoprecipitated from the conditioned medium and pro-
cessed by TEV protease. A major peak at 4695.24 Da was
identified, which corresponds to a peptide having glutamine
15 of the Ab sequence as its C-terminal amino acid (Figure 7D
and E). This is in agreement with the C-terminus of APPsa
isolated from human brain (Pasternack et al, 1992). In
addition, a less intensive peak was observed at 2348.09 Da.
This is exactly half the molecular weight of the more
prominent peak and corresponds to the same peptide, but
with a double-positive charge instead of a single-positive
charge. Importantly, upon ADAM10 knockdown, both peptide
mass peaks were nearly completely suppressed, which is
consistent with the reduction in a-secretase cleavage
observed in the immunoblots (Figure 7C). Peptides with a
C-terminus at the b- or b0-cleavage sites were not detected.
As these cleavages make up a small proportion of total
APP shedding (see C3-inhibitor treatment in Figure 4C), it
is likely that these peptides were below the detection limit in
our analysis or were not stable enough during the isolation
procedure for the mass-spectrometric analysis. When
the APP-TEV-FLAG-expressing cells were incubated for 4 h
instead of overnight, a second mass peak at 4824.43 Da
was observed (Figure 7D). This corresponds to the peptide
having amino-acid lysine 16 of the Ab sequence as its
C-terminal amino acid (Figure 7E). The heterogeneity of
one amino acid at the C-terminus is in agreement with the
finding that in vitro ADAM10 cleaves between lysine 16 and
leucine 17 (Lammich et al, 1999) and may then be followed
by an as yet unidentified carboxypeptidase cleavage,
removing lysine 16 (Esch et al, 1990). The knockdown of
C
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Figure 7 Mass-spectrometric analysis of APP a-secretase cleavage
in stable ADAM10 knockdown SH-SY5Y cells. (A) Schematic repre-
sentation of the APP-TEV-FLAG construct, its cleavage by a-secre-
tase and the further processing with TEV protease to generate small
peptides for mass-spectrometric analysis. M, membrane. (B) SH-
SY5Y cells stably expressing APP-TEV-FLAG were analysed by
immunoblot for APPs total (22C11), APPsa (4B4) and FLAG im-
munoreactivity in the conditioned medium and for cellular APP and
b-actin in the cell lysate. (C) Quantification of APPs total, FLAG
reactivity and APPsa of three independent experiments. Given are
mean and standard error. (D) APP-TEV-FLAG was immunoprecipi-
tated from medium after overnight (ON) or 4 h culture, digested
with TEV-protease and analysed by mass spectrometry. Medium
was used from control (Con) or ADAM10 knockdown cells (sh9).
(E) Table containing peptide sequence, charge, measured masses
(from D) and calculated masses and deviation of the measured
peptides in Da.
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ADAM10 also suppressed the generation of the longer peptide
(Figure 7D).
Taken together, the mass-spectrometric analysis—in addi-
tion to the use of the cleavage site-specific antibody 4B4—
provides a second, independent method to show that
ADAM10 is essential for a-secretase cleavage of APP.
PMA stimulates ADAM17 cleavage of APP
independently of ADAM10
The phorbol ester PMA stimulates the metalloprotease clea-
vage of many cell surface membrane proteins, including APPs
(Figure 1; Buxbaum et al, 1998). PMA-induced shedding of
APP requires ADAM17 activity, because this stimulation is
lost in mouse embryonic fibroblasts deficient in ADAM17
(Buxbaum et al, 1998). Thus, we next investigated, whether
the PMA stimulation of APP shedding also required ADAM10.
To test this, SH-SY5Y cells expressing endogenous APP were
transiently transfected with control siRNAs or siRNAs against
ADAM9, 10 or 17 and then treated with or without PMA
(Figure 8A and B). In control-transfected cells, PMA strongly
increased APPsa (4B4) (Figure 8A), in agreement with
Figure 1. knockdown of ADAM17 suppressed the PMA-in-
duced increase in APPsa production. However, when
ADAM10 or 9 were knocked down, PMA-stimulated APPsa
generation occurred as in wild-type cells (Figure 8A). This
shows that ADAM10 is not required for PMA induction of
APP shedding and suggests that under these conditions
ADAM17 can directly cleave APP.
Discussion
The a-secretase is an important proteolytic activity with the
ability to prevent Ab generation. In this study, we system-
atically evaluated the contribution of ADAM9, 10 and 17 to
a-secretase cleavage of APP. Using a new, APPsa-specific
antibody and two different cell lines as well as primary
neurons expressing endogenous APP, we found that
ADAM10, but not ADAM9 or 17, is essential for a-secretase
cleavage. The requirement for ADAM10 was further validated
by mass-spectrometric determination of APP-cleavage pro-
ducts. From this we conclude that ADAM10 is the physiolo-
gically relevant, constitutive a-secretase of APP and that
ADAM9 and 17 are not redundant for this cleavage. This is
particularly remarkable, because ADAM10 and 17 appear to
have a broad substrate specificity and can cleave similar
peptides in vitro at the same peptide bonds (Caescu et al,
2009). The clear specificity in cells suggests the existence of
additional, as yet unknown factors, which control the
protease specificity in the cellular environment.
Different metalloproteases, most notably ADAM9, 10 and
17 have previously been suggested as candidate a-secretases,
because they cleave APP-derived synthetic peptides in vitro
and because their overexpression in cells or mice increases
APP shedding (Koike et al, 1999; Lammich et al, 1999;
Roghani et al, 1999; Slack et al, 2001; Postina et al, 2004).
However, data resulting from overexpression studies do not
prove that a particular protease is the physiologically relevant
protease for a given substrate. In fact, experiments using cells
with a knockout or a knockdown of the corresponding
proteases gave less clear results about their involvement in
APP a-secretase cleavage. RNAi-mediated knockdown of
ADAM9, 10 or 17 reduced APP shedding by 20 to 60%
(Asai et al, 2003; Allinson et al, 2004; Camden et al, 2005;
Freese et al, 2009; Taylor et al, 2009). In contrast, knockout
cells deficient in ADAM9, 10 or 17 showed no change in APP
shedding (Buxbaum et al, 1998; Hartmann et al, 2002;
Weskamp et al, 2002). Only in a subset of ADAM10-deficient
fibroblasts, APP a-secretase cleavage was altered to a variable
degree (Hartmann et al, 2002). The reason for this variability
is not yet clear. Importantly, because ADAM10 knockout mice
die embryonically and ADAM17 knockout mice die perina-
tally, only embryonic fibroblasts, but not neurons, from
these animals have been analysed for APP shedding. Taken
together, the finding, that APP shedding was never fully
abolished, was taken as evidence that all three proteases
may have redundant functions with regard to APP a-secretase
cleavage. In contrast to the previous studies, we used the
novel antibody 4B4 that specifically detects the a-secretase
cleaved APP (APPsa) without a contribution of other
APP-cleavage products, such as APPsb or APPsb0. Using
this new antibody, siRNAs and shRNAs against ADAM10 or
treatment with the metalloprotease inhibitor TAPI almost
completely blocked APPsa generation in HEK293 and SH-
SY5Y cells and in primary neurons. ADAM9 and 17 were not
required for APPsa formation. Only in HEK293 cells, the
ADAM17 knockdown led to a very modest decrease in total
APP secretion, raising the possibility that in specific cell
lines ADAM17 may have a modulatory function in APPsa
generation. Our knockdown data for ADAM9 and 17
complement the previous finding that ADAM9-deficient pri-
mary hippocampal neurons and ADAM17-deficient mouse
embryonic fibroblasts do not show evidence of an altered a-
secretase cleavage compared with their corresponding wild-
type control cells (Buxbaum et al, 1998; Weskamp et al,
2002). At present, it is unclear, why additional studies using
siRNAs against ADAM9 or 17 reported a moderate reduction
of APP a-secretase cleavage. However, because those pre-
vious studies used only one siRNA per target gene or no
control siRNA or relatively high siRNA concentrations (Asai
et al, 2003; Allinson et al, 2004; Camden et al, 2005; Taylor
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Figure 8 PMA-induced stimulation of APP shedding is independent
of ADAM10, but requires ADAM17. SH-SY5Y cells were either
transfected with control siRNA pool (Con) or siRNA pools against
ADAM9 (A9), ADAM10 (A10) and ADAM17 (A17); 2 days after
transfection, cells were treated with 1mM PMA (þ ) or ethanol as
solvent control () for 4 h. (A) Conditioned media were analysed
for APPsa (4B4), APPsaþb0 (W02) and cell lysates were analysed
for cellular APP (22C11). (B) Knockdown efficiency was analysed
by blotting against the different proteases ADAM9, 10 and 17 in
membrane preparations of the respective experiments.
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et al, 2009), it seems possible that earlier conclusions about
ADAM9 and 17 as APP a-secretase may have been due to off-
target effects (Jackson et al, 2003), but not due to the specific
reduction of ADAM protease expression.
Interestingly, a cleavage by both ADAM10 and 17 was also
suggested for the Notch1 receptor. Proteolytic Notch cleavage
and signal transduction are required for cell differentiation
processes. Recent work established that ADAM10 is the
relevant protease for the physiological ligand-induced
Notch1 cleavage and signalling, but that under certain li-
gand-independent conditions, including disease-linked
Notch1 mutations, Notch1 cleavage can also be mediated
by ADAM17 (Cagavi Bozkulak and Weinmaster, 2009; van
Tetering et al, 2009).
APP a-secretase cleavage occurs constitutively, which
requires ADAM10, as shown in this study. In addition, a
heterogeneous group of molecules can stimulate APP
a-secretase shedding (Bandyopadhyay et al, 2007), which is
referred to as regulated a-secretase cleavage. Two stimuli
activating APP a-cleavage are the neuropeptide pituitary
adenylate cyclase-activating polypeptide (PACAP) and the
phorbol ester PMA. The PACAP peptide appears to stimulate
the ADAM10 cleavage of APP (Kojro et al, 2006), suggesting
that ADAM10 is not only the constitutive a-secretase, but also
contributes to the regulated a-secretase activity. In addition,
ADAM17 can act as regulated APP a-secretase activity, at
least upon stimulation with the phorbol ester PMA. We found
that this activation does not require ADAM10, but ADAM17,
which is in agreement with a previous publication using
ADAM17-deficient MEF cells (Buxbaum et al, 1998). Future
studies need to address whether ADAM17 cleavage of APP
also occurs under physiologically or pathophysiologically
relevant conditions other than upon treatment with the
synthetic phorbol ester PMA.
Previous studies, which will be discussed below, suggested
that a- and b-secretases compete for APP as a substrate, such
that a change in b-secretase cleavage results in the corre-
sponding opposite change in a-cleavage and vice versa. On
the basis of this assumption, an activation of a-secretase
cleavage is considered as a therapeutic approach to reduce
b-secretase cleavage and Ab generation. Although this com-
petition seems to be clearly the case for the regulated
component of the a-secretase cleavage (see below), we
show here that this is not always the case for the constitutive
a-secretase cleavage of APP. The knockdown of ADAM10 did
not significantly increase APPsb levels in HEK293 and SH-
SY5Y cells. Likewise the b-secretase inhibitor C3 blocked
APPsb generation in SH-SY5Y cells, but did not increase
APPsa levels, which is in agreement with a recent study
using a different b-secretase inhibitor in CHO cells (Kim et al,
2008). The reason for this uncoupling of a- and b-secretase
cleavage under constitutive conditions is not yet clear. The
cellular APP levels may not be rate limiting for a- and
b-secretase cleavage, such that a reduction of one cleavage
does not increase the other cleavage. Alternatively, it may
reflect that a- and b-secretase cleavage occur in different
cellular compartments (described below), such that a
reduced a-secretase cleavage would not necessarily increase
the endosomal APP levels available for b-secretase cleavage.
In contrast to the cell lines, the knockdown of ADAM10
induced a mild increase in b-secretase cleavage in the pri-
mary neurons. This effect was more pronounced for APPsb
than for Ab. The difference between the neurons and the cell
lines may result from the different b-secretase expression
levels in both cell types. Although the b-secretase BACE1 is
ubiquitously expressed, its expression is particularly high in
neurons during embryonic development (such as the E16
neurons used here) and in the first 2 weeks after birth and
then drops sharply (Willem et al, 2006). Future studies need
to address whether a knockdown of ADAM10 still increases
b-secretase cleavage in adult neurons, where BACE1 levels
are reduced. In fact, a lack of competition between constitu-
tive a- and b-secretase cleavage in the adult brain comes from
a study, where a dominant-negative ADAM10 mutant de-
creased APPsa, but did not alter APPsb levels in a transgenic
mouse brain (Postina et al, 2004).
The a-secretase cleavage predominantly occurs at the
plasma membrane (Sisodia, 1992), but also in the trans-
Golgi network (TGN), at least upon stimulation with PMA
(Skovronsky et al, 2000). In contrast, b-secretase cleavage of
wild-type APP occurs mainly in the endosome and to a lower
extent in the TGN (Koo and Squazzo, 1994; Vassar et al,
1999). Previous studies reported a competition between
a- and b-secretases for APP as a substrate. This was typically
the case when the corresponding protease was overexpressed
or when an APP mutant was used or when a-secretase
cleavage was activated above its constitutive level. Under
these conditions, a- or b-secretase cleavage mostly occurred
in a cellular compartment where the constitutive cleavage
does not take place to the same extent. For example, over-
expression of the b-secretase BACE1 strongly reduced
a-secretase cleavage (this study and Vassar et al, 1999),
presumably because overexpressed BACE1 artificially cleaves
APP in early compartments of the secretory pathway before
APP has access to a-secretase at the plasma membrane.
A second condition, where a competition between a- and
b-secretase cleavage was observed, is the Swedish mutant
form of APP (SweAPP), which is linked to a familial form of
AD. Compared with wild-type APP, the SweAPP is more
efficiently cleaved by b-secretase and is processed to more
Ab and less APPsa, presumably because the SweAPP is
already cleaved by b-secretase in the TGN before it has access
to a-secretase (Haass et al, 1995). As another example, PMA
increased APPsa and reduced APPsb and Ab in APP-trans-
fected CHO cells (Skovronsky et al, 2000). The authors
argued that PMA shifts APP a-secretase cleavage away from
the plasma membrane towards the Golgi/TGN, such that APP
is cleaved earlier in the secretory pathway and less APP is
available for b-secretase cleavage. This shows that the regu-
lated component of a-secretase (i.e. the increase of a-secre-
tase cleavage above its constitutive level) can compete
with b-secretase and consequently reduces Ab generation,
in agreement with the idea that a pharmacological activation
of a-secretase may be a therapeutic approach to AD
(Fahrenholz, 2007).
Another outcome of our study is that the ADAM10 knock-
down increased the levels of C99 in SH-SY5Y cells, although
the amount of b-secretase cleavage (measured by APPsb
levels) was unchanged. From this finding, we conclude that
C99 can principally be processed in two pathways. In the first
one, C99 is directly cleaved by g-secretase leading to Ab
generation. In the competing pathway, C99 is first cleaved
by a-secretase, leading to C83 generation, which may prevent
Ab generation. Upon ADAM10 knockdown, the latter
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pathway is blocked, leading to an increase in C99, while
leaving APPsb levels unchanged. As C99 is short-lived, we
used a g-secretase inhibitor to visualize it. The increase in
C99 upon ADAM10 knockdown is unlikely to occur to the
same extent in the absence of a g-secretase inhibitor. If that
were the case, we would expect an increase in Ab, as it is the
direct cleavage product of C99. This, however, was not the
case. From this we conclude that the direct C99 cleavage by
g-secretase is the predominant pathway for C99 processing
under normal conditions. However, when g-secretase clea-
vage is blocked, the competing pathway by a-secretase
becomes more prominent resulting in C99 turnover to C83.
A cleavage of C99 by a-secretase is consistent with a previous
study, showing that overexpressed C99 can be converted to
C83 in neurons (Cupers et al, 2001). A possible competition
between a- and g-secretases for C99—even under conditions,
where g-secretase is not inhibited—is supported by a recent
study, which detected N-terminal Ab fragments, such as
Ab1–15 and Ab1–16, that seem to result from a-secretase
cleavage of C99 (Portelius et al, 2009).
Our new antibodies, which are specific for APPsa and do
not detect APPsb0, may be helpful in the search for biomar-
kers of AD. Previous studies reported that APPsa levels are
significantly decreased in the CSF of sporadic AD patients
compared with controls, but there was not a complete
separation between both groups (Sennvik et al, 2000;
Fellgiebel et al, 2009). Potentially, the use of APPsa-specific
antibodies, such as 4B4 may help to separate AD and control
subjects more clearly. In addition, changes in APPsa levels
may help to identify individuals with mutations in ADAM10.
Mutations in the prodomain of ADAM10, which reduce
ADAM10 protease activity, have recently been genetically
linked to an increased risk for late-onset AD in seven distinct
families (Kim et al, 2009).
In summary, our study defines ADAM10 as the physiolo-
gically relevant, constitutive a-secretase for APP and will
allow to further explore the function of ADAM10 in AD.
Materials and methods
Reagents, plasmids and shRNA
The following antibodies were used: FLAG M2 (Sigma), ADAM10
(Calbiochem-422751), ADAM17 (Chemicon), ADAM17 (Oncogene),
ADAM9 (Cell Signaling), HRP-coupled anti-rabbit, anti-mouse
(DAKO), HRP-coupled anti-rat (Santa Cruz), Calnexin (Stressgen),
b-actin (Sigma), monoclonal antibody (mAb) 22C11 (anti-APP
ectodomain) and mAb W02 (against amino acids 5–8 of Ab) from
Konrad Beyreuther; polyclonal antibody (pAb) 5313 (anti-APP
ectodomain), pAb 6687 (against APP C-terminus), pAb 3552
(against Ab) and mAb 2D8 (against Ab1–16) from Christian Haass
and pAb 192Wt from Dale Schenk. Rat mAb 4B4 (IgG2a, APPsa
specific), mAb 7A6 (IgG2a, APPsa specific; detects also murine
APPsa) and rat mAb BAWT (IgG2a, APPsb specific, used for
immunoprecipitation) were generated against peptides EVHHQK-
COOH (amino acids 11–16 of Ab), YEVHHQ-COOH (amino acids
10–15 of Ab) and ISEVKM-COOH (amino acids directly preceding
the b-secretase-cleavage site), respectively (Ullrich et al, 2010). The
following reagents were used: metalloprotease inhibitor TAPI-1,
BACE inhibitor C3 and Dodecyl maltoside (DDM) from Calbiochem;
siRNA pools siGenome against ADAM9, 10 and 17 and siRNA pool
on target plus against ADAM17 and corresponding controls from
Dharmacon. Lipofectamine 2000, RNAimaxx and TEV protease
from Invitrogen. Cloning of plasmids is described in the Supple-
mentary data section. shRNA sequences are listed in Supplementary
Table 1.
Cell culture, transfections, RNAi, sample preparation,
immunoblot, Ab measurements
HEK293-Tcells were cultured in Dulbecco’s modified Eagle medium
(DMEM, Gibco) containing 10% foetal calf serum (FCS/Gibco) and
G418 (Invitrogen) to maintain the large-T antigen. SH-SY5Y cells
were cultured in F12/DMEM (Lonza) supplemented with 15% FCS
(Gibco) and non-essential amino acids (PAA). knockdown of
ADAM9, 10 and 17 in HEK293T and SH-SY5Y cells was performed
transfecting 10 nM of siGenome pool targeting ADAM9, 10, 17 and
corresponding controls or transfecting 10 nM of OnTarget plus pool
targeting ADAM17 and corresponding controls (in SH-SY5Y). One
day after transfection, medium was replaced. After overnight
incubation, conditioned medium and cell lysate (in 150 mM NaCl,
50 mM Tris pH 7.5, 1% Nonidet P-40) were collected. For detection
of ADAM9, 10, 17 and calnexin, cell membranes were prepared as
described (Sastre et al, 2001). Detection of secreted and cellular APP
was as described (Schobel et al, 2008). For precipitation of APPsb,
500ml of conditioned medium were incubated with 30 ml protein G
sepharose and 50 ml of BAWT antibody for 2 h on a rotary shaker.
APPsb was detected with 192wt antibody. For precipitation of
APPsa, 500 ml of conditioned medium were incubated with 30 ml
protein A sepharose and 3.3ml of 5313 antibody. APPsa was
detected with 4B4 antibody. Inhibition of a- and b-secretases was
performed with 50mM TAPI-1 and 1mM C3, respectively, for 24 h.
Endogenous human Ab was immunoprecipitated with antibody
3552 and detected with rat mAb 2D8 as described (Page et al, 2008).
Murine Ab40 was measured in conditioned media of murine
primary cortical neurons, which were diluted 25-fold before
analysis with an ELISA-kit (IBL, JP27720) according to the
instructions of the manufacturer.
Lentivirus production and transduction
Lentiviruses were generated by transient cotransfection of HEK293T
cells with the plasmids psPAX2, pCDNA3.1 ()-VSV-G and as
transfer vector pLVTHMmod or pLKO2mod-EGFP-WPRE for gene
knockdown or FU-DZeo for gene overexpression using Lipofecta-
mine 2000. For transduction of cell lines, medium was replaced by
fresh antibiotic-free medium 1 day after transfection. Overnight
conditioned medium was filtered through 0.45mm sterile filters and
directly added to the target cells. After 6 h, incubation medium was
exchanged against cell type-specific growth medium of the target
cells. Lentiviral particles for infection of murine primary cortical
neurons were concentrated by one run of ultracentrifugation for 2 h
at 22 000 r.p.m. in a SW28 rotor (Beckman) of the overnight
conditioned medium 48 h after transfection. Following ultracentri-
fugation, the supernatant was removed and the viral pellet carefully
resuspended in TBS-5 (50 mM Tris, 130 mM NaCl, 10 mM KCL,
5 mM MgCl2, 5% (w/v) BSA) after a 4 h incubation period at 41C.
Lentiviral stocks were stored at 801C until use.
Preparation and lentiviral transduction of neurons
Primary neuronal cultures were obtained from the cerebral cortex of
E16 C57/BL6 mouse embryos, incubated with 200 U of papain
(Sigma Aldrich) (30 min at 341C) and subsequently mechanically
dissociated. All experimental procedures on animals were per-
formed in accordance with the European Communities Council
Directive (86/609/EEC). Neurons were plated in six-well plates
(B1.5106 cells/well) pre-coated with 25mg/ml poly-D-lysine
(Sigma Aldrich). Plating medium was B27/neurobasal (Gibco)
supplemented with 0.5 mM glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin. Neurons were infected with lentiviruses at
3 DIV. Cell lysates and supernatant were collected at 8 DIV.
Mass spectrometry of APP-cleavage sites
SH-SY5Y cells were infected with FUD-Zeo-DsRed-UAS-APP-TEV-
FLAG and FUD-Zeo-Gal4-VP16. Infected cells were subsequently
FACS sorted according to their DsRed expression to obtain a
homogenous-expressing population. Afterwards, cells were infected
with PLVTHM encoding shRNAs against ADAM10 sh7 and sh9 or a
control shRNA. Secreted APP-TEV-FLAG was immunoprecipitated
with FLAG-M2 agarose. Immunoprecipitation was followed by three
washes with STED (NaCl 150, Tris 50 mM, EDTA 2 mM, 0,5%
DDM), three washes with STE and three washes with ddH2O.
Precipitated APP-TEV-FLAG ectodomain was eluted with 40 ml
100 mM glycine pH 2.5. The eluate was subsequently neutralized
with 200ml 100 mM Tris pH 8.0 and supplemented with 0.5 mM
EDTA and 1 mM DTT and addition of 0.5ml TEV protease. Protease
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digest was incubated at 41C overnight on a rotary shaker. The digest
was diluted with 15 ml of PBS. To precipitate the digested FLAG
peptide, FLAG M2 agarose was added and incubated at 41C for 2 h
on a rotary shaker. Agarose was washed three times with PBS and
three times with ddH2O. Afterwards, peptides were eluted in a 1/20/
20 mixture of trifluoracetic acid/acetonitrile/ddH2O saturated with
a-Cyano matrix. A total of 1ml was spotted on a hydrophobic target
and measured with a Voyager DestR in linear mode. The MALDI-
TOF mass spectrometer was externally calibrated with a peptide
standard mixture (Sequazyme calibration mixture III).
Quantitative real-time PCR
Total RNA was extracted using RNeasy Mini kit (Qiagen) from
primary neurons following the manufacturer’s instructions. Con-
centrations and purities of total RNA were spectrophotometrically
assessed at 260 and 280 nm. Total RNA was reverse transcribed into
cDNA in a 20ml reaction volume, using high-capacity cDNA Reverse
Transcription kit (Applied Biosystems/ABI). Real-time PCR reaction
was carried out on a 7500 Fast Real-Time PCR machine (ABI) with
the POWER SYBRs-Green PCR Master Mix (ABI) based on a
modification of the manufacturer’s recommended protocol. Reac-
tions were performed in duplicate in 96-well plates (ABI) according
to the following protocol: pre-incubation at 951C for 10 min,
followed by 40 cycles of 15 s at 951C and 1 min at 601C. Used
primers including ADAM9, 10 and 17 and the three reference
genes Actb, GapDH and Tbp are listed in Supplementary Table 2.
Validation experiments were performed to verify the amplification
efficiency of each gene, which consistently ranged from 1.8 to 2.2.
The statistic analysis was performed by the DCt value method. The
relative expression of ADAM9, 10 and 17 was normalized to all
three reference genes.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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